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SUMMARY
Recent open studies of sulphasalazine have suggested that it may have 
"second line" antirheumatic activity. Previous experience with 
sulphasalazine in the treatment of inflammatory bowel disease has 
also suggested that it may be less toxic than the commonly used second 
line agents. In addition, the complex pharmacology of sulphasalazine 
may allow manipulation of a number of variables to improve the 
efficacy:toxicity ratio and may also shed some more light on the 
rheumatoid disease process. I, therefore, decided to investigate 
further the use of this drug in rheumatoid arthritis. My specific 
aims were: (1) to investigate by means of a placebo controlled trial
the efficacy of sulphasalazine; (2) to document its toxicity and 
relate toxicity and efficacy to a number of variables; (3) to 
investigate its single dose pharmacokinetics; (4) to define its 
optimal clinical use; (5) to examine for an effect on free radical 
scavengers as a potential mode of action; (6) to identify its active 
therapeutic moiety.
The first study described is a double blind comparison of 
sulphasalazine 3g/day, placebo and sodium aurothiomalate (GST) in 90 
patients randomised to one of the three treatments. At 24 weeks 
significant improvement was seen in inflammatory indices in 
sulphasalazine and GST but not placebo groups and the degree of 
improvement in the sulphasalazine and GST groups was also greater than 
that in the placebo group. Improvement was apparent by 6 weeks and 
was maintained until at least week 43. The drop out rate in the 
sulphasalazine group was similar to that in the GST group. The 
commonest reason for discontinuing sulphasalazine was nausea/vomiting
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but potentially serious toxicity did occur.
In an attempt to relate dose and serum levels to efficacy a further 60 
patients were randomised to sulphasalazine 3.0g/day or sulphasalazine 
1.5g/day. There was a statistically non-significant trend towards 
greater efficacy and toxicity in the 3.0g/day group. When analysis 
was carried out with dose expressed as mg/kg body weight, however, a 
direct relationship was demonstrated between dose and degree of 
improvement and the optimum therapeutic dose was in excess of 
40mg/kg/day. No direct relationship could be demonstrated between 
efficacy and serum levels of sulphasalazine and its metabolites.
Analysis of the 60 patients who had been randomised to 3.0g/day in 
the above two studies demonstrated no difference in efficacy between 
slow and fast acetylators. In a further prospective study of 60 
patients, fast acetylators (40 patients) were assigned to 3.0g/day and 
slow acetylators (20 patients) to 1.5g/day. No significant difference 
was demonstrated between the groups but there was a trend towards 
greater improvement in the fast acetylator group. These results imply 
that any tendency for fast acetylators to do less well (as may have 
been expected) is unlikely and if it does exist is of minimal 
importance in comparison to the effect of dose. Overall, acetylator 
phenotype results were available in 149 patients and nausea/vomiting 
was more common among the slow acetylators. No excess serious 
toxicity was apparent in slow acetylators.
Eight elderly patients underwent single dose pharmacokinetic studies 
before chronic dosing was commenced. Four patients subsequently 
discontinued therapy because of nausea/vomiting and these patients had 
achieved higher peak levels and areas under the curve (AUCs) for
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sulphasalazine and its metabolites. The elderly patients, however, 
excreted in their urine, as sulphasalazine and its metabolites, a 
greater proportion of the ingested dose than a previously documented 
group of young normal volunteers.
Of the total of 158 patients treated with sulphasalazine 31 were £65 
years old. Significantly more elderly patients had to stop because of 
adverse effects. No single adverse reaction could be identified as 
more common in those patients.
Further analysis of these 158 sulphasalazine treated patients 
demonstrated no association between gender, disease duration, 
previous second line drugs or disease activity and either toxicity or 
efficacy. In this group, potentially serious toxicity was common (7 
leucopenias, 2 hepatitis, 1 thrombocytopenia). These problems, 
however, all occurred within the first 12 weeks of treatment.
Twenty-two consecutively treated patients who achieved 24 weeks 
therapy had serial measurements of red cell superoxide dismutase 
activity, red cell thiol levels and plasma thiol levels carried out. 
Changes in these parameters similar to those seen with other second 
line drugs were seen. This suggests that, although it lacks an 
intrinsic aliphatic thiol group, sulphasalazine affects the oxygen 
derived free radical scavenging system. This may represent a mode of 
action of sulphasalazine.
Finally, in an attempt to separate efficacy from toxicity and also, 
perhaps, to give further information on the aetiological and 
pathological mechanisms of rheumatoid arthritis, a further 60 patients 
were randomised to sulphapyridine or 5-aminosalicylic acid (5-ASA).
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significant improvement was seen in the sulphapyridine but not the 5-
ASA group and by the end of 24 weeks (although initially compatible)
the sulphapyridine patients had less active disease.
From the data provided in this thesis I can draw the following
conclusions ; -
1) In a placebo controlled trial sulphasalazine was an effective
second line agent.
2) Potentially serious toxicity may occur but tends to occur 
within the first 12 weeks of treatment and the most intensive 
monitoring can be concentrated over this period.
3) Sulphasalazine exhibits a dose/response relationship in 
rheumatoid arthritis and the optimum dose is >40mg/kg/day. No 
relationship can be demonstrated between efficacy and serum 
levels of sulphasalazine or its metabolites.
4) Other than dose there are no clinical predictors of efficacy.
5) No clinical predictors of potentially serious toxicity can be 
demonstrated although elderly patients experience a greater 
overall drop out rate because of toxicity. Slow acetylators have 
a higher incidence of upper gastrointestinal side effects and 
patients who experience such symptoms tend to achieve higher peak 
levels and AUCs for sulphasalazine and its metabolites in single 
dose studies.
6) Sulphasalazine, although it contains no thiol group, alters the 
oxygen derived free radical scavenging system and the redox 
status of red blood cells. This may represent a mode of action.
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7) Sulphapyridine and not 5-ASA is the active moiety of 
sulphasalazine in rheumatoid arthritis. This finding may be of 
interest in the aetiopathogenesis of the disease.
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Section 1
Introduction and historical background
Rheumatoid arthritis affects approximately 3% of the Western 
population. In its most severe form it is a relentlessly progressive 
disease which leads to destruction and failure of the joint. No 
practical form of therapy, pharmacological or physical, has been shown 
convincingly in placebo controlled studies consistently to slow or 
prevent this progression. The substances which have shown most 
promise in this respect, however, are the so-called second and third 
line agents such as gold salts, d-penicillamine, chloroquine, 
levamisole, cyclophosphamide and azathioprine. In addition, these 
drugs doubtlessly produce major symptomatic relief which cannot be 
obtained using first line agents (non-steroidal anti-inflammatory 
drugs) alone. All of these currently used second and third line 
agents were initially introduced into medicine for the treatment of 
conditions other than rheumatoid arthritis. One of the major factors 
limiting the use of these agents is their potential toxicity. Less 
than 30% of patients commencing such a drug will still be receiving 
the same agent 4 years later although approximately 66% of those 
ceasing treatment will have received at least one similar agent and 
some will require as many as 5 such drugs over a 4 year period (1) 
(Figs I, II, III). The number of available second and third line 
drugs is at present severely limited and there is a clear need for 
additional such agents, preferably with a lower overall toxicity and 
in particular a lower incidence of potentially serious side effects.
Sulphasalazine (SASP), a drug well known to most physicians for the 
treatment of inflammatory bowel disease and which is generally
26
% on 
Treatment
% of patients remaining on original 2nd line agent at 48 months
100
8 0 .
6 0 -
40 - GST
20 - Penicillamine
Levamisole
12 483624 300 6 18 42
Months
Fig. I Life table showing the rate of drop out from individual 
second line drugs over a 48 month period.
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Fig. II Graph showing the percentage of rheumatoid patients 
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second line agent during 4 year follow up.
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discontinuing their first second line drug.
accepted as a safe, relatively non-toxic drug in this condition, was 
first introduced by Nana Svarz in 1941 for the treatment of "rheumatic 
polyarthritis". Nana Svarz believed "rheumatic polyarthritis" had an 
infective aetiology and thought that the combination of an antibiotic 
(sulphapyridine) and a salicylate (5-aminosalicylic acid) would be of 
value. The first report in the English language was published the 
following year (2). She described 20 selected patients (11 with 
polyarthritis and 9 with ulcerative colitis) who had responded well to 
oral sulphasalazine in a dose of 4-6g daily with a subsequent 
maintenance dose of 1.5-3g/day. She published another study of this 
drug in arthritis in 1948 (3) with similar results, and postulated 
that its efficacy might be related to its "affinity for connective 
tissue". Neither of these studies, however, contained a control group 
and her polyarthritis group included a wide range of arthritic 
conditions such as rheumatoid arthritis, ankylosing spondylitis and 
Reiter's syndrome.
In 1949 Sinclair and Duthie (4) published a study in 60 rheumatoid 
patients comparing sulphasalazine with intramuscular gold and with no 
specific treatment (20 in each group). An initial high incidence of 
toxicity with sulphasalazine forced them to use a smaller maintenance 
dose than that employed by Svarz. This study showed neither 
sulphasalazine nor gold to be any better than non-specific treatment 
for patients with rheumatoid arthritis. All patients, however, were 
initially hospitalised for at least 4 weeks (median 9 weeks) and 
during this time received a non-specific regimen of bed rest, dietary 
supplements, splinting and physiotherapy. Furthermore many of the 
patients were assessed many months after cessation of drug therapy. 
These confounding factors make it difficult to draw definite
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conclusions from this study. Despite these shortcomings, and the 
results of a further controlled study published one year later (5) 
which showed a beneficial effect of sulphasalazine in polyarthritis, 
the use of this drug declined. Notwithstanding its undoubted benefit 
in inflammatory bowel disease (6, 7) it remained out of favour in 
rheumatology for 30 years until McConkey et al published results of an 
uncontrolled trial which suggested that sulphasalazine might be an 
effective second line agent (8, 9). Figure IV shows a meeting between 
Dr McConkey and Professor Nana Svarz in the late 1970's.
Section 2 
Chemistry and metabolism
Sulphasalazine (4- pyridyl-(2)-aminosulphonyl-3-carboxy-4-hydroxyben- 
zol) (Fig. V) is an azo compound of sulphapyridine and 5- 
aminosalicylic acid (5-ASA). It is a brown-yellow powder which is 
difficult to dissolve in water and dilute acid but is soluble in 
alkali and in strong acids (2).
Sulphasalazine is detectable in the serum one and a half hours after 
ingestion of a single oral dose. In healthy volunteers peak levels are 
reached after 3-5 hours, it displays a mean serum half-life of 5.7 
hours (this rises to 7.5 hours with repeated dosing) and it is almost 
completely absent from the serum after 24 hours (10, 11).
Sulphasalazine is not absorbed from the stomach as it is insoluble in 
weak acids. Absorption from the small intestine is variable between 
individuals. Usually less than 5% (no more than 20.5%) of the ingested 
dose is recoverable unchanged from urine or bile, whereas about 80% of 
the dose may be excreted as sulphapyridine or its metabolites (11,
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Fig. IV Dr Brian McConkey, who reintroduced sulphasalazine into 
rheumatology, meeting Professor Nana Svarz who 
originally synthesised the compound.
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Fig. V The structure of sulphasalazine.
12). This implies that a large proportion of ingested sulphasalazine 
is split into its separate components either before or after 
absorption. Patients with ileostomies provide a useful model for 
investigating this question further and in these patients, although 
the amount of unaltered sulphasalazine obtained from the urine is 
similar to normal individuals, only about 7% of the ingested dose of 
sulphasalazine is recoverable from the urine either as sulphapyridine 
or its metabolites. Biliary excretion of sulphapyridine and its 
metabolites is negligible. The above data suggest that very little 
sulphasalazine is metabolised in the small bowel or liver and that 
most ingested sulphasalazine reaches the caecum unaltered (12, 13). 
This is confirmed by the finding of about 70% of an ingested dose of 
sulphasalazine unchanged and another 14% as free sulphapyridine in the 
ileostomy effluent (13, 14). In the colon sulphasalazine is broken 
down by a process of azo reduction by the colonic bacteria to 
sulphapyridine and 5-aminosalicylic acid (5-ASA). The finding that 
serum and urine levels of sulphapyridine and its metabolites are 
significantly higher in patients with transverse colostomies than 
patients with ileostomies suggests that most of the cleavage takes 
place in the caecum or proximal colon. Van Hees (16) has shown that 
less than 1% of an oral 3g dose of sulphasalazine is recoverable in 
its original form from the faeces in normal subjects and less than 8% 
can be recovered as sulphapyridine. In contrast to sulphapyridine at 
least 50% of the 5-ASA component of the original sulphasalazine is 
excreted in the faeces. Thus almost all the sulphasalazine which 
reaches the colon is split into its two components and while the 
sulphapyridine is largely absorbed the 5-ASA remains mainly within the 
colonic lumen. Serum levels of 5-ASA (primarily in free form) in
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ulcerative colitis patients reach only l-4ug/ml and urinary excretion 
(mainly as acetyl-5-ASA) is usually around 22% (range 1-40%) of the 
ingested quantity (12, 17). Sulphapyridine is not identifiable in the
serum until 3-5 hours after ingestion of sulphasalazine and reaches 
peak levels after about 24 hours (11) whereas, with an equimolar dose 
of sulphapyridine, peak serum concentration is reached after only 
one and a half hours; this lag is explained by the delay in absorption 
of the sulphapyridine moiety of sulphasalazine (10). Steady state 
concentration of sulphapyridine is reached by 5 days (10). Once 
absorbed, sulphapyridine, which is highly protein bound, undergoes N- 
acetylation and ring hydroxylation in the liver and is finally 
conjugated with glucuronic acid. Unchanged sulphapyridine plus 
acetylsulphapyridine comprise approximately 75-90% of total 
circulating sulphapyridine (18). Metabolites of sulphapyridine are 
excreted by the kidneys more rapidly than unmetabolised 
sulphapyridine. The rate of acétylation is genetically determined, 
there being two types of acetylator:- fast (autosomal dominant) and 
slow (autosomal recessive). This polymorphism governs the activity of 
the hepatic acetyl transferase enzyme (19, 20) (Fig. VI). In Western
Europe approximately 60% of the population are slow acetylators and 
40% fast acetylators (20). Elimination half-life of sulphapyridine is
5.5 hours in fast acetylators and 15.3 hours in slow acetylators (21).
There is some controversy regarding the effect of acetylator status on 
steady state serum sulphapyridine levels. Schroder et al (22) found 
no significant difference in serum total sulphapyridine levels between 
slow and fast acetylators after 72 hours of sulphasalazine treatment, 
although they did demonstrate a difference after 24 hours and showed a 
greater serum concentration of acetylsulphapyridine and lower
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Fig. VI The fate of the sulphasalazine molecule after it 
reaches the large bowel.
concentration of unmetabolised sulphapyridine in fast acetylarors 
after both 24 and 72 hours. On the other hand, Van Hees (15) , Das et 
al (17) and Azad Khan et al (23, 24) showed a significantly lower 
steady state concentration of total sulphapyridine in fast 
acetylators. As sulphapyridine is more rapidly excreted as its acetyl 
metabolite (acetylsulphapyridine) one might expect total serum 
sulphapyridine to be greater in slow acetylators. There is good 
evidence that normal volunteers and patients with ulcerative colitis 
who are slow acetylators have a higher incidence of adverse effects 
(23, 25).
After administration of sulphasalazine orally, sulphasalazine, 
sulphapyridine, N-acetylsulphapyridine, sulphapyridine-0-g 1 ucuronide, 
acetylsulphapyridine-O-glucuronide, N-acetyl-5-OH-sulphapyridine-O- 
glucuronide, 5-ASA and acetyl-5-ASA can all be detected in urine (18) ; 
2.5% of the total dose is excreted in the bile as sulphasalazine and a 
further 0.45% as sulphapyridine or its derivatives (12).
Section 3 
Mode of action in inflammatory bowel disease and immunological effects 
of sulphasalazine
Sulphasalazine was first introduced because of the theoretical 
beneficial effects of a combined antibacterial and anti-inflammatory 
agent in ulcerative colitis and rheumatoid arthritis, both of which 
were thought, possibly, to have an infective aetiology. This was 
despite the findings of earlier studies showing sulfanilamide 
compounds alone to have no effect in either of these conditions (26). 
One reason which was postulated at this time for the effectiveness of
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sulphasalazine was its "affinity for connective tissue and thus its 
ability to deliver its active ingredients to the required sites" (3, 
27) .
It is unclear whether it is the sulphasalazine, sulphapyridine, 5-ASA 
or one of their metabolites which is the active agent in ulcerative 
colitis.
Less than one third of ingested sulphasalazine is absorbed (12) and 
serum levels of sulphasalazine bear no relationship to the efficacy of 
the drug in ulcerative colitis (17). This suggests that circulating 
sulphasalazine is unlikely to be the active component in this 
condition.
Das et al (17), claimed a relationship between circulating 
sulphapyridine levels and the efficacy of sulphasalazine in ulcerative 
colitis. They reached this conclusion, however, by the observation 
that patients who did not respond to therapy had lower serum total 
sulphapyridine levels than responders and on increasing the dose of 
sulphasalazine clinical improvement was accompanied by a concomitant 
rise in blood levels of sulphapyridine. This relationship could be 
explained by reduced sulphapyridine absorption in the active phase of 
the disease and this explanation is supported by Azad Khan who 
demonstrated no relationship between circulating total sulphapyridine 
levels and the relapse rate in ulcerative colitis (24).
It has been suggested that in vivo sulphasalazine alters the immune 
process by decreasing the number of activated monocytes and B- 
lymphocytes and increasing T-lymphocyte numbers and function although 
these findings could not be repeated in vitro using sulphasalazine or
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its metabolites (28). Thayer et al (29), although they demonstrated a 
reduction in the numbers of complement receptor bearing B-lymphocytes, 
could show no effect on T-1 ymphocytes. Other workers have 
demonstrated that, in vitro, sulphasalazine and sulphapyridine inhibit 
the natural killer activity of peripheral mononuclear cells whereas 
even at high concentrations 5-ASA produces only minimal inhibition of 
this function (30). In vitro sulphasalazine also almost completely 
inhibits the synthesis of 5-hydroxy-6, 8, 11, 14-eicosatetranoic acid
(5-HETE) and 5, 12-dihydroxy-6, 8, 11, 14-eicosatetranoic acid (5, 12- 
di-HETE) (leucotriene B4) by human neutrophils (31), and blocks 
binding at neutrophil derived peptides that activate chemotaxis and 
superoxide production (32). Similar but less marked effects were 
found with 5-ASA with only minimal inhibition by sulphapyridine. In 
addition sulphasalazine has been shown, in an animal model, to 
suppress specific antibody production in the intestine and also, 
possibly, to produce non-imraunologically active antigen binding 
substance (33). It would seem, therefore, that sulphasalazine 
possesses immune regulating properties but the exact mechanisms 
require clarification.
Patients with ulcerative colitis have been shown to have raised faecal 
and colonic venous blood prostaglandin E 2 (PGE2 ) and in vitro both 
sulphasalazine and 5-ASA by itself have been shown similarly to 
inhibit either prostaglandin synthesis or the interaction of PGE2 with 
receptors (34).
It has also been shown that 5-ASA suppositories or retention enemas 
are of benefit in ideopathic proctitis (35, 36) and that oral 5-ASA 
appears as effective as sulphasalazine in ulcerative colitis (37).
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Finally, sulphasalazine has been shown to alter bowel flora in 
patients with ulcerative colitis (38) and this is most likely to be a 
function of the sulphapyridine component. The mode of action of 
sulphasalazine in inflammatory bowel disease is, therefore, unclear 
although a local anti-inflammatory activity of 5-ASA would seem most 
likely.
Section 4 
Adverse Effects
Svartz (2) found side effects (with the exception of fever and rash) 
to be rare and she listed nausea and vomiting, "cyanosis", 
nephrolithiasis, anaemia, fever and exanthem as observed side effects. 
She also described a fatal case of "agranulocytosis" from another 
hospital. Das et al (25) and Van Hees (16) have added to this list:- 
frank haemolysis, transient reticulocytosis, macrocytosis, leucopenia, 
pancytopenia, thrombocytopenia, folate deficiency, headaches, 
dizziness, anorexia, and epigastric discomfort. Other workers have 
reported male infertility (39, 40), hepatic hypersensitivity (41, 42,
43), systemic granulomatous reactions (44), late hepatic toxicity 
(45), pancreatitis (46), neurotoxicity (47), pulmonary involvement 
(48, 49, 50, 51, 16) and drug induced systemic lupus erythematosus
(52, 53, 54) as possible toxic effects.
Das (18) reviewed a number of studies of adverse reactions to
sulphasalazine and quoted an overall incidence ranging from 15-70%. 
The actual incidence appears to be related to the dose of
sulphasalazine, total sulphapyridine serum levels and acetylator 
status (16, 23, 25) .
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Nausea and Vomiting
Das (25) found nausea or vomiting within a few days of starting 
treatment in 6 out of 34 patients with inflammatory bowel disease. 
Two patients developed their symptoms after the first dose and they 
proved to be fast acetylators. The other 4 developed symptoms over 
the next few days and they were all slow acetylators. In these 
patients symptoms were related to high serum levels of total 
sulphapyridine. The fact that these symptoms are related to serum 
levels of sulphapyridine would suggest a central mechanism for nausea 
and vomiting.
"Cyanosis"
The exact nature of the blue discolouration which affects some 
patients on sulphasalazine is not clear. It is said not to be related 
to haemoglobin oxygenation, or to the formation of methaemoglobin or 
sulphaemoglobin (2). It is closely linked to the dose of 
sulphasalazine and serum levels of total sulphapyridine (25). This 
side effect has not been reported during more recent studies of 
sulphasalazine therapy.
Nephrolithiasis
Apart from a mention in Svartz's paper (2) this does not appear to 
have been a problem.
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Anaemia
The major cause of anaemia during sulphasalazine therapy appears to be 
haemolysis. Although frank haemolytic anaemia is relatively rare, 
evidence of haemolysis is commonly detected in about 50% of patients 
receiving sulphasalazine. Haemolysis during sulphasalazine treatment 
is due to decreased membrane stability and is associated with an 
increase in methaemoglobin and occasionally the production of Heinz 
bodies. Haemolysis seems to be related to total serum sulphapyridine 
levels and those with frank anaemia may be those with the highest 
levels (15, 55). Folate deficiency has also been described in
patients taking sulphasalazine and Franklin et al (56) suggest that 
sulphasalazine acts as a competitive inhibitor of folate absorption. 
Selhub et al (57) also found sulphasalazine to be a competitive 
inhibitor of dihydrofolate reductase, methylenetetrahydrofolate 
reductase and serine transhydroxymethylase activity (all 3 enzymes are 
involved in folate metabolism).
Van Hees (16), on the other hand, failed to confirm this mechanism and 
suggests that folate deficiency is secondary to chronic haemolysis 
resulting in increased folate utilisation.
Leucopenia and agranulocytosis
This is a rare complication but probably the most serious. Less than 
30 cases have been reported but at least 5 deaths have occurred (16). 
One case of pancytopenia has also been reported.
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skin Rashes
The incidence of skin rash with sulphasalazine is poorly recorded but 
appears to vary between 0-10% (16, 22 , 25) and, as with 
agranulocytosis, is not dose related. The rashes are usually mild but 
occasionally more serious rashes, eg, Lyell's Syndrome have been 
reported (58, 59).
Hepatotoxicity
Acute hepatitis, usually associated with fever, rash and 
lymphadenopathy is known to occur with sulphasalazine (41, 42, 43) and 
this appears to be immunologically mediated. A systemic granulomatous 
reaction affecting the liver has also been described (44). Recently a 
case of hepatitis after 15 years sulphasalazine treatment has been 
described (45).
Male infertility
Sulphasalazine has been shown to reduce the absolute sperm count and 
cause morphological abnormalities in spermatozoa in a high proportion 
of patients (39, 40). This appears to be completely reversible and 
there are no reports of increased incidence of foetal abnormalities or 
perinatal morbidity/mortality in babies whose fathers were on 
sulphasalazine at the time of conception.
Lung disease
Eight patients with infiltrative lung disease, often with systemic 
features of fever, weight loss and eosinophilia, have been described 
(16, 48, 49, 50, 51). Most cases have reversed although at least 1 
fatality has occurred.
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Drug induced lupus erythematosus
A number of cases of drug induced lupus erythematosus have been 
described in ulcerative colitis patients and most of these were 
receiving sulphasalazine. Eight cases of possible lupus syndrome were 
described by Alacron-Segovia et al (52). All of these cases appeared 
to be associated with the administration of sulphasalazine or sulpha 
drugs. LE cells were present in all these cases but the clinical 
features in some of the cases were not consistent with a diagnosis of 
drug induced lupus. At the time of this report anti-nuclear and anti- 
DNA antibody estimations were not available.
A further case (53) was accompanied by a raised DNA binding although 
the temporal relationship with sulphasalazine was convincing. In 
classic drug induced lupus, however, DNA binding is normal and this 
case may, therefore, represent an exacerbation of spontaneous systemic 
lupus erythematosus which is well recognised with sulphonamides. The 
case described by Crisp and Hoffbrand (54) again displayed a "slightly 
raised" DNA binding but again the temporal relationship with 
sulphasalazine administration was convincing.
Desensitisation
Patients who have experienced mild idiosyncratic reactions to 
sulphasalazine may benefit from a desensitisation regimen starting 
with Img orally per day and slowly increasing the dose. This may 
facilitate the eventual re-introduction of the drug (60, 61).
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Pregnancy
Retrospective studies have failed to show a deleterious effect due to 
sulphasalazine on the outcome of pregnancy (62, 63).
In a series of patients with Crohn's disease only 3-4% had to 
discontinue sulphasalazine because of adverse events (6). In an other 
series of 200 patients with ulcerative colitis only 13 dropped out 
because of side effects (Truelove S.C., personal communication).
Section 5
Drug interactions
Drug interactions may take place either within the gut or following 
absorption.
Interactions within the intestinal lumen
Concomitant administration of antibiotics leads to a reduction in the 
degradation of sulphasalazine in the large bowel resulting in a lower 
serum sulphapyridine level and increased faecal excretion of 
sulphasalazine (15, 16).
Cholestyramine, which is occasionally given to patients with 
inflammatory bowel disease, binds both sulphasalazine and its azo 
reduction products in the gut. This results in slower intestinal 
passage of sulphasalazine with a reduction in sulphasalazine cleavage 
by the bacteria of the large bowel. Cholyestyramine binding of 5-ASA 
may also inhibit its local anti-inflammatory effect (16). 
Sulphasalazine is also known to chelate iron and when sulphasalazine 
and ferrous sulphate are administered together absorption of
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sulphasalazine but not sulphapyridine is reduced (11). Calcium 
gluconate, although it retards absorption of sulphasalazine, has no 
effect on the overall quantity absorbed (11). Mention has already 
been made of the possible inhibition of folate absorption.
Interaction after absorption
Concomitant phenobarbitone administration results in a decrease in 
serum acetyl-sulphapyridine, an increase in serum sulphapyridine-o- 
glucuronide levels and a reduction in serum sulphasalazine levels. 
The clinical significance of these findings is unknown (13).
Theoretically, as it is highly protein bound, sulphapyridine might be 
expected to displace other highly bound drugs such as warfarin or the 
sulphonylureas. To date, however, there is no firm evidence of 
significant clinical interaction.
Conclusions
Sulphasalazine is a drug with a complex pharmacology and apparently 
low toxicity which merits further investigation as a second line anti­
rheumatic drug.
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Summary 
Chapter 1
Rheumatoid arthritis is a common, progressive, potentially crippling 
condition. Because of its relentlessly progressive nature and the 
toxicity of the second line drugs available at present to treat it 
there is a need for more effective, less toxic drugs. Although 
sulphasalazine was first introduced for the treatment of "rheumatic 
polyarthritis" its use in this condition rapidly declined and it 
remained in use only as a treatment for inflammatory bowel disease. A 
number of uncontrolled studies have recently suggested, once more, 
that it has second line anti-rheumatic properties.
Only a small proportion of an ingested dose of sulphasalazine is 
absorbed as such and most reaches the large intestine intact where it 
is split by bacterial action to sulphapyridine and 5-amino salicylic 
acid (5-ASA). The 5-ASA remains largely within the bowel lumen and is 
excreted unchanged in the faeces. The sulphapyridine is almost 
completely absorbed, undergoes hepatic metabolism (the rate of which 
depends upon the genetically determined acetylator phenotype) and is 
then excreted in the urine.
Sulphasalazine or its metabolites affect a number of biological 
systems and can produce antimicrobial, immunoregulating and anti­
prostaglandin effects.
Although nausea is a common side effect of sulphasalazine, serious 
side effects (agranulocytosis, hepatitis and pulmonary infiltrates) 
are rare and it is relatively free of drug interactions. Some of its 
adverse effects are thought to be related to acetylator phenotype.
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Sulphasalazine is, therefore, a suitable drug to investigate further 
for anti-rheumatic properties.
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CHAPTER 2
Section 1
What is a second line drug?
Drugs used in the treatment of rheumatoid arthritis are conventionally 
classified as first line drugs ("non-steroidal anti-inflammatory drugs 
(NSAIDs)", "aspirin like drugs", "cyclo-oxygenase inhibitors") or 
second line drugs ("disease modifying antirheumatic drugs", "specific 
antirheumatic drugs", "slow acting drugs", "d-penicillamine like 
drugs"). In addition cytotoxic drugs or corticosteroids are 
occasionally employed and these are sometimes referred to as third 
line or even fourth line drugs. Most patients suffering from 
rheumatoid arthritis require only first line therapy. A minority, 
however, with progressive generalised inflammatory disease which is 
not adequately controlled by first line drugs alone require the 
addition of second line drugs such as gold salts, d-penicillamine or 
chloroquine. These drugs differ from first line drugs in their 
relatively slow onset of action, their frequently prolonged beneficial 
effect when treatment is stopped and their effect on a number of 
systemic indices of inflammation (Table I). It is this latter 
property, in addition to a clinical benefit, which most readily 
distinguishes second line drugs. It has also been suggested that 
these drugs slow the progression of joint destruction (67, 68, 69, 
70). Numerous effects of second line drugs at a cellular level have 
been described and many of these effects have been proposed as 
possible modes of action. Examples of these effects are shown in 
Table II. No single mode of action has been shown to explain their 
therapeutic action, although most proposed mechanisms have
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Erythrocyte sedimentation rate (ESR)
Haemoglobin level
Platelet count
C-reactive protein
Haptoglobin
Conconavalin-A binding 
Rheumatoid factor titre 
Serum IgG levels 
Serum IgM levels 
Serum IgA levels 
Serum thiols 
Plasma viscosity 
Serum histidine
Table I Laboratory parameters which may be altered by second line
drugs (64,65,66).
Drug Authors Proposed mode of action of
second line drug
Sodium
aurothiomalate Lipsky & Ziff (1977)
Inhibition of lymphocyte 
proliferation (71)
Sodium
aurothiomalate
Hopkins, Jayson & 
Van der Zeil (1983)
Inhibition of lymphocyte 
activation (72)
Sodium
aurothiomalate
Griffin & Stevens 
(1982)
Inhibition of proteolytic 
enzyme activity (73)
Sodium
aurothiomalate 
Levamisole 
D-penici1lamine
Mowat (1977) In vitro inhibition of 
neutrophil chemotaxis by 
sodium aurothiomalate and 
stimulation by levamisole.
In vivo early stimulation of 
neutrophil chemotaxis by 
levamisole and late stimula­
tion by d-penicillamine (74)
Sodium
aurothiomalate
Jessop, Vernon- 
Roberts & Harris 
(1973)
Inhibition of neutrophil 
phagocytic activity (75)
Aurothio-
glucose
D-penicillamine 
Auranofin
Jessop, Wilkins & 
Young (1982)
Suppression of phagocytic 
activity of synovial 
macrophages (76)
Sodium
aurothiomalate
Scheinberg, Santos 
& Finkelstein (1982)
Inhibition of monocyte chemo­
taxis and expression of Fc 
and C3 receptors (77)
D-penicillamine 
Sodium
aurothiomalate
Munthe, Kass & 
Jellum (1982)
Alteration of free radical 
scavenging mechanisms (78)
Sodium
aurothiomalate
Highton, Panayi & 
Shepherd et al 
(1981)
Reduction in immune complex 
levels (79)
Table II Proposed modes of action of second line agents.
concentrated on alterations of the immune system.
The clinical effect of cytotoxic drugs are broadly similar to those 
of second line drugs and, in general, they are used when the choice of 
second line agents is exhausted. For practical purposes cytotoxic 
drugs are often classified along with second line drugs (Fig. VII).
Section 2
Methods of assessing activity of second line drugs
2.1 Classification of drug response
Rheumatoid arthritis is characterised by inflammation of synovial 
joints with associated pain, stiffness, swelling and joint destruction 
which in turn produce loss of function (both reversible and 
permanent). Any drug used in the treatment of rheumatoid arthritis 
should help to ease the symptoms of pain and stiffness and reduce 
local inflammation. In addition second line agents produce 
improvement in systemic features of inflammation and may also improve 
long term function and reduce the rate of joint destruction.
Ideally the assessment of a drug for "second line properties" should 
include observations of its effect on:-
(1) Symptoms of pain and stiffness and evidence of local joint 
inflammation.
(2) Systemic inflammatory parameters.
(3) Joint destruction.
(4) Patient function.
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Categories (1) and (2) are often referred to as "process measurements" 
(measurements of disease activity) and categories (3) and (4) as 
"outcome measurements".
Unfortunately there is no single test which will give reliable, 
reproducible results which are both sensitive and specific with regard 
to disease activity and outcome. One is therefore forced to use a 
battery of tests to assess drug effect. Even when results from such a 
battery of tests are available some may be conflicting. Clinicians 
often fail to agree on the relative importance of the various results 
and their use of these results in clinical practice may even differ 
from their perceived importance of the same information (80, 81).
2.2 Measurements of symptoms and local joint inflammation
Joint tenderness
Numerous methods of assessing joint tenderness have been produced but 
the two in most widespread use are the American Rheumatism Association 
Joint Score which is basically a count of inflamed joints (total = 66 
joints) (82), and the Ritchie Articular Index (83) which scores joint 
tenderness, using digital pressure, on a scale of 0-3 (total = 26 
joints or groups of joints). These two indices correlate well with 
each other (83).
Although the Ritchie Index shows good intra-observer reproducibility 
inter-observer reproducibility is poor and serial measurements must be 
taken by the same observer. Because of its simplicity, speed and good 
intra-observer reproducibility, however, the Ritchie Articular Index 
has proven popular with many researchers (84).
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Pain
Perception of pain is notoriously difficult to quantitate and much 
depends upon the patient's personality, environment and psychological 
status (85). In clinical trials pain is measured either on a visual 
analogue pain scale (VAPS) or on a descriptive pain scale. A VAPS is 
a 10cm line the ends of which define the extremes of pain, eg, "as bad 
as it could be" and "no pain". This is sometimes modified by the 
superimposition of descriptive terms, eg, mild, moderate, severe, 
along the line and is then referred to as a graphic rating scale (86). 
A number of factors influence both the ability of patients to use such 
scales to record pain and the sensitivity of the method; these 
include:- whether the scale is vertical or horizontal, the exact 
wording of instructions and labelling of the scale, the presence or 
absence of subdivisions and whether the patient is allowed to see 
their previous scoring (86, 87). Reproducibility of the score also 
shows variability along the length of the scale (88). Occasionally 
patients are unable to understand the concept of a VAPS.
Many descriptive pain scales have been devised using from 4 to 9 
divisions (84). There seem to be no advantage in using a large number 
of divisions and a 5 point scale using the grading of "no pain, mild 
pain, moderate pain, severe pain and very severe pain" has been shown 
to be effective in differentiating active treatment from placebo (89).
A failing common to all these methods of pain assessment is the fact 
that pain relief is an exponential rather than linear fucntion and it 
is easier to go from very severe to severe pain than from mild to no 
pain (90). Another approach has been to attempt to quantitate pain 
relief rather than absolute pain levels. This is only applicable to
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certain types of clinical trials (86) and suffers from patients' 
understandable inability to remember pain severity.
Morning stiffness
This is a common feature of inflammatory arthritis and occurs in 97% 
of patients with active, untreated rheumatoid arthritis. It has an 
average duration of three and a half hours (91). Measurement of 
severity of stiffness requires special appliances (92, 93) and by 
convention, therefore, duration of morning stiffness (or "limbering up 
time") is used in most clinical trials of antirheumatic drugs.
Hand grip strength
Hand grip strength is measured using a standard rubber bag or sewn 
sphygmomanometer cuff inflated to a pre-determined pressure (usually 
20 or 30mraHg). This is squeezed three times by each hand and the mean 
value for each hand calculated. Hand grip strength is dependent upon 
a number of parameters, both physical (pain, stiffness, muscle power, 
deformity) and psychological. It can also be affected by patient 
skill and learning and shows both inter-observer and diurnal 
variation. Although it does reflect changes in clinical disease 
activity it is a relatively insensitive test (84, 94). If used in the 
evaluation of rheumatoid arthritis it should be measured by the same 
observer at the same time of day.
Digital joint circumference
This can be measured using either jewellers rings or a plastic spring 
gauge. It changes with anti-inflammatory drug treatment although 
large inter-observer error has been demonstrated (95). Provided it is
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confined to patients with soft tissue joint swelling this measurement 
can be useful in assessing an anti-inflammatory effect.
Other clinical methods of assessment
Many other less commonly used methods of clinical assessment have been 
utilised. These include such measurements as the time taken to walk 
50 ft, a count of the number of analgesic tablets used and a global 
assessment which is a measure of either the physician's or the 
patient's subjective view of the patient's generalcondition without 
specific reference to any particular symptom or sign. These other 
methods offer little in terms of sensitivity or specificity.
Thermography
Thermography is a method of recording infra-red emission and 
displaying this on a video screen in the form of a two-dimensional 
colour picture with temperature steps being represented by different 
colours. From this pattern a thermographic index can be calculated 
and changes in this pattern reflect accurately the reduction in 
inflammation produced by the injection of local corticosteroids (96) 
and after the use of NSAIDs, penicillamine and cytotoxic drugs (97). 
Thermography, however, is a time consuming operation and requires 
expensive specialised equipment. A technique of microwave radiometery 
which measures microwave emission rather than heat is presently being 
assessed and may prove promising (98).
Radio-isotope studies
Joint inflamamtion may be assessed using intravenous or intra- 
articular injections of radio-isotopes.
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The most commonly used intravenous radio-isotope is radio-technetium 
(9^‘^Tc ). Elevated uptake of can be detected over inflamed
joints and a number of polyarticular indices have been devised (99). 
The index correlates well with other clinical and laboratory
measurements of inflammation and it reflects changes with prednisolone 
and gold (100).
Measurement of the rate of clearance of intra-articularly administered 
xenon ( Xe) allows accurate estimation of synovial blood flow (101) 
and again, this correlates with other parameters of disease activity 
and changes with the use of anti-inflammatory drugs.
2.3 Systemic inflammatory parameters
Erythrocyte sedimentation rate (ESR)
ESR is a non-specific measure of inflammation which is often, but not 
always, raised in active rheumatoid arthritis as well as in numerous 
other inflammatory conditions. The level of ESR in rheumatoid 
arthritis depends upon the fibrinogen and ^  globulin concentrations 
in the plasma as well as numbers and configuration of the cells 
(102). It is also related to the age of the patients and the serum 
cholesterol concentration. The ESR is not influenced by NSAIDs such 
as indomethacin or aspirin (103) but falls with second line drugs such 
as gold (104) and penicillamine (105) and also with prednisone (103, 
104). ESR correlates well with most other inflammatory indices (100) 
and, along with C-reactive protein (GRP) levels, relates to 
radiological progression (106). Although a very non-specific test, 
ESR was recently voted a "best buy" in measurements at a workshop on 
assessment of drug efficacy in rheumatoid arthritis (107).
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C-reactive protein (CRP)
CRP is an acute phase reactant which is synthesised in hepatocytes. 
It circulates in the ^ globulin fraction of serum proteins and is 
thought to have some immunoregulatory function. It is present in low 
concentration in normal serum and is raised in most inflammatory 
conditions including rheumatoid arthritis (108). Although there is 
some dissociation between CRP and ESR, these two parameters, in 
general, correlate well in rheumatoid arthritis (109). Like ESR it 
reflects disease activity (110), is reduced by treatment with gold, 
dapsone and prednisone (104) and is related to radiological 
progression (106). It is not, however, altered by changes in serum 
immunoglobulins, cholesterol concentration, red cell concentration, 
size or shape, or age (111).
Other acute phase proteins
These are a heterogeneous group of glycoproteins and include ^-acid 
glycoprotein, qC.  ^ antitrypsin, caeruloplasmin, haptoglobin, 
seromucoid and protein bound hexose and fibrinogen. These show a 
pattern of response in rheumatoid arthritis similar to that of CRP and 
ESR but are not as well documented in this respect although seromucoid 
serum hexose-protein ratio and protein bound hexose concentrations 
have been suggested to reflect most consistently disease activity 
(112).
These proteins can be measured "en masse" by their ability to bind to 
conconavalin A (a plant lectin isolated from the Jack bean). 
Conconavalin A binding correlates well with levels of individual acute 
phase reactants and a fall in Conconavalin A binding accompanies
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clinical improvement with penicillamine therapy (65). Apart from CRP 
acute phase reactants are seldom used in clinical practice.
Haemoglobin
Anaemia is a feature of active rheumatoid arthritis. It is said to 
occur in less than half the cases of active disease (113) although 
most physicians would probably regard this as an underestimate. 
Haemoglobin level correlates well with other indices of disease 
activity (100). Haemoglobin levels rise as the disease becomes less 
active but its usefulness is obviously limited as it can be affected 
by, among other things, blood loss, nutritional status, 
haemoconcentration and haemodilution.
Platelet count
A thrombocytosis occurs in active rheumatoid arthritis and the level 
of the platelet count correlates with other parameters of disease 
activity. A similar pattern is also seen in Crohn's disease (66).
Plasma and serum viscosity
In rheumatoid arthritis plasma viscosity is related to the 
concentration of fibrinogen and other macromolecules while serum 
viscosity is mainly affected by the concentration of globulins 
(114). They are both unaffected by such variables as age and 
haemoglobin levels. Plasma viscosity has been shown to correlate well 
with articular index and it changes significantly with the use of 
second line drugs (115). The relationship between plasma viscosity 
and clinical parameters, however, could not be confirmed in a cross 
sectional study by Larkin and co-workers (116). They also failed to
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show correlation of serum viscosity with clinical parameters and 
surprisingly could demonstrate no relationship of ESR with clinical 
parameters. This same study demonstrated an effect of smoking on ESR 
and for this reason suggested that viscosity measurements might be 
more reliable.
Rheumatoid factor
IgM rheumatoid factor as measured by the Rose-Waaler titre fails to 
show significant correlation with most parameters of disease activity 
(100). Many studies of second line agents do not inclcude assessment 
of rheumatoid factor titres but titres are reduced by gold salts (117) 
and by d-penicillamine (118).
Serum sulphydryl levels
Serum sulphydryl (thiol) groups are involved in the scavenging of 
oxygen derived free radicals and levels correlate inversely with 
disease activity in rheumatoid arthritis (100). Serum sulphydryl 
reactivity increases with the second line drugs, gold, penicillamine 
and levamisole but not with NSAIDs (119).
Combined indices used in the assessment of disease activity in 
rheumatoid arthritis
Numerous indices combining various clinical and laboratory 
measurements of disease activity have been devised in an attempt to 
give an overall description of disease activity. Because of the 
multiplicity of measurements and the necessarily subjective nature of 
many of these, none of the indices have met with universal success or 
acclaim. These indices are summarised in Table III.
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Recently in an attempt to define second line drugs a correlation 
matrix has been developed. This correlates changes in laboratory and 
clinical parameters of disease activity and is claimed to 
differentiate between NSAIDs and second line drugs as only the latter 
produce changes in laboratory indices which correlate with clinical 
changes (64).
2.4 Radiological progression
The parameters discussed above are all "process measurements", ie, 
reflect disease activity only at the time of assessment. Changes in 
the radiological appearances of the joints, however, represent a 
measurement of outcome, ie, the end effect of the inflammatory 
process.
There are two main methods of quantitating radiological changes of 
rheumatoid arthritis in common use. The method described by Larsen et 
al (123) involves comparison of 5 standard graded radiographs for each 
joint whereas that of Sharp et al (124) relies upon numerical 
evaluation of narrowing of the joint space and osseous defects in hand 
radiographs. These methods rely upon qualitative judgement and are 
tedious to carry out; joint space narrowing is related to the degree 
of flexion and erosions of the carpus are often difficult to assess 
because of overlapping carpal bones. A simplified Sharp's method 
counting only osseous defects of 11 joints in each hand has recently 
been described (125). This method displayed good inter and intra­
observer variation.
One of the major drawbacks of radiological assessment of drug effect 
in rheumatoid arthritis is the inability to maintain adequate placebo
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groups for the time necessary to observe real changes (126) whereas 
the comparison of the rate of radiological progression prior to and 
during treatment is not valid as this relies on the fallacious 
assumption that the rate of progression of erosive disease is linear 
(127). No study has satisfactorily demonstrated a reduction in the 
rate of erosive disease with second line drugs. Sigler et al (68) 
compared 15 gold and 13 placebo treated patients and found 
significantly more radiographic changes in the placebo group. These 
authors, however, achieved the remarJcable feat of keeping a placebo 
group for 2 years with no drop-outs which suggests that, perhaps, the 
disease activity was mild. In an uncontrolled comparison of gold and 
penicillamine (59), penicillamine but not gold was found to retard the 
rate of progression. In another two studies of gold salts it was 
suggested that radiological progression was delayed. In one of these 
(70), greater radiological progression was found in the low dose group 
(<500mg total gold) than in the high dose group (>500mg total gold); 
these groups, however, were not comparable at the start of the study. 
In the other study (uncontrolled) patients who had a clinical response 
to gold showed a reduced rate of progression of erosive disease (128). 
Another study using similar numbers of patients demonstrated that, for 
the degree of retardation of radiological progression found, between 
120 and 170 patients would have to complete 2 years treatment with the 
active drug and a similar number would need to complete 2 years 
treatment with placebo before a statistical test with a power of 80% 
could demonstrate a statistically significant difference between the 
groups (12 5).
The dearth of knowledge of the natural history of erosive disease in 
untreated rheumatoid arthritis and the lack of adequate control groups
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in studies of the effect of second line drugs on erosive disease make 
it seem unlikely that a decisive answer to this question can be 
produced using present methods. Recent work on microfocal radiography 
(129) may provide a more sensitive technique with which to answer this 
question.
2.5 Patient function
The major aims of antirheumatic therapy are to abolish pain, prevent 
joint destruction and maintain or improve function. The measurement 
of function can be approached in a number of ways. Measurements of 
the patient’s ability to carry out simple tests such as walking a set 
distance or squeezing a sphygmomanometer cuff have been dealt with 
above. Several questionnaires have been produced to assess, overall, 
the patient's ability to carry out everyday tasks. The earliest of 
these was the functional classification described by Steinbrocker, 
Traeger & Batterman (130) which recognised 4 functional classes. 
Other similar 4 of 5 point scales have been described but 
classification into such a small number of groups obviously deprives 
one of sensitive measures of joint function. Numerous longer 
questionnaires have been devised and one of the best known is that of 
Lee et al (131) which scores 17 everyday tasks of varying complexity. 
This is not affected by short term use of anti-inflammatory drugs but 
is by joint surgery. A recent development in the field of functional 
assessment (one which can, perhaps, be regarded as a third generation 
functional index) is the health assessment questionnaire (132) which 
deals not only with activities of daily living but also with other 
aspects of the patient's ability to cope with everyday life such as 
discomfort, drug toxicity and economic impact (as well as death!).
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This type of assessment of the patient's overall health status brings 
us closer to a measure of the World Health Organisation's definition 
of health as, "a state of complete physical, mental and social well­
being and not merely the absence of disease or infirmity". Although 
this questionnaire and a similar assessment, the Arthritis Impact 
Measurement Scale (133) have been validated as regards reproducibility 
and relationship to other relevant methods of assessment they have not 
yet been shown to be of value in the long term evaluation of 
antirheumatic compounds nor have their relationship to short term 
treatment or major life events been demonstrated. A recent study 
examining the effect of joint arthroplasty on these two "health status 
instruments" and on another three similar instruments has shown a good 
correlation between the various questionnaires with little to choose 
between them (134). More work must be done on these various 
questionnaires before they can achieve an accepted place in the long 
term assessment of rheumatoid arthritis.
2.6 Conclusion
A multiplicity of methods of assessing the effects of antirheumatic 
drugs on the process measurements of disease activity in rheumatoid 
arthritis are available. There is little to choose between most of 
these and provided one uses a variety of both clinical and laboratory 
parameters one should be able to detect a second line effect. The 
final choice of parameters therefore lies with other considerations 
such as ease of measurement for the patient, the preferences of the 
physician and of the laboratory staff and the local availability of 
laboratory tests. It is important, however, that for the measurement 
of clinical parameters the assessor is kept constant.
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The choice of outcome measurement is much more difficult. Radiology 
is the only way of measuring disease progression but its value is 
greatly limited by our inability to maintain a proper placebo group 
for the necessary period. Satisfactory studies of radiological 
progression of disease is therefore probably an unattainable goal in 
the assessment of second line drugs.
Measurements of patient function or more general health assessment 
measurements again suffer from lack of long term control data and have 
not yet been shown necessarily to represent long term disease 
outcome. However, until a better measure of outcome is available, 
health assessment questionnaires appear a useful instrument with which 
to assess outcome.
Section 3 
Toxicity of currently used second line drugs
One of the major problems with the present range of second line drugs 
is their high incidence of adverse effects. In a recent study 55% of 
123 patients commenced on one of three second line drugs (gold, 
penicillamine or levamisole) experienced definite or possible toxicity 
necessitating withdrawal of treatment over the first 4 years and a 
further 22% dropped out for other reasons (Table IV) (1). The other 
major group of second line drugs, the antimalarials, although they 
have a different range of toxicity (inhibition of smooth muscle 
contractility, headaches, corneal and retinal pigmentation) also has a 
substantial drop out rate and requires close ophthalmological 
monitoring (135). The cytotoxic drugs such as azathioprine, 
cyclophosphamide and methotrexate which are used in rheumatoid
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arthritis are also notorious for their high incidence of (often 
serious) adverse reactions (67, 136).
Although HLA tissue typing has some value in identifying patients who 
are susceptible to certain toxic effects with gold salts and 
penicillamine (137) and sulphoxidation status may also help with the 
latter drug (138), there is no clinically useful test which will 
accurately predict the patient who will suffer serious toxicity. The 
high rate of potentially serious side-effects limits the use of these 
drugs to the most severe inflammatory disease both because of the high 
risk:benefit ratio and also because of the logistic problems of close 
monitoring : - it has been calculated that, in the first 6 months of 
treatment (even allowing for a high drop out rate), 100 patients (50 
gold, 50 d-penicillamine) would require 1,340 clinic visits for blood 
and urine checks and even if shared care with the general practitioner 
is carried out this represents 470 hospital visits (139).
A drug which has a low total incidence of side-ef fects with no need 
for close blood or urine monitoring, no or very few serious side- 
effects and an effective method of identifying patients at risk or 
toxicity would therefore be a useful addition to the second line 
armamentareum.
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chapter 2 
Summary
Second line antirheumatic drugs are characterised by the production of 
improvement in both clinical and laboratory parameters of inflammation 
These effects may take weeks or months to develop and may remain for 
similar periods after treatment is stopped. They may also retard 
disease progression. Their mode of action is unknown.
Numerous clinical and laboratory measurements are available for the 
assessment of drug activity but no one single measurement can be used 
to assess disease activity. Measurements can be classified as process 
measurements or as outcome measurements. There is a multiplicity of 
available process measurements. A number of these should be used in 
conjunction to try to give an overall view of disease activity and a 
number of cumulative indices have been designed with this aim. 
Outcome measurements comprise functional indices (the newest 
generation of which are not yet properly validated) and radiological 
assessment. The effect of current second line drugs on radiological 
progression is slight and prolonged follow up of a large number of 
patients is required. Both methods also suffer from the impossibility 
of maintaining adequate long term control groups.
Currently available second line agents all have serious drawbacks in 
terms of toxicity and patient tolerance and the addition of another, 
perhaps less toxic, agent to this list would be of practical use.
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CHAPTER 3
Recent clinical studies of sulphasalazine in rheumatoid arthritis and 
an outline of the proposed aims of this thesis.
Section 1 Recent studies of sulphasalazine in rheumatoid 
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2.1 Proposed aims of thesis
2.2 Outline of individual studies
Summary
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Section 1
Recent studies of sulphasalazine in rheumatoid arthritis.
After the initial spate of interest and publications on sulphasalazine 
in the 1940s there followed a 30 year silence. In 1978, however, 
interest was renewed when McConkey et al re-investigated 
sulphasalazine following the observation that it had similarities in 
its spectrum of clinical activities to dapsone which, although 
effective in the treatment of rheumatoid arthritis, is of little 
practical use in this condition because of its toxicity. They 
described an open study of sulphasalazine in rheumatoid arthritis (8). 
In this study 32 patients were given sulphasalazine in a dose of up to 
3g/day and results at 22 weeks were described. Twenty-two patients 
completed this period of follow-up. Significant improvement in CRP 
and clinical score was seen by 6 weeks and in ESR by 12 weeks. These 
improvements were maintained over the twenty-two weeks. Seven 
patients had stopped because of side effects (2 dyspepsia, 4 headache 
and 1 neutropenia). In a second publication 2 years later (9) this 
series was extended to 74 patients and follow-up was extended to 50 
weeks. Patients were started on O.Sg/day and the dose was gradually 
increased to a usual dose of 2g/day. Thirty-eight patients continued 
treatment for 50 weeks and again there was significant improvement in 
clinical score, CRP and ESR. It is difficult to comment upon the 
pattern of toxicity in this paper because of the inclusion of patients 
from the first study although it is recorded that 5 patients developed 
megaloblastic anaemia. Bird et al (140) exposed sulphasalazine to the 
rigours of their correlation matrix (64) and suggested that it has 
second line properties.
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Simultaneous with the publication of study 1 described in the next 
section there appeared a joint study from Leeds and Birmingham which 
compared, in a double blind fashion, 31 patients allocated randomly to 
sulphasalazine and 32 to d-penicillamine. Twenty-three patients 
completed 16 weeks sulphasalazine therapy and after 16 weeks both 
drugs produced significant improvement in inflammatory indices and no 
serious toxicity was seen in the sulphasalazine treated patients 
(141).
Subsequent to completion of the relevant work in this thesis the 
results of a study comparing 27 sulphasalazine (2g/day) and 29 placebo 
treated patients were published in abstract form only. This study 
showed a significant improvement in the sulphasalazine treated 
patients (142).
More recently 3 uncontrolled longer term follow-up studies of 
sulphasalazine have been published comparing this drug to sodium 
aurothiomalate, penicillamine and dapsone (143) to penicillamine (144) 
and to sodium aurothiomalate (145). All 3 studies confirmed the 
efficacy of sulphasalazine in rheumatoid arthritis. Because of the 
chronological relationship of these studies to this present thesis 
they will be discussed more fully in the appropriate chapters.
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Section 2
Aims and outline of studies
2.1 Proposed aims of the thesis
My aims in this thesis are:-
(1) To test, by means of a double blind placebo controlled
trial, the hypothesis that sulphasalazine displays second 
line properties in the treatment of rheumatoid arthritis.
If this hypothesis is true my subsequent aims are:-
(2) To document the toxicity of sulphasalazine in rheumatoid
arthritis and to investigate the relationship of a number of 
variables including dose, serum levels, age, disease 
duration, previous therapy, acetylator phenotype and disease 
activity to the efficacy and toxicity of sulphasalazine in 
rheumatoid arthritis.
(3) To define the single dose pharmacokinetics of sulphasalazine
in elderly rheumatoid patients and to relate drug handling 
to toxicity.
(4) By means of (2) and (3) to attempt to define the optimal
clinical use of the drug in rheumatoid arthritis.
(5) To examine, as a possible mode of action, the effect of
sulphasalazine (a non thiol containing drug) on the free 
radical scavenging system. This is of particular importance 
as many second line drugs affect this system and it is 
thought that modification of free radical scavenging
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mechanisms by a second line drug may be a function of 
available thiol groups provided by the drug.
(6) To identify the active therapeutic moiety of sulphasalazine
in an attempt to separate efficacy from toxicity and, by 
knowledge of the individual action of the two components, 
perhaps also to comment further upon the possible 
aetiopathogenesis of rheumatoid arthritis.
2.2 Outline of individual studies
In an attempt to fulfil the above aims I have designed the following
studies :-
(1) A double blind placebo controlled trial of sulphasalazine
with the additional use of a sodium aurothiomalate treated 
group as a "positive control" (30 patients per group).
(2) A comparison of sulphasalazine 1.5g/day with sulphasalazine
3.0g/day (30 patients per group). In this study serum 
levels of sulphasalazine and its metabolites will also be 
measured in an attempt to relate these levels to dose and 
efficacy.
(3 ) A comparison of a group of slow acetylators allocated to
sulphasalazine 1.5g/day and a group of fast acetylators 
allocated to sulphasalazine 3.0g/day (60 patients in total).
(4 ) A single dose pharmacokinetic study of 8 elderly patients.
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(5) A comparison of 30 patients treated with sulphapyridine 
alone and 30 patients treated with 5-aminosalicylic acid 
alone.
(6) Serial measurement of intra- and extra-cellular thiol levels 
and intracellular superoxide dismutase activity in an 
unselected subgroup of the above sulphasalazine treated 
patients.
(7) Documentation of acetylator phenotype in all sulphasalazine 
treated patients and analysis of its relationship to 
efficacy and toxicity.
(8) Analysis of the influence of age, sex, disease duration, 
previous therapy and activity of disease in the above 
patients on efficacy and toxicity of sulphasalazine.
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Summary 
Chapter 3
Following a 30 year period of disuse in rheumatology, sulphasalazine 
was resurrected in 1978 when an open trial suggested it had the 
characteristics of a second line drug. Further open studies had 
similar findings but no placebo controlled studies were published. 
Subsequent to completion of the controlled study described in Chapter
4 a number of further studies were published which confirmed the
second line activity of sulphasalazine.
The aims of this thesis are to:-
(1) show by means of a placebo controlled study whether 
sulphasalazine has a second line effect
(2) to investigate the effect of several variables on efficacy 
and toxicity of the drug
(3) to investigate the pharmacokinetic profile of sulphasalazine
in an elderly rheumatoid population
(4) to use this information to define the optimal clinical use
of sulphasalazine
(5) to examine the effect of sulphasalazine on scavengers of
oxygen derived free radicals
(6) to identify the active therapeutic moiety of sulphasalazine.
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Studies of efficacy and toxicity of sulphasalazine in rheumatoid 
arthritis.
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Section 1
Introduction
To date there has been no placebo controlled trial of sulphasalazine 
as a second line agent in the treatment of rheumatoid arthritis. In 
this section I describe the results of such a study. The effect of 
sulphasalazine is compared to that of sodium aurothiomalate and 
placebo in the treatment of rheumatoid arthritis over a one year 
period. In addition the results of a further three studies (Studies 
2, 3 and 4) which were designed to investigate the effect of a number
of variables such as age, acetylator phenotype and dose are described 
only in as much as they are relevant to the overall pattern of 
toxicity and efficacy. The effects of these and other variables on 
toxicity and efficacy of sulphasalazine are described in subsequent 
chapters.
Section 2
Patients and Methods
2.1 Selection of patients
Criteria for selection of patients were similar in all studies. All 
had classical or definite rheumatoid arthritis (146) which remained 
clinically active (ie, the patient complained of severe pain and/or 
stiffness and had clinical evidence of synovitis) despite the optimum 
use of first line drugs and analgesics. All patients remained on 
first line drugs throughout the studies (except where they stopped 
them spontaneously because they no longer felt they needed them). In 
addition patients in Study 4 had to be 65 years of age or over.
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Criteria for exclusion from the studies are listed below:-
a) Patients who had previously received sulphasalazine (in study 1, 
also patients who had previously received gold salts).
b) Patients who were receiving corticosteroids or who had received 
such drugs in the 3 months preceding entry to the trial (except 
study 4).
c) Patients who were receiving second line drugs or had received 
such drugs in the 3 months preceding entry to the trial (except 
study 4).
d) Pregnant or breast feeding females and patients (males and 
females) actively attempting to produce a family.
e) Patients with known sulphonamide or aspirin sensitivity.
f) Patients with known malabsorption or liver disease.
All patients in Studies 1, 2 and 3 gave their informed verbal consent 
and in Study 4 written consent was obtained. The permission of the 
local Ethics Committee was obtained in all studies.
2.2 Drugs and dosages
In study 1, 90 patients were randomly allocated to sulphasalazine, 
3g/day, sodium aurothiomalate or placebo (30 patients per group). In 
study 2, 60 patients were randomly allocated to sulphasalazine
1.5g/day or sulphasalazine 3g/day (30 patients per group). In study 
3, acetylator phenotype was assessed before entry and slow acetylators 
were given sulphasalazine 1.5g/day while fast acetylators were 
allocated to sulphasalazine 3.0g/day (40 fast acetylators, 20 slow 
acetylators). In study 4, 8 patients aged 65 or over were given 2 
single oral doses of sulphasalazine 2g or 3g, 1 week apart for
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pharmacokinetic measurements. One week after the second dose patients 
were commenced on a therapeutic dosage regimen aiming at 3g/day.
Patients allocated to sulphasalazine were initially given 0.5g/day 
enteric coated sulphasalazine orally (Salazopyrin EN 0.5g, Pharmacia) 
and the dose was increased by weekly increments of 0.5g/day to the 
allocated dose of 1.5g or 3g in 3 divided doses. Patients were 
advised to take their medication after food. If dose related toxicity 
occurred, patients were maintained on the maximum tolerated dose 
provided this was greater than Ig/day. In studies 2, 3 and 4 patients 
were allowed prochlorperazine in a dose of up to lOmg t.i.d. for 
nausea and/or vomiting.
Placebo tablets identical in appearance to sulphasalazine were used. 
They were given in a dosage regimen equivalent to sulphasalazine 
3g/day.
Sodium aurothiomalate (Myocrisin, May & Baker) was given by 
intramuscular injection. On the first occasion a lOmg test dose was 
administered and, in the absence of adverse reactions, 50mg was given 
weekly until a clinical response was achieved. The frequency of 
injections was then gradually reduced with the eventual aim of 
maintaining each patient on 50mg each 4-6 weeks. If no clinical 
response was achieved by the time a total of Ig (20 injections) had 
been given therapy was discontinued.
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2.3 Blinding
Patients and physician in study 1 were unaware whether the tablets 
contained sulphasalazine or placebo. Placebo tablets were not given 
to the sodium aurothiomalate group nor were placebo injections given 
to the tablet treated patients. Patients and physician were, 
therefore, aware whether the patients were receiving tablets or 
injections. The metrologist (clinical research nurse) carrying out 
the subjective and semi-objective measurements and the various 
laboratories involved with measurement were unaware of the nature of 
the patient's treatment. In studies 2 and 3 patient and physician 
were aware of the dose given but again neither the metrologist nor the 
laboratories were aware of the dose.
The design of the 4 studies is summarised in Table V.
2.4 Toxicity monitoring
A full blood count, including platelet count, was performed at the 
time of each injection in all patients treated with sodium 
aurothiomalate and the urine was checked for the presence of blood or 
protein using a "multistix". In study 1 sulphasalazine and placebo 
treated patients had these measurements carried out at 6 weekly 
intervals. In subsequent studies these parameters were measured 
fortnightly for the first 12 weeks and thereafter 6 weekly. All 
patients had "liver function tests" [serum alanine transaminase (ALT); 
aspartate transaminase (AST); alkaline phosphatase and bilirubin] and
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urea and electrolytes" measured every 6 weeks for the first 24 weeks 
and subsequently 12 weekly. In addition at each visit patients were 
asked to report adverse events and were asked specifically if they had 
developed skin rash or mouth ulcers.
2.5 Withdrawal from therapy
Table VI shows criteria used for withdrawal from therapy. No hard and 
fast rules were used to indicate withdrawal of therapy and the final 
decision was left to "clinical judgement". Patients were strongly 
encouraged not to stop treatment because of inefficacy before week 24. 
Patients could, of course, insist on withdrawal at any time.
2.6 Assessment of efficacy
Measurements were carried out before treatment, at 6 weekly intervals 
for the first 24 weeks and, thereafter 3 monthly. Functional index 
questionnaire was repeated after 1 year.
Efficacy was assessed in all patients receiving therapy at a 
particular time point even if those patients discontinued therapy at 
that visit. Thus the number of patients in whom efficacy was assessed 
is occasionally greater than would seem apparent from the drop-out 
tables.
All clinical assessment was carried out "blind" by a single clinical 
metrologist (a qualified nurse who has been specially trained in 
measurement techniques).
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(1) WBC < 4 X 10^/1
(2) Platelets < 150 x 10^/1
(3) Haematuria/proteinuria > trace (sodium aurothiomalate)
(4) Skin rash
(5) Mouth ulceration
(6) Abnormality in serum transaminases
(7) Any other adverse events which were likely to be due to
drug therapy and which were either potentially dangerous 
or too severe to allow continuation of therapy
(8) Failure to respond or loss of response despite optimum
dosage (discouraged during the first 24 weeks of all 
studies)
Table VI Criteria for withdrawal from therapy
Articular index (AI)
Ritchie articular index was used. Each of 26 joints or groups of 
joints were scored on a scale of 0-3 depending upon the patient's 
reaction to firm digital pressure. This gives a maximum possible 
score of 78 (83).
Pain score (PS)
Patients were scored from 0-4 on a 5 point descriptive pain scale. 
Using this method a pain score is described as follows:- 0 = no pain, 
1 = mild pain, 2 = moderate pain, 3 = severe pain, 4 = very severe 
pain (89).
Duration of morning stiffness/limbering up time (LUT)
Patients were asked to recollect the duration of morning stiffness on 
the day before assessment.
Hand grip strength
This was measured using a canvas covered rubber bag measuring 9cm by 
17 cm attached to an anaeroid manometer and inflated to 20mm Hg. 
Three measurements were taken for each hand and the mean value 
calculated.
Functional index (FI)
In studies 1 and 2 functional index as described by Mitchell et al 
(147) was used. This index has been used in a previous second line
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study in the Centre for Rheumatic Diseases and has been found to 
change with successful second line treatment (Capell H A, Personal 
Communication). This functional index consists of an administered 
questionnaire (Appendix I) and is applicable only to females. 
Correlations between the functional index measurements carried out in 
these studies and various process measurements are shown in Table VII. 
A similar pattern was seen when change in functional index was 
correlated with change in inflammatory parameters.
Laboratory indices
The following laboratory indices of inflammation were measured; 
Westergren erythrocyte sedimentation rate (ESR) , haemoglobin level 
(Hb) , platelet count, Rose Waaler titre (RF), immunoglobulins G, A and 
H (IgG, IgA, IgM) total serum globulins and total serum albumin. 
These measurements were all carried out by the routine haematology, 
biochemistry and immunology laboratories at Glasgow Royal Infirmary, 
Gartnavel General Hospital and the Western Infirmary, Glasgow.
In study 3 C-reactive protein (CRP) levels were measured by the 
biochemistry department of Gartnavel General Hospital by an immuno- 
nephelometric method using a Beckman auto-analyser and reagents. In 
study 3, serum B12 and folate and red cell folate were measured at 6 
weekly intervals and, in an attempt to identify intravascular 
haemolysis, urine haemosiderin was also measured on these occasions.
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Erythrocyte sedimentation rate 
(ESR)
-0.26 < 0.05
Haemoglobin (Hb) 0.18 > 0.05
Platelet count (Plats) -0.06 > 0.05
Rose Waaler titre (Rf) -0.08 > 0.05
Articular index (AI) -0.43 < 0.001
Pain score (PS) -0.44 < 0.001
Grip strength 0.58 < 0.001
Limbering up time (LUT) -0.52 < 0.001
Albumin 0.32 < 0.01
Globulins -0.14 > 0.05
IgA -0.35 < 0.005
IgG -0.19 > 0.05
IgM -0.22 > 0.05
Disease activity index (DAI) -0.53 < 0.001
Table VII Correlation (Spearman Rank) of all values for
functional index (Studies 1 and 2) with 
inflammatory indices (n =88).
Disease activity index
A disease activity index (DAI) based on that of Mallya and Mace (122) 
was calculated. This was modified from the original in a number of 
ways.
1) The pain score based on division of a visual analogue scale into
4 equal segments was replaced by gradation of the five point pain
score as follows;- No pain/mild pain = 1; moderate pain = 2;
severe pain = 3; very severe pain = 4.
2) The score was expressed as a total out of a possible maximum of
24 rather than converted into a mean score out of 4 and then
classified into 4 disease activity groups as described by Mallya 
and Mace.
To validate these alterations, DAI from patients in study 1 was 
correlated with individual inflammatory parameters and was shown to 
correlate well with most of these (Table VIII).
2.7 Statistical analysis
This was carried out using the relevant non-parametric statistical 
tests (148). All tests were two tailed. Where statistical analysis 
was carried out by computer, an SPSS package was used. Further 
information on statistical analyses is contained in Appendix 2. The 
protocols of studies 1, 2 and 3 stipulated that statistical assessment 
was to be carried out at 24 weeks. Having analysed the 24 week data 
first and drawn appropriate conclusions from these, earlier and later 
data were subsequently analysed to define more fully the rate of onset 
and duration of drug action.
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Erythrocyte
sedimentation rate (ESR)* 0.646 < 0.001
Haemoglobin (Hb)* -0.53 < 0.001
Platelet count (Plats) 0.37 < 0.001
Rose-Waaler titre (RF) 0.0358 > 0.05
Articular index (AI)* 0.57 < 0.001
Pain score (PS)* 0.66 < 0.001
Grip strength* -0.49 < 0.001
Limbering up time (LUT)* 0.63 < 0.001
IgA 0.026 > 0.05
IgG 0.48 < 0.001
IgM 0.33 < 0.001
Total globs 0.4 < 0.001
Albumin -0.45 < 0.001
Alkaline phosphatase 0.03 > 0.05
Functional index -0.52 < 0.001
* individual components of DAI
0.
Table VIII Correlation of modified Mallya-Mace Index [Disease
activity index (DAI) ] with other inflammatory indices 
at times 0, 6 wks, 12 w)cs, 24 wks, 48 wks in
sulphasalazine, sodium aur/thiomalate and placebo 
groups (n = 307) (Spearman rank correlation)
Section 3
Results
3.1 Study 1
Patient characteristics at the start of study 1 are shown in Table IX. 
No significant difference could be demonstrated between the treatment 
groups in respect to demographic or inflammatory indices at the 
commencement of the study (Kruskal-Wallis one-way analysis of variance 
p > 0.05). There was, however, a trend towards more inflammatory 
disease in the group allocated to sulphasalazine therapy.
After 24 weeks 18 patients remained both on sulphasalazine and sodium 
aurothiomalate whereas 14 remained on placebo. By 48 weeks these 
figures had fallen to 12, 12 and 6 respectively. Toxicity was the 
most common reason for withdrawal from both sulphasalazine and sodium 
aurothiomalate whereas most patients who stopped placebo did so 
because of inefficacy. Table X gives the exact times and reasons for 
discontinuing the various treatments and Figs VIII and IX display this 
information graphically. Using life table analysis and log rank test 
(appendix 2) discontinuation of drug because of inefficacy occurred 
more frequently in the placebo group (X = 8.71, p < 0.01) than in 
the sulphasalazine group. Patients on sulphasalazine and patients on 
sodium aurothiomalate showed significant improvement (Wilcoxon 
matched-pairs signed-ranks test) in inflammatory indices at 24 weeks 
In many cases this improvement occurred as early as 6 weeks and this 
improvement persisted to at least 48 weeks. No such improvements were 
seen with placebo patients. Tables XI, XII and XIII show median 
values and ranges for inflammatory parameters and several possible
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SULPHASALAZINE 
V PLACEBO
SODIUM SULPHASALAZINE V
AUROTHIOMALATE SODIUM
V PLACEBO AUROTHIOMALATE
ESR <0.01 <0.005 NS
Hb NS NS NS
Plats <0.05 NS NS
RF NS NS NS
AI <0.01 <0.05 NS
LUT <0.001 <0.05 NS
Pain score NS <0.05 NS
Grip
strength NS NS NS
DAI <0.05 <0.001 NS
FI - - - ,
IgA NS NS NS
igG NS NS NS
IgM <0.05 <0.05 NS
Total globs <0.05 NS NS
Alb <0.05 NS NS
AST NS NS NS
ALT NS NS NS
Alkaline
Phosphatase <0.05 NS NS
MCV NS NS NS
Creatinine NS NS NS
Table XV Study L Percent change in indices (wk 0 - 24) Mann-
Whitney ü test - p values (NS = not significant; p >
0.05).
SULPHASALAZINE 
V PLACEBO
SODIUM
AUROTHIOMALATE 
V PLACEBO
SULPHASALAZINE
SODIUM
AUROTHIOMALATE
ESR <0.05 <0.05 NS
Hb NS NS NS
Plats NS NS NS
RF NS NS NS
AI <0.05 NS NS
LUT <0.001 <0.05 NS
Pain score NS <0.05 NS
Grip
strength NS NS NS
DAI <0.005 <0.05 NS
FI * * NS
IgA NS NS NS
IgG NS NS NS
IgM NS NS NS
Total globs NS NS NS
Alb NS NS NS
AST NS NS NS
ALT NS NS NS
Alkaline
Phosphatase NS NS NS
MCV <0.01 NS <0.05
Creatinine NS NS NS
Table XVI Study L Percent change in indices (Wk 0 - 48) Mann-
Whitney U test - p values (NS = not significant; p > 
0.05).
* = analysis could not be carried out because of 
inadequate numbers remaining in placebo group
Age (yrs)
Disease Duration (yrs) 
ESR (mm/hr)
Hb (g/dl)
Platelets (x 10^/1)
Rheumatoid factor titre 
(Rose Waaler)
Articular index
Limbering up time (mins)
Pain score
Grip strength (mmHg)
DAI
Functional index 
IgA (g/1)
IgG (g/1)
IgM (g/1)
Total globs (g/1)
Albumin (g/1)
AST (u/1)
ALT (u/1)
Alkaline Phosphatase 
(u/1)
MCV (fl)
Creatinine (umol/1)
ALLOCATED DOSE
I.5g/day
57 (30-69)
7 (1-30)
54 (12-130)
II.9 (8.9-15.6) 
353 (203-798)
1/64 (0-1/1024) 
23 (2-57)
112 (0-all day) 
3 (1-4)
80 (45-190)
17 (12-21)
49 (21-79)
3.8 (1.8-5.7)
12.8 (9.0-19.2)
1.2 (0.5-3.0)
32 (23-42)
38 (32-44)
17 (6-28)
11 (4-25)
232 (92-530)
82 (68-98)
65 (40-108)
3g/day
54.5 (28-71)
12 (1-22)
68 (17-140)
11.3 (8.6-17.0) 
425 (227-888)
1/64 (0-1/1024) 
19 (3-61)
67 (0-all day)
3 (1-4)
83 (44-140)
17.5 (12-23)
55 (8-82)
3.2 (0.8-7.1)
13.9 (6.6-40.2)
1.3 (0.7-7.0)
35 (24-56)
37 (25-44)
16 (8-28)
13 (5-30)
219 (24-880)
82 (67-94)
70 (50-217)
Table XVII Study 2. Demographic and inflammatory indices at 
commencement of study.
to 18 and 17 respectively. Table XVIII shows the reason for and the 
week of discontinuing therapy. Of the 18 patients initially allocated 
to 1.5g/day who remained on treatment at 48 weeks, 13 were receiving 
their allocated dose and 5 were receiving a higher dose (two 2.0g; 
three 3.0g). Of the 17 patients still on treatment at 48 weeks who 
were initially allocated to 3.0g/day, 12 were receiving this dose, 
whereas 3 were receiving lower doses (one 1.5g/day, one 2.0g/day and 
one 2.5g/day) and 2 were receiving a higher dose (both 4.0g/day).
Patients who were receiving doses in excess of the allocated dose were 
doing so because the allocated dose failed to adequately control their 
disease. Those patients who were receiving a dose lower than the 
allocated dose were doing so because of dose related toxicity.
Tables XIX and XX show median values and ranges for inflammatory 
indices and some indicators of toxicity over the 48 week follow-up 
period. Similar changes were found irrespective of whether the 
results were analysed by actual dose or by allocated dose and the 
results are therefore presented as allocated dose. Once more there 
was an improvement in some indices as early as 6 weeks and this was 
expanded and consolidated at later assessments. The relationship of 
dose to efficacy and toxicity will be explored in Chapter 5.
3.3 Study 3
In this study the 40 fast acetylators were allocated to 3.0g/day and 
the 20 slow acetylators to 1.5g/day. The role of acetylator phenotype 
will be discussed in Chapter 6 and only efficacy and toxicity aspects 
of this study will be further described at present. The follow-up 
period in this study was confined to 24 weeks. Table XXI shows the
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1.5g/day 
(n = 20)
3g/day 
(n = 40)
Age (yrs) 50.5 (40-73) 52.5 (35-73)
Disease Duration (yrs) 10.0 (2-25) 8.5 (1-33)
ESR (mm/hr) 37.5 (2-125)** 73 (10-150)
Hb (g/dl) 12.3 (7.4-16.1)** 11.4 (7.8-16.6)
Platelets (x 10^/1) 355 (118-607) 421 (126-802)
Rheumatoid factor titre 
(Rose Waaler) 1/256 (0-1/1024) 1/512 (0-1/1024)
Articular index 17.5 (2-39) 16 (0-39)
Limbering up time (mins) 120 (0-all day) 76 (0-all day)
Pain score 2.4 (1-4) 2.7 (1-4)
Grip strength (mmHg) 67.5 (39-167) 83.5 (38-190)
GRP (ug/1) 25.5 (<6.0-40.1)* 40.5 (<6.0-100)
DAI 15 (13-21) 17 (13-22)
IgA (g/1) 3.1 (1.2-6.3) 3.2 (0.3-6.5)
IgG (g/1) 12.3 (9.3-23.6) 14.4 (6.2-24.4)
IgM (g/1) 1.1 (0.6-3.7) 1.4 (0.4-9.9)
Total globs (g/1) 32 (21-48) 35 (26-52)
Albumin (g/1) 38 (35-43) 38 (24-48)
AST (u/1) 13 (6-21)** 18 (10-39)
ALT (u/1) 12 (4-31) 15 (3-40)
Alkaline Phosphatase 
(u/1) 212 (102-380) 255 (89-830)
Table XXI Study 3. Demographic and inflammatory parameters at 
commencement of treatment ~ median (ranges)
*Wilcoxon p<0.05; **Wilcoxon p<0.01 - 1.5g v 3.0g
1.5g/day 3g/day
(n = 20) (n = 40)
MCV (fl) 85 (71-102) 81 (65-93)
Serum (P9/ml) 274 (115-720) 303 (82-835)
Serum folate (ng/ml) 2.3 (1.5-4.9) 2.5 (1.1-6.0)
RBC folate (ng/ml) 181 (85-254) 163 (5-247)
Creatinine (umol/1) 70 (45-130) 70 (40-18
Table XXI Study 3. Demographic and inflammatory paramaters at
(Cont) commencement of treatment - median (ranges)
*Wilcoxon p<0.05; **Wilcoxon p<0.01 - 1.5g v 3.Qg
starting characteristics of the patients. Unfortunately the slow 
acetylator/low dose patients entered the study with significantly 
lower ESR (Mann-Whitney p < 0.01) and CRP (Mann-Whitney p < 0.05) and 
a higher haemoglobin level (Mann-Whitney p < 0.01). Other 
inflammatory parameters showed no statistical difference.
Reasons for and time of drop out are shown in Table XXII. After 24 
weeks 15 (75%) of those allocated to low dose and 27 (68%) of those 
allocated to high dose remained on treatment. Of those allocated to 
low dose, one was temporarily off treatment, 9 were receiving 
1.5g/day, 3 were receiving 2g/day and 2 were receiving 3g/day at 24
weeks. Of the 27 patients allocated to 3g/day, who continued 
therapy to week 24, 14 were receiving this dose, 5 were receiving 
4g/day and 8 were receiving lower doses (one Ig/day, three 1.5g/day, 
two 2g/day, two 2.5g/day).
Tables XXIII and XXIV show the changes in disease activity and some 
indicators of toxicity. A general pattern of improvement is again 
seen in the 3g/day group but in this instance this is not as apparent 
in the lower dose group. The relevance of this will be discussed in 
Chapter 6. Urine was positive for haemosiderin in only 3 patients and 
in no instance was its presence associated with frank clinical 
haemolysis. A further 2 patients had positive test for haemosiderin 
before but not during treatment.
3.4 Study 4
Following the initial pharmacokinetic part of the study the 8 elderly 
patients were commenced on a therapeutic regimen of sulphasalazine 
(3g/day). Four patients had to stop early because of upper
80
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gastrointestinal symptoms. Formal clinical indices of disease 
activity were not measured. Patient characteristics are shown in 
Table XXV.
3-5 Total experience with sulphasalazine in rheumatoid arthritis with 
reference to efficacy and toxicity
The studies so far described contain information on one hundred and 
fifty-eight patients with rheumatoid arthritis treated with 
sulphasalazine with a follow-up period of 24 weeks. In an attempt to 
give an overview of this experience Fig X shows the overall drop out 
rate over the first 24 weeks and Fig XI shows the reasons for 
discontinuation of therapy.
One hundred and eight (68%) of patients continued sulphasalazine past 
24 weeks. Of the 108 patients who continued, 19 were receiving a 
lower than allocated dose because of dose related toxicity at their 
allocated dose. Ninety of the 158 patients studied were followed for 
at least 48 weeks and of these 47 (53%) remained on treatment, of whom 
6 were receiving a lower than allocated dose because of dose related 
toxicity.
In total 21 (14%) patients stopped over the first 24 weeks because of 
nausea and/or vomiting, a further 54 experienced the side effect 
without discontinuing therapy and of these 38 managed to achieve their 
allocated dose. In these patients symptoms tended to be transient and 
in general occurred early. Three patients developed a marked rise in 
hepatic enzymes while receiving sulphasalazine; one of these stopped 
the drug simultaneously because of upper gastrointestinal symptoms; 
one was stopped because of the hepatic abnormalities and biopsy showed
81
Patient Age
yrs
Reason for
Discontinuing
therapy
Week of
Discontinuing
therapy
69 Nausea
75 Vomiting
73 Vomiting
79 Nausea and vomiting 6
69
80
78
65
Continued for at 
least 24 weeks
Table XXV Toxicity data on patients in Study 4
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Fig. X Pattern of discontinuation of sulphasalazine theraoy 
over the first 24 weeks (n = 158) .
REASONS FOR DISCONTINUING SULPHASALAZINE DURING FIRST 24 WEEKS 
OF THERAPY, (n =158)
CONTINUED TREATMENT
OTHER
INEFFICACY
MUCOCUTANEOUS
TOXICITY
LEUCOPENIA
NAUSEA/VOMITING
Fig. XI Reasons for discontinuing sulphasalazine therapy over 
the first 24 weeks (n = 158).
drug induced changes (Appendix 3) and the third patient's hepatic 
enzymes were normal when re-checked and in this case transient 
infection or laboratory error would seem the most likely explanations. 
In addition 5 patients showed a mild rise in ALT (maximum 69u/l) and 
3 mild rises in AST (maximum 80u/l) outwith the normal range but 
showed no progressive changes and medication was continued. Overall a 
generalised rise in hepatic transaminases was seen during the study 
(Table XXVI). Although both acute hepatotoxicity (41, 42, 43, 44) and 
hepatotoxicity after many years (45) has been described, no such 
generalised rise in transaminases has previously been reported.
A significant rise was seen in the mean cell volume over the study 
period, however, no patient developed a frank haemolytic anaemia and 
in study 3 (Tables XXIII and XXIV), B12 and folate levels did not 
alter significantly either in the group as a whole, in the sub-group 
of patients who developed an MCV > 96fl or in any individual patient. 
Even in those 28 patients whose MCV rose to > 96fl (the upper limit of 
normal) a significant rise in haemoglobin level was seen by week 24 
(Wilcoxon matched-pairs signed-rank test p < 0.05).
Seven patients (4%) had treatment discontinued because of leucopenia. 
In 5 of these cases total WBC did not fall below 2.0 x 10^/1 but in 2 
cases a profound neutropenia of < 0.5 x 10 polymorphs/1 was found; 
all patients recovered with conservative management. All seven cases 
of leucopenia occurred within the first 12 weeks of treatment and in 
some of these patients, including one of the patients with a profound 
leucopenia, there was a progressive reduction in WBC. Another one 
patient developed thrombocytopenia shortly after stopping 
sulphasalazine because of upper gastrointestinal symptoms.
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Mouth ulcers occurred within 2 weeks of starting treatment in 2 cases 
and in both cases resolved with conservative management after therapy 
was stopped. One of these patients had severe Sjogren's syndrome 
noted before starting sulphasalazine. A further 5 patients stopped in 
the first 24 weeks and one at week 36 because of skin rash. In most 
cases this was raaculopapular in type but in one case the patient 
developed large urticarial lesions on her back. All cleared up with 
discontinuation of therapy. No evidence of persistent proteinuria or 
haeraaturia attributable to sulphasalazine therapy was apparent.
Descriptions of individual patients who developed serious toxicity are 
given in Appendix 3.
Fig XII shows the reasons for discontinuing sulphasalazine therapy 
between weeks 24 and 48. It is apparent that at this stage inefficacy 
is the most common reason for stopping treatment.
Table XXVI shows changes in various indices during 24 weeks treatment 
in 150 patients (this excludes the 8 patients in study 4 for whom 
complete efficacy data were not available). Again, as in individual 
groups a general improvement in most indices is seen. In 8 patients 
the DAI fell to 8 or less which corresponds to Mallya and Mace's 
"inactive" group (122).
Section 4 
Discussion
4.1 Efficacy
A second line drug in the treatment of rheumatoid arthritis is
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n = 61 (68%) n = 47 (53%)
wk 24  ______________________________  wk 48
nausea/vomiting 2
rash 1
inefficacy 10
other 1
Fig. XII Pattern of drop out in Studies 1 and 2 (n — 90) over
the second 24 weeks of treatment.
^  0 ^  24
Age (yrs) 55.7 (28-77)
Disease Duration (yrs) 8.2 (1-57)
ESR (mm/hr) 65 (2-150)) 35*** (2-129)
Hb (g/dl) 11.4 (7.4-17.0) 11.9**** (7.1-17.7]
Platelets (x 10^/1) 395 (118-888) * * * *320 (134-809)
Rheumatoid factor titre
(Rose Waaler) 1/128 (0-1/1024) 1/64 (0-1/1024)
Articular index 19.3 (0-61) 7.2**** (0-33)
Limbering up time (mins) 91 (0-all day))
* * * *
30 (0-all day)
Pain score 2.7 (1-4)
* * * *
1.8 (0-4)
Grip strength (mmHg) 80 (35-190) 91**** (9-245)
DAI 16.9 (12-23) 13.6**** (7-21)
igA (g/1) 3.2 (0.3-7.5) 2.8**** (0.2-7.9)
IgG (g/l) 13.4 (6.2-40.2) 12.1**** (4.3-28.8)
IgM (g/l) 1.25 (0.4-8.7) 1.06**** (0.2-3.4)
Total globs (g/l) 34.5 (21-56) 29.5**** (19-45)
Albumin (g/l) 37.6 (24-53) 40.5**** (34-48)
AST (u/1) 16 (5-39) 19**** (7-301)
ALT (u/1) 12 (3-40) 16**** (5-282)
Alkaline Phosphatase 235 (24-880) 215* (10-850)
(u/1)
MCV (fl) 82 (66-102) 87**** (69-114)
Creatinine (umol/1) 70 (40-217) 75 (42-155)
Table XXVI Clinical, haematological and biochemical indices for
all sulphasalazine treated patients in Study 1, 2 and 3 
who completed 24 weeks' therapy - median (range) 
Wilcoxon V  Wk 0 - *p<0.05; **p<0.01; ***p<0.005;
****p<0.001
characterised by its ability to improve both clinical and laboratory 
indices of disease activity.
In study 1 these criteria were fulfilled by sulphasalazine and by 
sodium aurothiomalate but not by placebo. Both sulphasalazine and 
sodium aurothiomalate produced a similar pattern of improvement in 
these indices and, in the studies where functional index was measured, 
sulphasalazine in a dose of 3g/day also caused significant improvement 
in this outcome measure. Neither sulphasalazine nor sodium 
aurothiomalate (a well proven and widely accepted second line drug) 
produced absolute 24 week values which were significantly different 
from placebo and even at 48 weeks such differences were minimal. This 
apparent discrepancy between intra- and inter-group comparisons is 
discussed below.
In most cases sulphasalazine or sodium aurothiomalate was stopped 
because of side effects whereas significantly more patients stopped 
placebo because of lack of effect. It is likely, therefore, that the 
placebo treated patients who continued therapy were a biased group 
selected on the basis of milder disease activity and therefore able to 
continue on inactive treatment. This is confirmed statistically in 
that the 6 placebo patients who continued treatment to 48 weeks had a 
significantly lower starting ESR and DAI than those who stopped (Mann- 
Whitney Ü Test - p < 0.05), whereas there were no statistically 
significant differences in initial inflammatory parameters between 
those patients on sodium aurothiomalate or sulphasalazine who stopped 
therapy and those who continued therapy (Mann-Whitney p > 0.05). In 
addition, those placebo patients who continued had a significantly 
lower ESR and DAI at week 0 than patients allocated to sulphasalazine
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who continued treatment. This self selection of the patients with 
milder initial disease activity to remain on placebo therapy renders 
the comparison of absolute values for inflammatory parameters between 
the groups of little value and most probably explains the apparent 
paradox of highly significant within group improvements in the active 
treatment groups but an inability to demonstrate, at the time of 
assessment, marked differences between the absolute values for 
inflammatory parameters in the active and placebo treated patients. 
This pattern which consists of a high drop out rate because of 
inefficacy in placebo or inactive groups combined with a failure to 
improve statistically over 24 or 48 weeks in those placebo patients 
who remain on treatment and and inability to demonstrate a significant 
difference between placebo/inactive and active drug groups using 24 or 
48 week values has been seen in a number of other similar studies of 
second line drugs published over the past few years from the Centre 
for Rheumatic Diseases (149, 150, 151) (Tables XXVII and XXVIII). As
patients who discontinue placebo therapy almost invariably commence an 
active drug an "intention to treat" analysis would offer no further 
advantage.
It is quite apparent on examining the pattern of p values in table 
XXVIII which agents are active second line drugs and which are not. 
One could conceivably argue, however, that the reason we do not see 
any major statistical improvement in patients who remain on placebo 
is that, as this group shows a bias towards lower disease activity at 
the outset, there is perhaps little scope for improvement. To test 
this hypothesis I have therefore selected from the 12 sulphasalazine 
patients who achieved 48 weeks treatment in study 1, the 6 patients 
with the lowest ESR, at week 0 (median = 47mm/hour, range = 18-
85
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55mm/hour). Table XXIX shows the pattern of improvement in 
inflammatory indices in these patients and it can be seen that 
although changes in the ESR are not seen, many other inflammatory 
indices do show improvement. Data presented in Chapter 8 from a 
larger number of patients with an initial ESR < 30mmHg confirm this 
finding.
The percent change in the various indices in the 3 treatment groups in 
study 1 has also been analysed (Tables XV and XVI) and again 
significant differences are seen between sulphasalazine and placebo 
groups and between sodium aurothiomalate and placebo groups but not 
between sodium aurothiomalate and sulphasalazine groups. Changes in 
absolute values showed significance but because of possible bias in 
the pattern of drop out this may not be as meaningful. It is also 
perhaps interesting to note that although the only improvement seen in 
the placebo group is in the DAI both the percentage change and final 
value is significantly better in the sulphasalazine and sodium 
aurothiomalate groups. Thus, overall, the evidence is strongly in 
favour of sulphasalazine being a second line agent.
The above findings may also suggest that, provided one uses the 
occasional placebo group and known active drug group as a quality 
control" in one's assessment system, rigidly designed placebo 
controlled trials may not be necessary and, if the differences in the 
pattern of drop out in the placebo group are not appreciated, may be 
frankly misleading.
comparison of sodium aurothiomalate and sulphasalazine groups shows no 
major differences other than perhaps a slightly higher drop out rate 
due to inefficacy and a slightly earlier onset of activity in the
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latter. This does not mean, however, that no difference in the 
of these drugs exists but merely that we would need much 
larger numbers to show this. The power of study 1 to demonstrate a 
significant difference in the change in ESR between sulphaslazine and 
placebo group is 89% (assuming, for the moment, a normal distribution 
for ESR) but only 12.8% to demonstrate a real difference between ESR 
changes for sodium aurothiomalate and sulphasalazine (Appendix 2). 
Such a difference, however, is probably not of practical importance as 
most patients with rheumatoid arthritis, once commenced on second line 
drugs, will require more than one such agent (1) and, as only about 
half a dozen of these drugs exist, all are needed.
In addition to a multitude of "process measurements", functional index 
(an outcome measure) was also assessed. Again this showed a 
statistically significant improvement in the sulphasalazine treated 
groups over 1 year of treatment. The functional index used here 
correlated well with inflammatory indices both in terms of absolute 
values (Table VII) and change over the one year treatment period. 
Such a relationship is important to demonstrate with drug treatment as 
it shows that the usual parameters measured (process measurements) do 
in fact have some bearing upon outcome at least in the short (1 year) 
term.
The other commonly used outcome measurement, namely radiological 
progression, was not assessed because my previous experience suggests 
that large numbers of patients need to be assessed over long periods 
and even then, as the effect of second line drugs is to slow 
deterioration rather than halt or reverse these changes, a large, 
representative, long term placebo group (almost an impossibility) is
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required (125).
4.2 Toxicity
The results shown here suggest that sulphasalazine is not the 
relatively non-toxic second line drug suggested from experience of its 
use in inflammatory bowel disease (6 and Truelove S.C. personal 
communication). At least 3 patients had serious life threatening side 
effects (2 had severe leucopenia and one developed thrombocytopenia 
after discontinuation of therapy). Several more showed leucopenia and 
raised transaminase levels which may have proven equally serious if 
not detected early. Sulphasalazine does, however, hold an advantage 
over other second line drugs in that the serious haematological and 
hepatic toxic effects were all apparent during the first twelve weeks 
of treatment and, therefore, the most intensive monitoring can be 
concentrated over this period. In addition minor changes occurred in 
MCV and transaminases which, although real, appeared to be of little 
clinical significance at 1 year follow up.
No evidence of nephrotoxicity, as is found with other second line 
drugs such as gold salts and penicillamine, occurred with 
sulphasalazine. This would suggest that sulphasalazine may be of use 
in patients who have evidence of proteinuria or haematuria prior to 
treatment but who do require second line drugs, as monitoring would 
prove easier than with most other second line agents.
The most frequent side effect of sulphasalazine was found to be the 
relatively mild one of nausea/vomiting. Methods of dealing with this 
will be discussed in Chapter 8.
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The range of haematological side effects was interesting in that it 
tended to differ from previously published reports in producing a high 
incidence of leucopenia but no evidence of frank haemolysis or of 
megaloblastic anaemia.
The three long term studies which were published after completion of 
the work in this chapter (143, 144, 145) followed a total of 201 
sulphasalazine treated patients (2g/day) over periods ranging from 12 
to 42 months. Only 2 of these patients developed leucopenia, one of 
whom was later diagnosed as having Felty's syndrome and it seems 
likely that the other patient with leucopenia has already been 
described (8, 9). Again in these studies the most common side effect 
necessitating treatment withdrawal was nausea/vomiting (15%). Two of 
these studies, however, showed a high late drop out rate because of 
inefficacy (143, 145) whereas the third (shorter term) study failed to 
confirm this (144). Certainly the finding in my work that 10 (11%) 
patients discontinued therapy between weeks 24 and 48 because of 
inefficacy, would support the finding of a high late drop out rate.
In contrast, of 200 patients commenced on sulphasalazine for 
ulcerative colitis and followed for up to 20 years, 184 remained on 
therapy. Of the 13 who stopped because of side effects 9 stopped 
because of cutaneous toxicity (8 rash, 1 alopecia) , 2 because of
gastrointestinal symptoms, 1 because of dyspnoea and one because of a 
leucopenia with a drop in WBC count from 6.5 x 10 /I to 2.5 x 10 /I. 
The other 3 patients stopped of their own volition as they felt well 
(Truelove S.C. personal communication).
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Section 5
Conclusions
In conclusion data presented in this chapter allow the following
conclusions to be drawn.
1. Sulphasalazine is an effective second line drug in the treatment 
of rheumatoid arthritis.
2. Serious toxicity can occur but tends to occur early. I would 
recommend fortnightly monitoring of full blood count and 
platelets over the first twelve weeks and, thereafter, 6 weekly 
monitoring. In addition liver function tests should be checked 
at weeks 0, 6 and 12 and 12 weekly thereafter. This is
considerably less monitoring over the longer term than is 
required with either gold salts or d-penicillamine.
3. The range of side effects of sulphasalazine is different from 
other second line drugs particularly in respect to the lack of 
evidence of nephrotoxicity.
4. Late drop out because of inefficacy may be a problem.
5. In view of 1), 2) and 3) sulphasalazine is a useful addition to 
the second line armamentareum.
6. Although desirable for the assessment of a drug as a second line 
agent, placebo groups are impractical in the medium term, 
impossible in the long term and may not be strictly necessary.
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SUMMARY 
Chapter 4
Ninety patients with active, definite or classical rheumatoid 
arthritis were randomly allocated to sulphasalazine 3g/day, placebo 
tablets or sodium aurothiomalate. Comparison of sulphasalazine and 
placebo was double blind. At the 24 week assessment using a Wilcoxon 
matched-pairs s i g n e d - r a n k  test, sulphasalazine and sodium 
aurothiomalate but not placebo treated patients showed significant 
improvement in laboratory and clinical indices of inflammation. The 
failure to show such marked differences between groups using a Mann- 
Whitney test is probably explained by the significantly higher drop­
out because of inefficacy in the placebo group which resulted in the 
remaining placebo treated patients suffering initially less active 
disease. Improvement could be seen as early as 6 weeks with 
sulphasalazine but with sodium aurothiomalate similar improvement was 
not seen until the 12 week assessment. Improvement was maintained to 
48 weeks.
Analysis of drug efficacy from subsequent studies primarily designed 
to test other hypotheses confirmed the above findings. Sixty-eight 
percent of patients continued sulphasalazine for at least 6 months and 
53% continued for 1 year. The most common toxic events related to 
sulphasalazine consisted of nausea and/or vomiting but more serious 
haematological and hepatic side effects also occurred.
9 1
CHAPTER 5
Relationship of dose and serum levels of sulphasalazine to its 
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Section 1
Introduction
Chapter 4 has shown sulphasalazine to be an effective second line drug 
in the treatment of rheumatoid arthritis. The rate of drop out 
because of side effects was high. As with ulcerative colitis (23) 
this may be related to the administered dose.
The dose of sulphasalazine used to treat rheumatoid arthritis has 
varied considerably in the various published studies. In her studies 
Nana Svarz used 4-6g/day initially and then reduced to a maintenance 
dose of 1.5~3g/day (2). A similar initial regimen was employed by 
Sinclair and Duthie who settled for a starting dose of 5g/day but 
reduced to a maintenance dose of Ig/day (4).
Recent studies have tended to use either 2g/day (9, 141, 142, 143, 
144, 145) or 3g/day (8, 140) built up gradually over a number of weeks 
and then retained as the maintenance dose.
In study 1, I chose a dose of 3g/day as the aim of this study was to 
investigate sulphasalazine for efficacy and thus the highest of the 
currently used doses seemed most appropriate.
In the treatment of ulcerative colitis it has been shown that the 
higher the dose of sulphasalazine the greater the therapeutic effect. 
The price of the higher dose, however, is a greater incidence of 
adverse effects (23). No direct comparison of differing doses of 
sulphasalazine in the treatment of rheumatoid arthritis has been made 
and there has been no attempt to demonstrate a relationship between 
dose and efficacy or to justify any of the currently used doses.
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To date no data are available on the relationship of blood levels of 
sulphasalazine or its various metabolites to its therapeutic efficacy 
in rheumatoid arthritis. Even in the ulcerative colitis literature 
there are contradictions. Das and co-workers (17) have shown that 
non-responders have lower total sulphapyridine levels than responders 
and that, on increasing the dose in these patients, clinical 
improvement is seen and this is accompanied by rising blood levels of 
total sulphapyridine. On the basis of this observation they suggest 
that the low blood levels of total sulphapyridine allow relapse of the 
disease whereas the higher blood levels produced by an increase in 
dose produce improvement in the disease. An alternative explanation 
of these data has been offered, however, suggesting that lower disease 
activity allows greater absorption of sulphapyridine and thus the 
higher blood levels found in patients with quiescent disease and the 
rise in levels with improvement are an effect rather than a cause of 
reduced disease activity (21). This claim is backed by longitudinal 
data which show no relationship between circulating blood levels of 
any metabolite and the liability to relapse in ulcerative colitis and 
a fall in serum levels of sulphapyridine during a spontaneous relapse 
which is maintained until remission (24).
In view of the possible dose related effects in ulcerative colitis it 
is important to investigate the relationship of dose to efficacy in 
rheumatoid arthritis. Is is also important to investigate t ne 
relationship of serum levels to efficacy as this may prove a useful 
method in choosing the optimum dose and, in addition, may give some 
indication as to the active metabolite of sulphasalazine.
94
In the first part of this chapter I describe the results of a study 
comparing 1.5g/day and 3.0g/day (Study 2).
The second part of the results section describes a subgroup of 
patients in Study 2 in whom blood levels of sulphasalazine and its 
metabolites were measured and related to disease activity.
Section 2 
Patients and methods
Sixty patients with active classical or definite rheumatoid arthritis 
(146) not controlled by first line drugs alone were studied. Patients 
were randomly allocated (30 per group) to enteric coated 
sulphasalazine 0.5g/day rising by weekly increments of 0.5g/day to 
either 1.5g/day (low dose) or 3.0g/day (high dose). All patients 
continued to receive NSAIDs and none received corticosteroids or other 
second line drugs during or in the 3 months prior to the study.
These patients have already been described (Chapter 4 - Study 2) and 
exclusion criteria and methods of assessment were as described 
earlier.
Clinical assesment was carried out "blind" by a single metrologist and 
laboratory assessment was carried out blind in the routine 
laboratories. Percent change in inflammatory indices was calculated 
as described in Chapter 4. Patients were seen for monitoring of full 
blood count and platelet count fortnightly for the first 12 weeks and 
6 weekly thereafter. Liver function tests were checked 6 weekly. 
During the study the patients were given free access to 
prochlorperazine in a maximum dose of lOmg t.i.d. for symptoms of
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nausea or vomiting.
In addition to the above measurements (the results of which will be 
described in the first part of the results section) 44 patients (No 
201"244 inclusive) had serum levels of sulphasalazine and metabolites 
(sulphapyridine and acetylsulphapyridine) measured at 12, 18 and 24 
weeks at which times they could be expected to be in a steady state. 
All samples were taken in the forenoon following an early morning dose 
of sulphasalazine. Samples were allowed to clot at room temperature 
and then centrifuged at SOOOrpm for 15 minutes and the supernatant 
stored at -20°C until analysis. The measurements were carried out by 
Pharmacia GB Ltd using high performance liquid chromatography (152, 
153). The mean serum levels of sulphasalazine and its metabolites 
were calculated for each patient from the 12, 18 and 24 week samples 
as it was felt that by "ironing out" other variables this would give a 
more accurate assessment of steady state levels than would a single 
level and would give the most easily handled representation of the 
serum levels. A crude assessment of "total sulphapyridine" was made 
by summating the sulphapyridine and acetyl sulphapyridine levels. 
Acetylator phenotype was calculated from:-
[acetylsulphapyridine]
% acetylated =      ^ 100%
[total sulphapyridine]
(19) .
These values were related to the two most representative of the 
inflammatory indices, the ESR and the disease activity index (DAI).
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Section 3
Results
3.1 Effect of dose
Table XVII shows the initial indices for the two groups (1.5g/day and 
3g/day). No difference between the groups could be demonstrated with 
respect to age, body weight, disease duration or inflammatory indices 
at week 0 (Mann-Whitney U test p > 0.05). After 24 weeks, 24 (80%) of 
patients allocated to l.Sg/day and 20 (66%) of those allocated to 
3.0g/day remained on sulphasalazine. Table XXX shows the reason for 
and time of discontinuation of therapy over the first 24 weeks.
Prochlorperazine was used by 12 patients (6 allocated to l.Sg/day and 
6 allocated to 3.0g/day). All but 2 of these were able to continue 
sulphasalazine to 24 weeks and 8 of those who continued achieved their 
allocated dose (3 - l.Sg/day, S - 3.0g/day).
Two patients allocated to l.Sg/day received a smaller dose because of 
dose related toxicity and 3 had their doses increased because of 
inefficacy. Two patients allocated to 3.0g/day could not achieve this 
dose because of dose related toxicity (Table XXXI).
Statistical analysis comparing l.Sg/day and 3.0g/day was subsequently 
carried out using both allocated dose and actual 24 week dose but as 
the results are very similar only analysis by allocated dose is 
described here.
Tables IXX and XX show the medians and ranges of inflammatory indices 
at each assessment and also the p value compared to the wk 0 results 
(Wilcoxon matched-pairs signed-rank test). Table XXXII compares both
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Mouth ulcers
Leucopenia
Acute dyspnoea
1.5g/day (n = 30)
Total Week
Stopped
3.0g/day (n = 30)
Total Week
Stopped
Rash 1, 18 11
Nausea/vomiting 4, 5, 12, 22
Lack of effect 24
Other 8, 10 6, 11
10
Table XXX Study 2. Reasonifor stopping sulphasalazine therapy - 
24 week follow up.
Mouth ulcers
Leucopenia
Acute dyspnoea
1.5g/day {n = 30)
Total Week
Stopped
3.0g/day (n = 30)
Total Week
Stopped
Rash 1, 18 11
Nausea/vomiting 4, 5, 12, 22
Lack of effect 24
Other 8, 10 6, 11
10
Table XXX Study 2. Reasonjfor stopping sulphasalazine therapy 
24 week follow up.
Actual
24 week dose
(g/day)
Patients allocated 
to 1.5g/day 
No of patients (%)
Patients allocated
to 3g/day
No of patients (%)
l.Og/day 2 (8%)
1.Sg.day 19 (80%) 1 (5%)
2.Og/day 2 (8%) 1 (5%)
2.5g/day
3.Og/day 1 (4%) 19* (90%)
Table XXXI Study 2. Actual dose of sulphasalazine at 24 weeks for
patients allocated to 1.5g/day and 3.0g/day.
*1 patient in this group discontinued treatment at the 
24 week visit.
1.5g/day 3g/day
n 24 21 P
ESR (mm/hr) 45 (5-129) 24 (7-118) NS
Haemoglobin (g/dl) 12.5 (9.3-15.6) 12.0 (10.2-17.7) NS
Platelets (x 10^/1) 312 (161-475) 341 (224-809) NS
Rose Waaler Titre 1/512 (0-1/1024) 1/512 (0-1/1024) NS
Articular Index 8.5 (0-30) 7 (0-24) NS
Pain score 2 (0-4) 1.5 (0-4) NS
Grip strength (itunHg) 95 (57-215) 95 (57-235) NS
LUT 60 (0-all day) 15 (0-all day) NS
Albumin (g/1) 41 (36-47) 40 (36-45) NS
Globulin (g/1) 31 (23-43) 32.5 (22-45) NS
Aik phos (u/1) 236 (125-780) 195 (10-250) NS
SGOT (u/1) 22 (12-32) 18 (7-80) NS
SGPT (u/1) 17 (6-38) 16 (7-69) NS
IgA (g/1) 3.0 (1.2-7.9) 3.7 (1.2-5.9) NS
IgG (g/1) 12.5 (7.0-22.4) 12.1 (6.5-28.8) NS
IgM (g/1) 1.0 (0.6-2.7) 1.17 (0.6-2.1) NS
Creatinine (umol/1) 75 (50-118) 75 (49-135) NS
Mean cell colume (fl) 87 (72-102) 89 (80-112) NS
DAI 14.6 (9-21) 12.2 (7-18) NS
Table XXXII Study 2. Comparison of inflammatory indices at week 24 
- medians (ranges)“ in patients allocated to 1.5g/day 
and those allocated to Sg.day (Mann-Whitney U test ). 
NS = p > 0.05.
groups in terms of the 24 wk values for inflammatory indices. 
However, platelet count, serum albumin, serum globulins, IgG, IgM and 
DAI did show a significantly greater percentage improvement in the 
3g/day group.
The range of body weights in the patients studied, however, varied 
from 40“91kg. In view of this it is probably more useful to compare 
dose expressed as mg/kg body weight. This figure (using the actual 
dose at 24 weeks) was correlated with both percent change in ESR and 
percent change in DAI over 24 weeks (Figs. XIII, XIV). In each case a 
significant negative correlation was found, ie, the greater the dose 
the greater the fall in ESR and DAI (Spearman Rank correlation rs = - 
0.428 and -0.515 respectively; p < 0.01 for both measurements).
Previous second line studies from this centre have suggested that the 
average expected improvement is around 50% improvement in ESR and 33% 
improvement in disease activity index (Personal communication H A 
Capell). Using these levels of improvement as our standard, patients
receiving in excess of 40mg/kg body weight showed such improvements 
more commonly than those receiving a lower dose (%, = 4.02; p < 0.05 
and = 8.188; p < 0.01 repsectively) (Figs. XV, XVI).
3.2 Effect of serum levels
Of the 44 patients who had serum drug levels measured, complete data 
was available for 29 (10 had stopped treatment before 24 weeks and in 
5 ESR or serum levels were not available for the appropriate 
assessment either because of clotted or missing specimens). Table 
XXXIII shows the medians and ranges for measurements of sulphasalazine 
and its metabolites and their relationship to dose and acetylator
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phenotype. As might be expected there was a close relationship 
between dose and serum levels (Table XXXIV, Figs. XVII, XVIII, XIX). 
In addition slow acetylators on high dose had significantly higher 
sulphapyridine and lower ace tylsulphapyr idine levels than fast 
acetylators on high dose but no difference was seen in the total 
sulphapyridine levels in fast and slow acetylators (Figs. XX, XXI, 
XXII). As in the whole group dose expressed as mg/kg body weight 
correlated with the improvement in ESR and disease activity index. No 
such correlation, however, was seen between serum levels of 
sulphasalazine or its metabolites and percentage change in ESR or 
disease activity index (Table XXXV) (p > 0.05).
Section 4 
Dicsussion
These data would suggest that patients who are allocated to 3g/day 
show a trend towards greater improvement than those allocated to 
1.5g/day. Although this difference only reached statistical 
significance for a few parameters, other measurements showed a similar 
trend; much larger numbers in each group would be required to show a 
definite difference in all indices. Comparison of fixed dose
regimens, however, is a very crude method of assessing the 
relationship between dose and efficacy especially in rheumatoid 
arthritis where some patients might have abnormally low body weight 
due to muscle wasting and others might be overweight due to 
immobility. When dose is expressed as mg/kg body weight the 
relationship between dose and efficacy becomes clearer: only two
measures of disease activity (ESR and DAI) were used in this
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Dose mg/kg with [sulphasalazine) rs = 0.473 ; p <0.01
Dose mg/kg with [unmetabolised sulphapyridine) rs = 0.399 ; p <0. 05
Dose mg/kg withjacetylsulphapyridine) rs = 0.469 ; p <0.01
Dose mg/kg with[total sulphapyridine) rs = 0.552 ; p <0.01
Table XXXIV Study 2. Correlations of dose in mg/kg with serum 
levels of sulphasalazine and its metabolites (Spearman 
Rank) (n = 29).
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Fig. XVII Serum sulphasalazine (SASP) levels in patients
allocated to high dose (3g/day) and low dose 
(1.5mg/day), p < 0.02.
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Fig. XVIII Correlation b e t w e e n  actual 24 week dose of 
sulphasalazine' expressed as mg/kg body weight and serum 
sulphasalazine (SASP) levels (rs = 0.473; p < 0.01).
o Slow acetylator rs = 0.54 p<0.05 
•  Fast acetylator rs = 0.64 p<O.Ü5
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Fig. XIX Correlation between actual 24 week sulphasalazine 
(SASP) dose expressed as mg/kg body weight and serum 
levels of unmetabolised sulphapyridine (SP) ; rs = 0.54; 
p < 0.05 (slow acetylators); rs = 0.64; p < 0.05 (fast 
acetylators).
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Fig. XX Relationship of serum levels of unmetabolised
sulphapyridine (SP) to acetylator phenotype in high and
low dose groups.
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Fig. XXI Relationship of serum levels of a c e t y l a t e d
sulphapyridine (ASP) to acetylator phenotype in high
and low dose groups.
100
80
E 60
O)n
CL
CO
(0
O 40
20
FAST V SLOW - NS
NS
NS
%
high/slow high/fast low/slow low/fast 
Allocated dose/Acelylator phenotype
Fig. XXII Relationship of serum levels of total sulphapyridine
(total SP) to acetylator phenotype in high and low dose
groups.
rs
% change in ESR with SASP levels 0.234 >0.05
% change in ESR with SP levels 0.275 > 0.05
% change in ESR with ASP levels 0.223 > 0.05
% change in ESR with total SP levels 0.285 > 0.05
% change in DAI with SASP levels 0.261 > 0.05
% change in DAI with SP levels ^0.176 > 0.05
% change in DAI with ASP levels 0.116 > 0.05
% change in DAI with total SP levels 0.106 > 0.05
Table XXXV Study 2. Correlation of serum levels of sulphasalazine 
(SASP) and its metabolites sulphapyridine (SP) , 
acetylsulphapyridine (ASP), total sulphapyridine (total 
SP) with percent changes in ESR and DAI.
(Spearman Rank correlation) (n = 29)
correlation but these have previously been shown to be sensitive 
markers of overall disease activity (100, 110, 122). Patients who
received 40mg/kg or more of sulphasalazine per day had a greater 
likelihood of clinically significant improvement in ESR and DAI. It 
is noteworthy that one of the three patients who received more than 
40mg/kg/day and who failed to lower the ESR by more than 50% had the 
lowest sulphasalazine levels measured in this study. This finding 
suggests poor compliance in that individual.
The demonstration of a relationship between dose and efficacy of 
sulphasalazine in rheumatoid arthritis is of the utmost importance as 
otherwise one might be content with a slight improvement in disease 
activity, whereas, armed with this knowledge one could now use a 
higher dose which might produce more marked beneficial effect.
In general, the concept of a direct relationship between dose and 
response to a second line agent is not well recognised in the practice 
of rheumatology and the tendency with second line agents is to expect 
an "all or none" response. Thus, both sodium aurothiomalate and d- 
penicillamine tend to be used in the minimum dose which produces an 
anti-inflammatory effect. The awareness of the possibility of a dose 
response phenomenon with second line agents could therefore be of 
major practical importance and should be more fully investigated with 
other second line drugs.
There was good correlation between dose and serum levels of 
sulphasalazine and its metabolites although such a relationship is not 
necessarily seen in ulcerative colitis (21). The effect of acetylator 
phenotype on serum levels of sulphapyridine and acetyl sulphapyridine 
in the 3.Og/day patients was as previously reported (17, 22, 23, 24)
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and the results in the 1.5g/day patients, although they did not reach 
statistical significance, showed a similar trend. Effect of 
acetylator phenotype on total sulphapyridine levels is more 
controversial and, although my results agree with Schroder et al (22), 
in other studies total sulphapyridine has been lower in fast 
acetylators (17, 23, 24). Despite the good correlation between dose 
of sulphasalazine and levels of sulphasalazine, sulphapyridine, 
acetylsulphapyridine and total sulphapyr idine it was not possible to 
show a relationship between circulating levels of these substances and 
efficacy of sulphasalazine in rheumatoid arthritis. This would 
suggest that perhaps another metabolite of sulphasalazine which
has not been measured (eg, 5-ASA or hydroxysulphapyridine) is the 
active metabolite or alternatively that the concentration of the 
active moiety in the compartment in which it produces antirheumatic 
activity may not be in direct equilibrium with the serum. It has been 
suggested that rheumatoid arthritis is an enteropathic arthropathy 
(154) and thus in addition to more obvious sites such as synovial 
tissue it may be that sulphasalazine or its metabolites exert their 
antirheumatic properties within the gut lumen, the intestinal mucosa, 
the portal circulation, or the liver.
This situation is analogous to the situation in ulcerative colitis 
where circulating levels of sulphasalazine bear no relationship to its 
beneficial effect (23) and although there is a relationship between 
total sulphapyridine levels and activity of ulcerative colitis, this 
is probably due to decreased absorption in the active phase of the 
disease as there is no relationship between total sulphapyridine 
levels and relapse rate (24).
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A similar situation occurs in rheumatoid arthritis with sodium 
aurothiomalate where neither serum gold nor serum thiomalate levels 
relate to the efficacy of the drug (155, 156, 157) and with d-
penicillamine where, again, blood levels correlate with neither 
efficacy nor toxicity (158).
In the present study, patients with nausea and/or vomiting dropped out 
early, and therefore it is not possible from this study to comment 
upon the relationship between circulating levels or acetylator 
phenotype and this side effect. Patients who experienced this 
symptom, however, and who could continue treatment did not show higher 
levels of any measured metabolites although obviously this is a group 
with less severe gastrointestinal symptoms. In study 1, 20% of
patients stopped sulphasalazine because of nausea and vomiting, while 
in this study only 5 (7%) (4 (13%) on 3g.day and 1 (3%) on 1.5g/day)
stopped for this reason. Increased experience with the drug or the 
use of prochlorperazine may have contributed to a decline in the 
number of patients who stopped therapy because of nausea and vomiting.
Although numbers are too small for a meaningful statistical comparison 
there was a trend towards greater toxicity in the high dose group.
Section 5 
Conclusions
In conclusion the efficacy of sulphasalazine in rheumatoid arthritis 
appears to vary directly with dose but not with circulating levels or 
sulphasalazine or its measured metabolites. However, the response to 
this drug does not follow an "all or none pattern. The best way Oi.
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using this drug clinically may be to aim at a high dose (>40mg/kg) and 
to attempt to treat nausea and vomiting symptomatically with 
prochlorperazine and if this fails to reduce the dose of 
sulphasalazine to one which is tolerated. In addition the 
dissociation between serum levels and efficacy suggests a site of 
action which is not in equilibrium with the serum; alternatively one 
of the lesser metabolites, such as 5-ASA, may be active.
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Summary 
Chapter 5
Sixty, patients with active, definite or classical rheumatoid arthritis 
were randomly allocated to sulphasalazine 1.5g/day or sulphasalazine 
3g/day. Significant improvement was seen in inflammatory parameters 
in both groups and no significant difference between groups could be 
demonstrated. When these patients were analysed in terms of dose 
expressed as mg/kg body weight a direct relationship between dose and 
reduction in disease activity was apparent. Patients who received in 
excess of 40mg/kg did significantly better than those who received a 
lower dose. Despite a direct correlation between the dose and serum 
levels of sulphasalazine, sulphapyridine, acetylsulphapyridine and 
total sulphapyridine, no relationship could be established between 
these levels and efficacy.
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CHAPTER 6
Influence of acetylator phenotype on the efficacy and toxicity of 
sulphasalazine in rheumatoid arthritis
Section 1 Introduction
Section 2
2.1
2.2
2.3
Patients and methods 
Retrospective study 
Prospective study 
Toxicity study
Section 3
3.1
3.2
3.3
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Section 1
Introduction
Once sulphasalazine is split in the large bowel, the major metabolic 
pathway followed by the absorbed sulphapyridine involves N- 
acetylation. This is carried out in the colonic mucosa and liver by 
the enzyme N-acetyl transferase (17). The rate of N-acetylation is 
genetically determined and follows a bimodal distribution. 
Individuals can thus be classed as slow (autosomal recessive) or fast 
(autosomal dominant) acetylators (20). The ratio of slow to fast 
acetylators varies between different populations but in the United 
Kingdom approximately 60% are slow acetylators and 40% are fast 
acetylators (159).
In addition to sulphapyridine a number of other drugs which possess an 
aromatic ring and an amino group exhibit acétylation polymorphism. 
These include isoniazid, hydralazine, procainamide, sulphadimidine, 
dapsone, phenelzine and nitrazepam. With many of these agents 
acetylator phenotype affects toxicity and/or efficacy of the drug. In 
general slow acetylators suffer from a higher incidence of side 
effects and fast acetylators derive less benefit although in the case 
of isoniazid hepatitis is commoner in fast acetylators as it is the 
acetylated form which is hepatotoxic (160).
Sulphapyridine metabolites are excreted more rapidly in the urine than 
is the unmetabolised form (10). A number of studies have shown a 
shorter elimination half-life and lower steady state levels of 
unmetabolised sulphapyridine (17, 21, 22, 24) in fast acetylators.
Most studies have also shown a lower total sulphapyridine
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concentration in the serum of fast acetylators (17, 24) although this
relationship is not as clear cut (22) and I have been unable to show 
it in Study 2. There is evidence in normal individuals and patients 
with inflammatory bowel disease that toxicity is seen more commonly in 
slow acetylators (22, 23, 25, 161).
It is thus possible that the rate of acétylation of sulphapyridine may 
influence the toxicity and/or efficacy of sulphasalazine in rheumatoid 
arthritis and, if this is the case, it may be possible to identify a 
subgroup who would benefit from a different approach as regards dosage 
or monitoring.
Acetylator phenotype is determined from calculating the ratio of 
acetylated to total drug in urine or serum either after a single dose 
or in the steady state. A number of protocols have been devised 
(Table XXXVI) and their results appear to correlate well with each 
other (19, 162).
In this chapter I have assessed the influence of acetylator phenotype 
on efficacy in both a retrospective study and, using different doses 
in fast and slow acetylators, in a prospective study. I have also 
compared the toxicity rate between fast and slow acetylators in the 
entire patient group who have been treated with sulphasalazine.
Section 2
Patients and methods
2.1 Retrospective study
Sixty patients were studied retrospectively with respect to acetylator
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phenotype. All patients had been allocated to enteric coated 
sulphasalazine 3g/day and comprised the 30 sulphasalazine treated
patients from study 1 and the 30 patients from study 2 who had been
allocated to 3g/day . Fifty-four patients were available for 
determination of acetylator phenotype. Patients who remained on 
sulphasalazine at the time of assessment of acetylator phenotype had 
this calculated from the urinary ratio of acetylated:total 
sulphapyridine (162) (Study 1) or the serum ratio of acetylated:total
sulphapyridine (19) (Study 2). Those who had discontinued
sulphasalazine but who had not exhibited sulphonamide hypersensitivity 
were typed from a urine sample collected between the 5th and 6th hour 
following a single oral dose of sulphadimidine (159, 162) whereas in 
those patients who exhibited possible hypersensitivity to sulphonamide 
isoniazid was used (163) and the urinary ratio calculated from a 
sample taken between the 6th and 8th hour (Table XXXVI). Assessment 
of drug efficacy was carried out at weeks 0 and 24.
2.2 Prospective study
In this study (Study 3) 60 patients had acetylator phenotype
determined using a single dose of sulphadimidine (162) before 
commencement of- therapy.
Slow acetylators (20 patients) were subsequently allocated to 1.5g/day 
enteric coated sulphasalazine and fast acetylators (40 patients) to 
3g/day enteric coated sulphasalazine. Assessment was, again, carried 
out at weeks 0 and 24. In both studies patients actual dose 
corresponded well to the allocated dose (Table XXXVII).
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2.3 Toxicity study
In total, acetylator phenotype was determined in 149 patients (the 114 
described above, the 8 patients from study 4 and 27 patients from 
study 2 allocated to 1.5g/day in whom acetylator phenotype was 
available). Of the 9 patients in whom acetylator phenotype was not 
available, one had died a non drug related death, one had left the 
area, 4 had refused to cooperate and 3 had equivocal results for 
acetylator phenotype on two occasions making classification 
impossible.
Section 3 
Results
3-1 Retrospective group
Thirty one (57%) of the 54 patients were fast and 23 (43%) slow
acetylators. At week 24, 19 fast and 16 slow acetylators remained on 
therapy. Table XXXVIII shows patient data for each group at weeks 0 
and 24. No significant difference could be demonstrated between the 
groups at week 0 for any parameter (Mann-Whitney U test p > 0.05). 
Both groups showed a statistically significant improvement in most 
parameters over the 24 weeks (Table XXXVIII). No significant 
difference could be seen between the groups either in the percent 
improvement in any of the parameters over the 24 weeks (Mann-Whitney U 
test p > 0.05), in the absolute week 24 values (p > 0.05) or in the 
number of patients who achieved an improvement of > 50% in ESR or of > 
33% in disease activity index (X? = 0.93 and 1.21; p > 0.05 in both 
instances).
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3.2 Prospective study
Table XXI, XXIII and XXIV show the values of various inflammatory 
indices in these patients. Unfortunately the slow acetylator/low dose 
group had significantly lower ESR and CRP and higher haemoglobin at 
week 0 than the fast acetylator/high dose group (Mann-Whitney U test p 
< 0.01 for ESR and Hb and p < 0.05 for CRP) although other parameters 
were comparable.
By week 24, however, this difference in ESR and haemoglobin was lost. 
Tables XXIII and XXIV show the pattern on improvement in the two 
groups over the 24 week period. The fast acetylator/high dose group 
showed a significant improvement in most indices but only the 
articular index in the slow acetylator/low dose group showed 
significant improvement at 24 weeks. In addition the percent change 
in ESR was significantly greater in the fast acetylator/high dose 
group when compared to the slow acetylator/low dose group (Mann- 
Whitney U test p < 0.05) (Fig. XXIII).
3.3 Toxicity study
Acetylator phenotype was available in 149 patients [83 (56%) fast and
66 (44%) slow acetylators]. Table XXXIX shows the reasons for and
time of discontinuing therapy over the first 24 weeks. Twenty-one of
66 slow and 23 of 83 fast acetylators stopped treatment over this
period (X^  = 0.33; p > 0.05). In total 18 stopped because of nausea
2
and/or vomiting, 13 slow acetylators and 5 fast acetylators OC — 
6.23; p < 0.02) (Fig. XXIV).
110
80-1 — "Fast acetylators/High dose 
— xSlow acetylators/Low dose
70-
60-
50-
ESR
(mm/hr)
40-
30-
20-
10-
24
Time - weeks
Fig. XXIII Study 3. Median ESR wks 0 and 24 in fast acetylator/
high dose group and slow acetylator/low dose group.
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Fig. XXIV Reasons for discontinuing therapy in the fast and slow
acetylator groups.
No difference was seen in the percent rise in serum hepatic 
transaminase concentration or mean cell volume between the fast and 
slow acetylators (Mann-Whitney U test p > 0.05).
Section 4 
Discussion
In this study the proportions of slow and fast acetylators (44% and 
56% respectively) are a reversal of those previously described in a 
British population (159). A previous study of acetylator phenotype in 
rheumatoid patients in the West of Scotland showed 72% of the 
rheumatoid patients and 64% of the control group to be slow 
acetylators (164). It is therefore unlikely that the finding of a 
reversed acetylator phenotype ratio in the present study is related to 
geography or the presence of rheumatoid arthritis per se. It is 
possible that there may be some relationship with severity of
rheumatoid arthritis as patients in a second line drug study group 
will tend to have more severe rheumatoid disease. More likely, 
however, it is merely a chance finding.
The questions asked in this chapter are;
1. does acetylator phenotype influence the toxicity of
sulphasalazine in rheumatoid arthritis?
2. does acetylator phenotype influence the efficacy of
sulphasalazine in rheumatoid arthritis?
The answer to the first question appears to be that acetylator 
phenotype does affect the pattern of toxicity of this drug in
rheumatoid arthritis with slow acetylators displaying a greater
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incidence of upper gastrointestinal side effects. This is despite the 
fact that, in the total group of 149 patients, because of the design 
of study 3, there was a preponderance of slow acetylators receiving a 
lower dose which might be expected to reduce the incidence of toxicity 
among the slow acetylators. Although this difference is real it does 
not necessarily imply that the dose of sulphasalazine should be 
limited in slow acetylators as 13 out of 23 (57%) slow acetylators 
allocated to 3g/day, (over 80% of those continuing treatment) achieved 
this dose. The finding of a higher incidence of upper 
gastrointestinal side effects in slow acetylators is in keeping with 
previous studies in non-rheumatoid patients (25, 161). It is
important to document this finding in rheumatoid arthritis, however, 
as in many instances rheumatoid patients are thought to react 
differently to drugs and, in fact, contrary to what one might have 
expected from the non rheumatoid literature (165), rheumatoid patients 
who are slow acetylators react no differently than fast acetylators to 
dapsone (166).
The present study fails to demonstrate any strong relationship between 
acetylator phenotype and potentially serious toxic effects such as 
agranulocytosis.
The answer regarding the relationship of efficacy to acetylator 
phenotype is less clear cut. The retrospective analysis shows no 
clear statistically significant difference between fast and slow 
acetylators and, in fact, not even a trend is apparent. This may 
represent the fact that there is no difference or it may be that a 
dose of 3g/day is too high to allow any subtle difference to be 
demonstrated. It is possible that a difference would show up at a
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lower dose.
In the prospective study the 2 dose regimens were chosen empirically 
on the hypothesis that slow acetylators should require a lower dose 
than fast acetylators to produce similar tissue levels of 
unmetabolised sulphapyridine. The initial difference in objective 
inflammatory indices between the two groups obscures the issue 
somewhat. The fact that this is lost by 24 weeks, however, suggests 
that the fast acetylator/high dose patients have achieved greater 
improvement even though this change from a significant difference 
between groups at week 0 to no significant difference at week 24 over 
the study period may not be as meaningful as a change from no 
significant difference to a significant difference. In addition the 
percent change in ESR was significantly greater in the fast 
acetylator/high dose group. Finally most parameters improved 
significantly at 24 weeks in the fast acetylator/high dose group 
although only articular index showed significant improvement in the 
slow acetylator/low dose group. All of these findings taken together 
would strongly suggest that fast acetylators who receive 3g/day show a 
greater improvement than slow acetylators who receive 1.5g/day despite 
the fact that the elimination half-life of sulphapyridine would be 
expected to be- longer in slow acetylators. This finding is balanced, 
in part at least, however, by the finding that all 5 patients who 
stopped sulphasalazine in the first 24 weeks because of inefficacy 
were fast acetylators.
Another possible confounding factor is that although there is a 
genetic basis for classifying individuals as fast or slow acetylators 
there is a wide spectrum of rate of acétylation within each group and
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it liiay thus be better to regard acetylator phenotype as a continuous 
variable. Such an approach would be impossible here, however, as a 
number of different methods were used to assess acetylator phenotype.
Overall these findings would suggest that acetylator phenotype does 
not play a major part in determining the efficacy of sulphasalazine in 
rheumatoid arthritis although the fact that patients who stopped 
therapy because of inefficacy were all fast acetylators makes this 
conclusion less certain than it might otherwise have been. It would 
appear, however, that if any difference does exist between slow and 
fast acetylators it is small compared to the influence of dose.
Section 5 
conclusions
The data described in this chapter suggest that acetylator phenotype 
is important in determining the incidence of nausea and/or vomiting in 
rheumatoid patients receiving sulphasalazine and that slow acetylators 
display a higher incidence of such side effects. No difference is 
demonstrated between fast and slow acetylators in terms of efficacy 
and, in fact, fast acetylators who receive a high dose appear to do 
better than slow acetylators who receive a low dose. If any 
difference in efficacy does exist between slow and fast acetylators 
this is of minor importance when compared to the effect of dose.
In practical terms, therefore, despite the higher incidence of upper 
gastrointestinal symptoms (a relatively mild side effect) in slow 
acetylators, the absence of a major influence of acetylator phenotype 
on therapeutic efficacy means that even in slow acetylators we should
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aim at the previously recommended dose of 40mg/kg. In the average 
70kg person this is (to the nearest tablet) 3g/day, a dose which over 
80% of slow acetylators who remain on therapy can achieve.
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Summary 
Chapter 6
After absorption the sulphapyridine component of sulphasalazine 
undergoes hepatic metabolism. The major metabolite of sulphapyridine 
is N-acetyl sulphapyridine and the rate of acétylation is genetically 
determined. From experience of other drugs which exhibit genetic 
polymorphism and from experience of sulphasalazine in ulcerative 
colitis it is likely that acetylator phenotype will influence toxicity 
and perhaps efficacy of sulphasalazine in rheumatoid arthritis.
Of the 60 patients in studies 1 and 2 who were randomly allocated to 
sulphasalazine 3.0g/day acetylator phenotype was available in 54. Of 
these 16 slow and 19 fast acetylators completed 24 week treatment. 
Both slow and fast acetylators showed similar improvement in 
inflammatory parameters. A further group of 60 patients had 
acetylator phenotype assessed before treatment ; the 20 slow 
acetylators were allocated to sulphasalazine 1.5g/day while the 40 
fast acetylators were allocated to 3.0g/day sulphasalazine. 
Unfortunately at the outset the slow acetylators had milder disease. 
At 24 weeks, however, improvement in inflammatory indices were 
confined to the.fast acetylator/3.0g/day group and their disease had 
reached the level of activity of the slow acetylator/1.5g/day group.
Of the total group of 158 patients acetylator phenotype was available 
in 149 and of these 66 were slow acetylators and 83 fast acetylators. 
These patients were followed for 24 weeks. Thirteen (20%) of the slow 
acetylators but only 5 (6%) of the fast acetylators stopped treatment 
because of nausea and/or vomiting (X* p  ^ 0.02).  Overall 21 (32%)
116
slow and 23 (28%) fast acetylators discontinued therapy (X^  p > 0,05). 
Acetylator phenotype was, however, unable to predict efficacy or 
serious toxicity. It is therefore not necessary routinely to assess 
acetylator phenotype before commencing sulphasalazine for the 
treatment of rheumatoid arthritis.
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CHAPTER 7
Sulphasalazine in elderly rheumatoid patients 
Section 1 Introduction ,
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Section 1
Introduction
The onset of rheumatoid arthritis commonly occurs in middle age but 
nevertheless may occur in later life. in addition, because of its 
chronic nature, many people continue to suffer active disease for many 
years. Thus, many elderly patients show evidence of active rheumatoid 
arthritis and require the addition of second line drugs. From 
previous experience it has become apparent that approximately 10% of 
patients receiving second line drugs at the Centre for Rheumatic 
Diseases are over 65 years old.
The process of ageing is accompanied by changes in many aspects of 
physiological function. This, in turn, may have profound effects on 
the pharmacodynamic and pharmacokinetic profiles of drugs. There is 
little evidence for significant age related changes in drug absorption 
and, although changes in plasma protein binding, volume of 
distribution and hepatic metabolism have been described no 
generalisation can be made about these functions in the elderly and 
their clinical significance is unknown. The most profound effect of 
age appears to be on the renal handling of drugs which are excreted in 
the urine (167).
For many years it has been recognised that digoxin and the 
aminoglycosides pose greater dangers in the elderly and that lower 
doses are required. Such differences relate to reduced renal 
function in elderly patients. More recently this aspect of treatment 
with antirheumatic drugs aroused interest when it was found that 
benoxaprofen (a drug which may have exhibited other than purely first
119
line properties) (168) displayed a slower rate of clearance and a 
longer plasma elimination half-life in elderly patients (169) and was 
subsequently found to produce serious toxicity in the elderly (170, 
171, 172).
Sulphapyridine, the major metabolite of sulphasalazine is excreted 
almost entirely by the kidneys either unchanged or following hepatic 
metabolism. It is possible, therefore, that the handling of 
sulphasalazine in the elderly may differ from that found in younger 
patients and that this may produce differences in the toxicity profile 
of the drug.
In this chapter I have therefore investigated the pharmacokinetics of 
sulphasalazine in an elderly rheumatoid population and related this to 
toxicity. I have also reviewed the pattern of toxicity and efficacy 
found in older patients as compared to that found in a younger age 
group.
Section 2 
Patients and methods
Eight patients with definite or classical (146) rheumatoid arthritis 
were studied. All patients were at least 65 years old and required 
the addition of a second line agent to their treatment regimen to 
control their disease activity. Patients were given a single dose of 
enteric coated sulphasalazine (5 patients were given 2g and 3 patients 
given 3g — this difference was because of a change in protocol to 
allow comparison with some previously documented young volunteers) 
washed down with 150ml water following a 10 hour overnight fast and
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followed by a further 2 hour fast. Venous blood was sampled before 
dosing and at 1.5, 3, 4.5, 6, 9, 12, 18, 24, 48 and 72 hours. In
addition 3 x 24 hour urine collections were made over this period. 
The dose and timing of sampling were chosen to make this study 
compatible with previous studies carried out by Pharmacia AB. Seven 
days later the protocol was repeated and after the last sample was 
collected patients were commenced on a therapeutic dose of the drug 
(0.5g/day rising by weekly increments of 0.5g/day to 3g/day or until 
the dose was limited by dose related toxicity).
Blood samples were stored at room temperature for 30 minutes and 
following centrifugation at 3000 rpm the supernatant was stored at 
-20°C. Urine volumes were measured and a 20ml aliquot stored at 
-20°C. Analysis for sulphasalazine, sulphapyridine, acetylsulpha­
pyridine, sulphapyridine glucuronate and acetylsulphapyridine 
glucuronate was carried out by Pharmacia AB using high performance 
liquid chromatography with UV detection (173). "Total serum 
sulphapyridine" was calculated as the sum of the sulphapyridine 
equivalents of the above substances expressed in ug/ml. Urinary 
excretion of metabolites was also expressed as molar equivalents of 
sulphasalazine to facilitate comparison of ingested and excreted 
quantities.
Plasma concentration-time curves were plotted for each patient using 
the mean values for the same time point measured one week apart. From 
these curves peak serum concentrations (C max) and area under the 
curve from time 0 to infinity (AUC) could be calculated. The AUC was 
calculated using the trapezoid rule. Serum elimination half life 
/2) was calculated from the terminal portion of a semi-log plot of
1 2 1
concentration against time. Acetylator phenotype was assessed from 
the serum ratio of acetylated: total sulphapyridine (19). Because of 
the absence of an intravenous dose and the incomplete absorption of 
sulphapyridine no realistic estimation of clearance could be made, in 
the second part of the results section the efficacy and toxicity of 
sulphasalazine in the total 158 patients described in Chapter 4 are 
related to age.
Section 3
3-1 Pharmacokinetic s
Pre-treatment data on the 8 patients are shown in Table XL. Derived 
pharmacokinetic indices are shown in Table XLI. Figs XXV, XXVI and 
XXVII show the plasma concentration-time curves in patient No 6 for 
the various metabolites on the 2 occasions of measurement separated by 
1 week. Similar close relationships between the two single dose 
studies were seen for all patients except patients No 2 and 5 whose 
2nd studies showed lower values compared to the first.
Four patients (Nos 1, 2, 3 and 4) stopped their therapeutic dosing 
regimens because of upper gastrointestinal symptoms. One of these 
patients (patient No 3) who stopped had received 3g doses in the 
single dose studies and achieved a much higher peak concentration (C 
max) and greater AUC for all metabolites than the other patients. 
This patient's results are, therefore, excluded from further analysis 
as they may have produced bias. Two patients (patients No 7 and 8) 
who continued therapy also received 3g doses in the single dose study. 
Despite this, however, they still produced low C max's and AUC's and.
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assuming that these values would be no higher with a 2g dose, these 
patients are included as any bias produced by the higher doses would 
be towards no demonstrable difference between patients who continued 
and those who did not.
Figs XXVIII, XXIX and XXX show the mean concentration-time curves for 
the two single dose studies for the group who were able to tolerate 
extended treatment and those who could not. Despite the fact that two 
patients in the group who eventually continued treatment received 
higher doses in the single dose studies it can be seen that these 
patients who stopped because of nausea/vomiting achieved a greater C 
max and to a lesser extent a longer t ^ / 2  and AUC for sulphasalazine 
and unmetabolised sulphapyridine (Table XLI).
3.2 Retrospective analysis of 158 patients
In the group of 158 patients 31 were >65 years old. There was no 
significant difference between the groups for any of the starting 
parameters (except, of course, age) in the 150 patients for whom full 
clinical details were available (Table XLII). The patients analysed 
comprised a mixture of doses and acetylator phenotypes but there was 
no major difference in the distribution of these variables (Table 
XLIII). The pattern of drop out from treatment for the two groups is 
shown in Table XLIV. Significantly more people in the elderly group 
stopped treatment in the first 6 months 0^ = 4.01; p < 0.05) for all 
reasons and also because of side effects (X ~ 4.42; p < 0.05) (Fig 
XXXI). Table XLV shows the pattern of change in the various parameters 
of efficacy over the 24 week follow up. No difference could be 
demonstrated between the two groups with reference to the percent
12 3
X— X Patients who stopped because 
of side effects. 
Patients who continued.
20-1
O)
IQ-
4836 72
Time (hours)
Fig. XXVIII Mean (+S.E.M.) sulphasalazine concentration-time curves
for those patients who continued treatment and those
who stopped because of side effects.
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of side effects.
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24 36 48 72
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Fig. XXIX Mean (+S.E.M.) unmetabolised sulphapyridine concentrat­
ion-time curves for those patients who continued
treatment and those who stopped because of side effects.
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of side effects. 
o— o Patients who continued.
20-
10-
36 48 72
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Fig. XXX Mean (+S.E.M.) total sulphapyridine concentration-time
curves for those patients who continued treatment and
those who stopped because of side effects.
Age (yrs)
Disease duration (yrs)
ESR (nun/hr)
Hb (g/dl)
Plats (X 10 V D
RF titre
AI
LUT (rains)
Pain score
Grip strength (raraHg)
DAI
Creatinine (umol/1)
< 65 
127
52.4 (28-64)
7.5 (1-47)
63.5 (2-150)
11.6 (7.6-16.6) 
395 (118-880)
19.2 (0-61)
90 (0-all day) 
2.65 (1-49) 
89.5 (38-190) 
16.7 (12-23)
69 (40-130)
> 65
23
69 (65-80)
9.2 (1-57)
72 (17-132)
11.3 (7.4-17.0) 
382 (203-780)
1/128 (0-1/1024) 1/64 (0-1/512)
20 (2-32)
126 (45-all day) 
2.75 (2-4)
76 (39-177)
17.3 (12-22)
73 (40-202)
Table XLII Pre-treatment values in the group of 150 patients 
(Studies 1, 2 and 3) divided by age (median and range).
Age <65 Age >65 Total
127 (%) 31 (%) 158 (%)
Fast acetylator/
3g/day 59 (46) 16 (52) 75 (49)
Slow acetylator/
3g/day 20 (16) 7 (23) 27 (17)
Fast acetylator/
1.5g/day 8 (6) 0 (0) 8 (5)
Slow acetylator/
1.5g/day 35 (28) 4 (13) 39 (25)
? Acetylator status
3g/day 2 (2) 4 (13) 6 (4)
1.5g/day 3 (2) 0 (0) 3 (2)
Table XLIII Distribution of acetylator phenotype and allocated dose 
by age.
<65 >55
n = 127 (%) n = 31 (%)
Nausea/vomiting 14 (9) 7  (2 2 .5 )
Rash/itch 4  (3 .2 ) 1 (3 )
Leucopenia 5  (4 ) 2 (6 )
Mouth ulcers 1  (0.8) l (3 )
Dizziness 0 1 (3)
Drowsiness 1  (0.8) 0
Hepatitis 1 (0.8) 0
Acute dyspnoea 1 (9.8) 0
Poor compliance - 1  (3 )
Inefficacy 5 (4) 0
Others 4 (3) 1 (3)
Total 36 (28) 14 (45)
Table XLIV Reasons for discontinuing sulphasalazine therapy during 
first 6  months of treatment (by age).
^ 65yrs (n=31)
NAUSEA /VOMITING M U C O ­CUTANEOUS LEUCOPENIA OTHER 4 5 %
22 5 % 6% 6 % 10-5%
<  65yrs (n = 127)
MUCOCUT­ LEUCO­ INEFFI­
NAUSEA/VOMITING ANEOUS PENIA OTHER CACY
9 % 3 5% 4% 7 5 % 4%
2 8 %
♦ X^ P < 0 0 5
Fig. XXXI Reasons for discontinuing therapy in the elderl;
the younger age groups.
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change over the study period or to the actual 24 week values (Mann- 
Whitney U Test p > 0.05). Serum creatinine concentration was not 
significantly greater in the 31 elderly patients when compared to the 
127 younger patients, nor was there any difference in the serum 
creatinine in the 21 of the 158 patients who stopped because of 
gastrointestinal side effects or in the 51 who stopped treatment for 
any cause nor between those elderly patients who stopped treatment and 
those who continued (Mann-Whitney U test, all p > 0.05).
Section 4 
Discussion
The pharmacokinetic study described here has a number of serious 
limitations. These include the discrepancy in dosage, the absence of 
an intravenous dose to determine bioavailability, volume of 
distribution and clearance and the fact that, of necessity, an elderly 
rheumatoid group exhibit an astounding degree of polypharmacy. In 
addition the fact that slow acetylators happened, coincidentally, to 
have a lower creatinine clearance complicates any attempt to separate 
these variables. Finally the small numbers make a statistical 
approach to comparison impossible.
Within the bounds of these limitations the pharmacokinetic study does 
suggest, in elderly patients, a relationship between upper 
gastrointestinal side effects and the ability to achieve high values 
for C max and AUC for sulphasalazine and unmetabolised sulphapyridine 
and, to a lesser extent, total sulphapyridine. From the evidence 
available in previous studies in non-rheumatoid patients such a
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relationship between sulphapyridine levels and toxicity was not 
entirely unexpected (25, 161), although a relationship has never
previously been demonstrated between sulphasalazine levels and side 
effects.
Although it is only a crude index of renal function the lack of 
relationship between serum creatinine concentration and toxicity in 
the 158 patients suggests that perhaps increased toxicity in the 
elderly is related to some factor other than renal function (perhaps 
absorption, metabolism or distribution). In this context it is of 
interest to note that in a group of 12 young normal volunteers 
(M. Ryde personal communication) only 61% of the ingested dose was 
recoverable from the urine whereas in the 8 elderly patients studied 
here 75% of the ingested dose was recoverable in the urine suggesting, 
perhaps, increased absorption, reduced biliary excretion or altered 
distribution. The peak serum levels, serum half lives and areas under 
the curve for sulphasalazine, sulphapyridine and its metabolites were 
not significantly different between the elderly patients and the young 
healthy volunteers.
When one examines the pattern of improvement in inflammatory indices 
(Table XLV) it is apparent that despite the failure to show any 
statistically significant difference between the 2 age groups more 
parameters improve in the <65 age group and in particular none of the 
haematological indices improve in the >65 age group despite both 
groups receiving a similar dose. This may be due to small numbers in 
this group but this is unlikely to be the entire explanation as with 
similar numbers in study 1 (Chapter 4) significant improvement was 
seen in these parameters.
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Section 5
Conclusions
In summary, elderly rheumatoid patients show a higher incidence of 
toxicity necessitating withdrawal of sulphasalazine while they display 
a tendency towards lesser improvement. Elderly patients who 
discontinue treatment because of upper gastrointestinal side effects 
achieve higher C max and AUC for sulphasalazine and its metabolites on 
single dose studies. Elderly patients, however, also appear to 
excrete a larger proportion of the ingested dose in the urine which, 
among other possibilities, may suggest more complete absorption. 
This, in conjunction with the fact that, overall, serum creatinine 
concentration does not correlate with toxicity suggests that a 
mechanism other than poor renal function may be responsible for the 
increased toxicity rate in the elderly. In practical terms one may 
expect greater toxicity and less efficacy in elderly rheumatoids. 
Toxicity, however, tends not be of a serious nature and therefore, if 
one decides to use this drug in an elderly patient, one should 
probably still attempt to reach the optimum therapeutic dose of > 
40mg/kg.
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Summary 
Chapter 7
In general drug toxicity tends to be more common in elderly patients. 
This is frequently due to pharmacokinetic differences resulting in 
higher drug levels and accumulation of drug in the body. I have 
investigated the single dose pharmacokinetics of sulphasalazine in 8 
elderly patients prior to chronic dosing. The 4 patients who 
eventually had to discontinue therapy because of nausea and/or 
vomiting achieved, on single dosing, higher peak levels and greater 
areas under the curve especially for sulphasalazine but also for 
unmetabolised sulphapyridine and total sulphapyridine when compared to 
those who were able to continue treatment. In addition elderly 
patients tended to excrete in their urine (as sulphasalazine, 
sulphapyridine and metabolites) a higher percentage of the ingested 
dose than did a previously documented group of young normal 
volunteers.
The total group of 158 patients studied contained 31 patients who 
were 65 years old or over. These patients had a greater incidence of 
discontinuing therapy for all reasons 45% v 28% (Chi squared, p < 
0.05) and for adverse effects 39% v 20% (Chi squared, p < 0.05) 
although the incidence of no single adverse event showed a significant 
difference between the groups. No relationship could be demonstrated 
between serum creatinine concentration, either in the elderly alone or 
in all patients, and adverse effects.
In addition, fewer inflammatory parameters improved significantly in 
the elderly patients. Thus, drop out rates from sulphasalazine are
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greater in elderly patients but no single adverse effect can be 
demonstrated as more common in this age group.
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CHAPTER 8
Investigations of the influence of a number of clinical and laboratory 
variables on the efficacy and toxicity of sulphasalazine in the 
treatment of rheumatoid arthritis.
Section 1 Introduction
Section 2 Patients and methods
Section 3 The investigation of individual subgroups
3.1 The influence of gender on efficacy and toxicity of
sulphasalazine in rheumatoid arthritis
3.2 The relationship of efficacy and toxicity of
sulphasalazine to duration of rheumatoid disease
3.3 The influence of previous second line therapy on
efficacy and toxicity of sulphasalazine
3.4 The influence of initial ESR on efficacy and toxicity of
sulphasalazine
3.5 The influence of initial disease activity index (DAI) on
efficacy and toxicity of sulphasalazine
Section 4 The use of prochlorperazine to treat sulphasalazine
related upper gastrointestinal problems.
Section 5 Discussion
Section 6 Conclusions
Summary
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Section 1 
Introduction
The previous two chapters have examined the effect of a number of 
variables which, either from experience of sulphasalazine in other 
conditions or from knowledge of the effect of these variables on other 
drugs, seemed likely to affect the efficacy or toxicity of 
sulphasalazine in the treatment of rheumatoid arthritis. There are 
also, however, a number of other variables which might affect one or 
both of these aspects of sulphasalazine therapy in rheumatoid patients 
and may help to identify a subgroup in whom this drug displays special 
properties.
It has been stated that, in general, drug side effects occur more 
frequently in females (174) and it has also been observed that 
sulphasalazine is more effective in male rather than in female 
rheumatoid patients (175). It is theoretically likely that patients 
with longer disease duration or who have previously used a large 
number of second line agents may show a poor response to treatment 
with sulphasalazine and also that those who have had a large number of 
previous agents may be more susceptible to complications of therapy.
Initial disease activity may also affect the response to second line 
drugs in that people with milder initial disease may show less overall 
improvement. Finally, in studies 2, 3 and 4 prochlorperazine was
prescribed freely for upper gastrointestinal symptoms and this may 
have influenced the overall toxicity pattern.
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This chapter, therefore, examines the influence of gender, disease 
duration, previous second line drugs, initial ESR and initial disease 
activity on the efficacy and toxicity of sulphasalazine and also 
examines the impact of allowing patients access to the anti—emetic 
preparation prochlorperazine.
Section 2
Patients and methods
Unless otherwise stated, data on drop-out rates are from all patients 
in studies 1, 2, 3 and 4 (n = 158), whereas, because of inadequate 
data in study 4, efficacy was assessed only in patients from studies 
1, 2 and 3 (n = 150). All follow-up periods refer to 24 weeks.
Methods of assessing disease activity are described in Chapter 4.
Statistical analysis is carried out using the Chi squared test and the 
relevant non-parametric tests (148), all tests are two tailed.
Section 3
The investigation of individual subgroups
3.1 The influence of gender on efficacy and toxicity of 
sulphasalazine in rheumatoid arthritis
Thirty-six (23%) of the 158 patients treated were males. At entry to 
the study males had, as expected, a significantly higher haemoglobin 
level, a significantly higher hand grip strength (Mann-Whitney U test 
p < 0.001 in both instances), and also a significantly lower platelet
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Xcount (Mann-Whitney U test p < 0.001).
Rather surprisingly males had a significantly lower articular inde 
(Mann-Whitney u test p < 0.001). Other inflammatory indices and 
demographic parameters showed no significant difference (Mann-Whitney 
U test p > 0.05) and there was no significant difference between the 
groups as regards distribution of acetylator phenotypes = 0.41; p
> 0.05) or allocated dose (%^ = 0.75; p > 0 .05 ).  Over the 24 week 
follow up 9 (25%) males and 41 (36%) females discontinued treatment ( 
= 0.92; p > 0.05). When only drop outs because of toxicity are 
considered again there is again no significant difference between 
groups either for total toxicity or nausea/vomiting alone (%^  = 0.86; 
p > 0.05). A similar pattern of improvement in inflammatory
parameters was seen in the two groups and no difference could be 
demonstrated between groups in the percent change in the various 
values for inflammatory indices (Mann-Whitney U test p > 0.05) (Table 
XLVI) although significant differences were still apparent between 
groups by week 24 for haemoglobin, platelet count and grip strength 
(Mann-Whitney U test p < 0.001, p < 0.05, p < 0.001 respectively) but 
not articular index.
3.2 The relationship of efficacy and toxicity of sulphasalazine 
to duration of rheumatoid disease
Forty-seven (30%) of the 158 patients had suffered rheumatoid 
arthritis for less than 5 years. At the commencement of the study 
patients with a disease duration of < 5 years had a significantly 
lower articular index and disease activity index (Mann-Whitney U test 
p < 0.001 and p < 0.05 respectively) and a significantly higher
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rheumatoid factor titre (Mann-Whitney U test p < 0.05). There was no 
significant difference between groups with respect to other markers of 
disease activity, age, acetylator phenotype or allocated dose (Mann- 
Whitney U test p > 0.05;X ^  = 1.23 and 0.62; p > 0.05). Both groups 
showed a similar improvement in inflammatory indices and no 
differences were demonstrated in the percent change in these indices 
between the groups (Table XLVII).
Neither total drop out rate nor drop out rate because of side effects 
(either total or nausea/vomiting) differed between groups (X^ = 0.53 
and 0.71; p > 0.05).
3.3 The influence of previous second line therapy on efficacy 
and toxicity of sulphasalazine
Of the 158 patient studied, 67 had received at least one second line 
agent or cytotoxic drug previously (30 - 1 previous agent, 1 1 - 2  
previous agents, 1 7 - 3  previous agents, 5 - 4  previous agents and 4 - 
5 previous agents). Table XLVIII shows how many people had received 
each individual drug.
For the purposes of analysis 3 groups of patients were compared;- 
those who had received no previous second line drug (91 patients), 
those who had received 1 previous second line drug (30 patients) and 
patients who had previously received 2 or more second line drugs (37 
patients). No significant difference could be found between groups in 
the distribution of acetylator phenotype or allocated dose (X = 0.42 
and 0.66; p > 0.05) but patients who had received 2 or more previous 
drugs had a significantly higher initial articular index (Kruskall-
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Previous 2nd/3rd line agent No
Sodium aurothiomalate 48
D-penicillamine 38
Levamisole 17
Chloroquine
(as hydroxy C or C-phosphate) 17
Azathioprine 10
Auranofin
" C l o z i c " *
Ketotifen**
Table XLVIII Number of patients (n = 158) receiving individual 
second line agents prior to the present studies.
* an ICI potential second line drug which because of 
toxicity was never marketed.
** A lipoxygenase inhibitor which was tested for 
second line activity but which failed to display 
any.
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Wallis p < 0.005) and lower hand grip strength (Kruskall-Wallis p < 
0.05). There was no significant difference between groups with 
respect to age, disease duration or other inflammatory indices 
(Kruskall-Wallis p > 0.05). Significant improvement in clinical and 
laboratory parameters were seen in all 3 groups and no significant 
difference could be demonstrated in the percent change in inflammatory 
parameters over 24 weeks (Table XLIX). At week 24 patients who had 
received 2 or more previous second line drugs retained a higher 
articular index (Kruskall-Wallis p < 0.05) but the groups displayed no 
demonstrable difference in any of the other parameters.
In total 33 (36%) patients who had received no previous second line 
agent stopped treatment over the first 24 weeks (15 [16%] because of 
upper gastrointestinal symptoms) compared to 9 (30%) (5 [17%] because
of upper gastrointestinal symptoms) in the 1 previous drug group and 8 
(22%) (1 [3%] because of upper gastrointestinal symptoms) who had
previously received 2 or more second line agents 0^ = 2.08 and 4.3; p 
> 0.05).
3.4 The influence of initial ESR on efficacy and toxicity of 
sulphasalazine
At the commencement of treatment 134 (84%) patients had an ESR >
30mm/hour.
No significant difference could be demonstrated in the distribution of 
acetylator phenotype or allocated dose between those patients and the 
24 patients with an initial ESR <30mm/hour ()f = 1.32 and 0.91; p > 
0.05). As one might expect, however, the patients in the low ESR
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group also had a significantly higher haemoglobin level (Mann-Whitney 
U test p < 0.01), grip strength (Mann-Whitney U test p < 0.05) and 
functional index (Mann-Whitney U test p < 0.05) and a significantly 
lower platelet count (Mann-Whitney U test p < 0.005) and disease 
activity index (Mann-Whitney U test p < 0.001).
Statistically significant improvement was seen in the clinical 
parameters of inflammation but not the haematological parameters in 
the low ESR group but in both clinical and haematological parameters 
in those patients with a high initial ESR. The improvement in 
haematological parameters expressed as a percentage of the initial 
value was significantly greater in patients starting with an ESR > 
30mm/hour (Table L). At week 24 patients who started with an ESR < 
30mm/hour still had a significantly lower ESR (Mann-Whitney U test p < 
0.001) and articular index (Mann-Whitney U test p < 0.05) and a 
significantly higher haemoglobin (Mann-Whitney U test p < 0.005) and 
grip strength (Mann-Whitney U test p < 0.05). Seven (29%) of the low 
ESR patients stopped treatment over the first 24 weeks (5 (21%)
because of nausea/vomiting) compared to 43 (32%) of those with an 
initial ESR of > 30mm/hour (16 (13%) because of nausea/vomiting). No 
difference could be demonstrated in the pattern of drop out (X = 0.09 
and 1.35; p > 0.05).
3.5 The influence of initial disease activity index (DAI) on 
efficacy and toxicity of sulphasalazine
A calculation of initial disease activity index was available in 142 
patients (patients in study 4 did not have enough data available for 
this calculation and 8 patients from studies 1, 2 and 3 had data
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dTwo groups of patients were compared, those with a DAI of <14 an 
those with a DAI of > 14. The former corresponds to Mallya & Mace's 
(122) "inactive" and "slightly active" disease groups and the latter 
to the "moderately" and "very active" groups. Of those patients with 
DAI £ 14 all fell into the "slightly active" group and none into the 
"inactive groups". Twenty four (17%) patients had an initial DAI < 14 
(range 12-14). At the outset of therapy these patients had a 
significantly higher haemoglobin and grip strength (Mann-Whitney U 
test p < 0.001 and p < 0.05 respectively) and a significantly lower 
ESR, platelet count, articular index, pain score and duration of 
morning stiffness (Mann-Whitney U test p < 0.005, p < 0.001, p < 
0.001, p < 0.05, p < 0.001 respectively). Over the 24 week period a 
significant improvement was seen in most indices in those patients 
with a DAI > 14 but only clinical parameters improved in those 
patients with a DAI < 14. Little difference was seen between groups, 
however, in the percent change in inflammatory indices over the follow 
up period (Table LI). At week 24 disease activity as indicated by 
haemoglobin, . grip strength, articular index, duration of morning 
stiffness and DAI was less in the patients with initially only 
slightly active disease (Mann-Whitney U test p < 0.01, p < 0.05, p < 
0.05, p < 0.05, p < 0.001 respectively). Eight (33%) patients with 
initial DAI < 14 discontinued treatment (4 because of nausea/vomiting) 
compared to 35 (30%) (11 because of nausea/vomiting) of those with
initially more active disease. Again no difference in the pattern of 
drop outs could be demonstrated (X — 0.12 and 1.18; p > 0.05).
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Section 4
The use of prochlorperazine to treat sulphasalazine related upper 
gastrointestinal problems
One hundred and twenty-eight of the 158 patients were allowed access, 
through their general practitioner, to prochlorperazine (up to lOmg 
tid) for the symptoms of nausea and/or vomiting.
In the first 24 weeks of therapy 59 (46%) of those with access to 
prochlorperazine experienced upper gastrointestinal symptoms. Twenty 
(33%) of these patients availed themselves of the offer of 
prochlorperazine and of these 3 (15%) eventually stopped
sulphasalazine because of their symptoms, 3 (15%) continued
sulphasalazine at a reduced dose and 14 (70%) achieved their allocated 
dose of sulphasalazine. Of the 39 patients who had access to 
prochlorperazine but failed to receive it, 12 (31%) discontinued
sulphasalazine because of nausea/vomiting and a further 12 (31%)
continued at a reduced dose. Of the 30 patients not given access to 
prochlorperazine 17(57%) suffered symptoms of nausea and/or vomiting 
and of those 6 (35%) stopped therapy for this reason and 2 (12%)
failed to achieve the allocated dose. Fig. XXXII represents this 
information as a flow diagram.
Section 5 
Discussion
As might be expected patients who have mild initial disease as 
identified by either a low ESR or a low DAI tend to have milder
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disease as represented by other inflammatory parameters. These 
patients, however, when given sulphasalazine, are still capable of 
showing a clinical response of a similar proportion to those with more 
severe disease. The lack of improvement in haematological measures of 
inflammation is of interest in that it demonstrates the ability of a 
second line agent, under certain circumstances, to improve the 
clinical findings independent of laboratory parameters. In terms of 
patient treatment it also demonstrates that in a small number of cases 
a low ESR or DAI is not a contraindication to second line therapy 
provided it is felt to be clinically indicated. This finding has 
conflicting implications for clinical trial design in that, on the one 
hand, if one is interested only in clinical improvement there is no 
need to restrict entry only to patients with a raised ESR (as is often 
done), on the other hand, if a trial was carried out predominantly in 
patients with a low ESR it would be impossible to differentiate first 
and second line drugs. This second argument is mainly theoretical, 
however, in that the majority of patients in a random group with 
disease severe enough to merit second line therapy will have a raised 
ESR.
As might also be expected patients who have a longer disease duration 
or who have had a number of previous second line drugs have some 
evidence of more severe disease although the observation that this 
evidence consists largely of a higher articular index perhaps 
indicates that this particular parameter may relate more closely to 
joint damage rather than to reversible synovitis.
There is some suggestion from data presented here that men are 
commenced upon second line drugs with a lower articular index value
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than are women. This could relate either to some difference in the 
perception of pain (either men are more stoical during the assessment 
of articular index or complain more at a set level of pain) or to some 
unconscious bias of the physician initiating treatment, perhaps in 
terms of bread winning capacity". Despite these differences 
demonstrated in the initial disease severity between various groups 
this chapter fails to identify any particular group in whom treatment 
is clinically indicated who would appear to benefit more or less from 
sulphasalazine therapy.
The pattern of drop out and dose reduction because of upper 
gastrointestinal problems is of interest. Despite supposed access to 
prochlorperazine via their family doctor, only one third of patients 
who had these symptoms actually received it and although the trend was 
for fewer of these patients to discontinue therapy this did not reach 
statistical significance. There is therefore no evidence that access 
to prochlorperazine allows patients to continue sulphasalazine 
(certainly if one considers "intention to treat" with 
prochlorperazine). This failure may be explained by reluctance of 
patients to take more tablets (especially if they are feeling 
nauseated) or reluctance of GP's to prescribe medications to treat 
iatrogenic symptoms. Any trend towards a better outcome in patients 
who received prochlorperazine might be explained by a process of 
selection of those patients whose gastrointestinal symptoms were mild 
enough to enable them to obtain a prescription from their GP and to 
take the prochlorperazine tablets.
139
Section 6
Conclusions
This chapter fails to identify any subgroup who show an altered 
clinical response to sulphasalazine therapy although patients who 
commence therapy with a low ESR show only a clinical but not a 
haematological response. Because of this lack of influence of any of 
these factors on drug efficacy when tested individually a multivariate 
analysis would not contribute any further information.
It also fails to demonstrate any definite advantage to allowing 
patients access to prochlorperazine via their GP for the treatment of 
drug induced sickness.
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Summary 
Chapter 8
In this chapter I have examined the influence of a number of other 
factors on the efficacy and toxicity of sulphasalazine in rheumatoid 
arthritis.
Gender, disease duration, number of previous second line agents, 
seropositivity, initial ESR and initial disease activity index all 
influenced some aspects of initial disease activity. Only initial 
ESR, however, was related to the degree of improvement seen. Patients 
with a low (^30mm/hour) initial ESR showed no significant improvement 
in ESR, haemoglobin or platelet count and patients with a higher 
initial ESR showed a greater degree of improvement in these indices. 
No difference was seen between these groups in the degree of 
improvement in clinical indices. This has implications both for day 
to day practice and clinical trial design as it shows that even 
patients with an initial low ESR are capable of showing clinical but 
not haematological improvement with a second line drug.
One hundred and twenty eight patients were given access, via their 
GP's, to prochlorperazine if they experienced nausea and/or vomiting. 
Only 33% of those who experienced upper gastrointestinal symptoms 
availed themselves of the offer. More of these patients, however, 
were able to continue sulphasalazine treatment and to reach their 
allocated dose. The self selection of this 33% of eligible patients 
makes this finding difficult to interpret.
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CHAPTER 9
The effect of sulphasalazine on scavengers of oxygen-derived free 
radicals in rheumatoid arthritis
Section 1 Introduction
Section 2 Patients and methods
2.1 Patients and treatment
2.2 Sampling and analysis
Section 3 Results
Section 4 Discussion
Section 5 Conclusions
Summary
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Section 1
Introduction
Table II shows some of the many and varied actions of second line 
drugs at the cellular level by which means they may exert their 
clinical effect. One action of these drugs which has proved constant 
for all drugs tested is the alteration of intracellular and 
extracellular thiol or gluthione levels {64, 176, 177, 178, 179).
Thiols (-SH groups) are strong reducing agents and are involved in 
maintaining several aspects of cell function and integrity such as 
active transport and protein synthesis (180). In addition thiols 
participate in the protective mechanisms directed against the effects 
of oxygen-derived free radical damage (181).
Free radicals in biological systems consist primarily of the 
superoxide (O2 ) and hydroxyl (OH') radicals the latter being produced 
from a reaction of the former with hydrogen peroxide (182). 
Production of these radicals may occur spontaneously or they can be 
produced much more rapidly by activated polymorphonuclear leucocytes 
(183) or as a result of ionising radiation (180). These species are 
highly reactive and can produce tissue damage in a number of ways. 
They can cause lipid peroxidation of cell walls resulting in cell 
damage and perhaps prostaglandin and leukotriene production (184, 185, 
186). Oxygen-derived free radicals are also involved in the process 
of neutrophil chemotaxis (187) and can produce damage to a wide range 
of biological molecules including DNA (188), hyaluronic acid and 
collagen (189, 190, 191). They have also been shown to inhibit
proteoglycan synthesis (192). In general it is the hydroxyl rather
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than the superoxide radical which is thought to be responsible for 
tissue damage.
Superoxide radicals are removed in a reaction catalysed by the copper 
containing enzyme superoxide dismutase (SOD) : -
SOD
O 2 " + 02“ + 2H"''-----------> H2 O2 + O2
The hydrogen peroxide thus produced is then removed in a further
reaction involving either catalase:
Catalase 
2 H2 O2 -----------> O2 + 2 H2 O
or the glutathione (GSH)/glutathione peroxidase system:
2RSH + H2 O 2 ----------------- > RSSR + 2 H2 O
glutathione
peroxidase
If these reactions do not remove hydrogen peroxide then in the 
presence of superoxide radicals and ferrous iron or another 
transitional metal ion a hydroxyl radical will be produced in the 
following reactions:
F e ^ ^ ^  4- O2 ” ---------^  O 2  +  F e ^ ^
Fe++ + H2 O 2 --- > Fe+++ + OH- + OH* (193)
It has also been suggested that thiol groups themselves can reduce O2
concentrations either by a direct effect or an effect on the O 2  
generating system (181). In rheumatoid arthritis red cell lysate 
superoxide dismutase activity is low, red cell lysate thiol levels are 
high and extracellular thiol levels are low (194, 195). Extracellular
thiol levels have been shown to bear an inverse relationship with
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disease activity (100). Although most of the extracellular thiol is 
bound to albumin, alterations in plasma thiol levels in rheumatoid 
arthritis do not merely reflect changes in albumin concentration 
(195). It is possible, therefore, that an alteration of the levels 
and ratios of these various scavengers of oxygen-derived free radicals 
could explain many of the apparently disparate actions of second line 
drugs. It has even been suggested that to demonstrate "second line" 
qualities a drug must possess an aliphatic (non-aromatic) thiol group 
(196, 197).
D-penicillamine has been shown to produce an early rise in erythrocyte 
glutathione levels which correlates with and precedes clinical 
improvement in rheumatoid arthritis (78, 198). A similar rise in red 
cell lysate thiols and concomitant fall in superoxide dismutase 
activity has been observed in patients responding to sodium 
aurothiomalate but not in those who failed to respond or who received 
placebo (176). By 24 weeks these changes are reversed, with 
responders having a lower lysate thiol level and higher superoxide 
dismutase activity than at week 0 (176). Furthermore, a close
relationship between red cell lysate thiol concentration and 
superoxide dismutase activity within erythrocytes has been 
demonstrated (176, 181, 194).
Plasma thiol concentrations show a negative correlation with disease 
activity (100) and have been shown to increase towards normal with 
second line drugs such as sodium aurothiomalate (64) and d- 
penicillamine (178, 195, 199) and with cytotoxic drugs such as
cyclophosphamide (179). First line drugs, such as- alclofenac, 
however, fail to produce such a change (178). In addition to the
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assessment of individual parameters certain relationships between 
these parameters may be of value. In particular LSH concentration is 
raised and plasma thiol concentration lowered in rheumatoid 
arthritis. After an initial further rise (78, 198) red cell thiol 
levels fall in patients who respond to second line therapy, whereas 
extracellular thiols rise (176). Thus the ratio alters during second 
line drug treatment. Together these compounds are a measure of the 
reduction capacity or, conversely, the oxidative stress, across cell 
membranes and the relationship between them is of importance in terms 
of protection against free radicals.
In order to define further the second line qualities of sulphasalazine 
and also to test the hypothesis that second line activity is linked to 
an effect on free radical scavengers an investigation into the action 
of sulphasalazine on these scavenging systems was carried out. An 
effect of sulphasalazine on those systems would be of great interest 
as, unlike many second line drugs, neither it nor its metabolites 
contain a free thiol group.
Section 2 
Patients and methods
2.1 Patients and treatment
Red cell lysate thiol levels, red cell lysate superoxide dismutase 
activity and plasma thiol levels were measured in 32 consecutive 
patients who were given sulphasalazine. All patients had definite or 
classical rheumatoid arthritis and had active disease which required 
the addition of a second line agent. Patients studied comprised the
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last 7 patients randomised to sulphasalazine in Study 1 
(Sulphasalazine v sodium aurothiomalate v placebo) - data on patients 
randomised to placebo or sodium aurothiomalate were insufficient to 
draw conclusions, and the first 25 patients to be recruited to Study 2 
(l.Sg/day v 3.0g/day). The studies were recruited consecutively. 
Twenty-two patients (13 allocated to 3.0g/day and 9 to 1.5g/day) 
completed the 24 week follow up period and only data from these 
patients are further described. In view of the relatively small 
numbers on each dose the patients are analysed as a single group.
2.2 Sampling and analysis
Samples were taken for estimation of red cell lysate superoxide 
dismutase activity, red cell lysate thiol concentration and plasma 
thiol concentration. Samples were taken at weeks 0, 6, 12 and 24. 
Weeks 0, 6 and 24 were chosen as they represent the times at which 
maximal change was seen (W E Smith personal communication) in previous 
studies.
Venous blood (10ml) was placed in a lithium heparin container and 
stored at 4°C for a maximum of 4 hrs until analyses was carried out. 
Blood was centrifuged at 3000 rpm for 10 minutes and the supernatant 
removed. Red cells were lysed using distilled water. After 2 hours 
lysis at 4°C 2ml haemolysate was removed and haemoglobin precipitated 
by a 0.8ml 3/5 v/v mixture of chloroform and ethanol followed by 0.3ml 
distilled water. The mixture was then centrifuged and the resulting 
clear supernatant used for analysis of thiols and SOD activity. 
Superoxide dismutase was measured in the red cell lysate by following 
its effect on the photochemically induced auto-oxidation of O-
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dianisidine (200). Red cell lysate and plasma thiol levels were 
measured using Ellman's reagent (201). Plasma thiols were measured at 
pH 7.6 and pH 6.5, the former representing "total" plasma thiols and 
the latter "fast reacting" plasma thiols. The difference between the 
two is referred to as "slow reacting" plasma thiols. The variation in 
thiol concentration at different pH's is thought to represent change 
in the configuration of the albumin molecule (202). Thiol and 
superoxide dismutase measurements were carried out at the University 
of Strathclyde by Mr Farid Khan under the supervision of Drs W E Smith 
and D Brown. Statistical analysis was carried out using the 
appropriate non-parametric tests.
Section 3 
Results
Table LI I shows the pattern of change in the various inflammatory 
indices and Table LIII shows the measured scavengers of oxygen derived 
free radicals over the 24 weeks of the study. Figs XXXIII, XXXIV and 
XXXV show the pattern of change in superoxide dismutase activity, 
lysate thiol and total plasma thiol concentrations repsectively.
By 6 weeks a significant .improvement was already seen in ESR, 
articular index, hand grip strength, albumin, total globulins and DAI 
and by 24 weeks significant improvement was seen in most inflammatory 
indices. At 6 weeks a significant fall in lysate superoxide dismutase 
activity and rise in lysate thiol concentration was apparent (Wilcoxon 
p < 0.01 and p < 0.05 respectively). By 24 weeks, however, the 
direction of these changes had reversed with the result that lysate
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Fig. XXXIII Median (range) red cell lysate superoxide dismutase
(SOD) activity in 22 sulphasalazine treated patients
over a 24 week treatment period.
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thiol was significantly lower than both the pre-treatment and 5 week 
values (Wilcoxon p < 0.05 and p < 0.01 respectively) and although 
superoxide dismutase activity was no different from the pre-treatment 
value (Wilcoxon p > 0.05) it was significantly higher than the 6 week 
value (Wilcoxon p < 0.05). In contrast plasma thiol concentration 
showed a statistically insignificant rise by week 6 (Wilcoxon p > 
0.05) but by week 24 was significantly higher than the pre-treatment 
value (Wilcoxon p < 0.001). This rise in plasma thiol concentration 
consisted almost entirely of a rise in fast reacting thiols (Wilcoxon 
p < 0.001) whereas slow reacting thiols showed no significant change 
(Wilcoxon p > 0.05).
A marked negative correlation was seen between the change in total 
plasma thiol concentration and the change in ESR over the 24 week 
follow up period (Spearman-Rank correlation r^ = -0.61, p < 0.02) (Fig 
XXXVI) and also between the change in plasma thiol and the change in
disease activity index (r^ = -0.53, p < 0.05). Neither the change in
lysate superoxide dismutase activity nor the change in lysate thiol 
concentration at either 6 or 24 weeks correlated with clinical or
laboratory parameters of inflammation .
At week 0 a strong relationship was noted between superoxide dismutase 
activity and lysate thiol concentration (Spearman-Rank correlation r^ 
= -0.75, p < 0.01) but by week 6 this correlation was lost (r^  = 
-0.43, p > 0.05) and this loss of correlation persisted through to 
week 24 (r^ = 0.32, p > 0.05). At no point during the study could a 
significant correlation between extracellular thiol levels and 
intracellular indices be demonstrated. No difference between 1.5g/day 
and 3.0g/day could be demonstrated at any point in either the absolute
149
ATotal plasma SH 0-24 wk v A ESR 0-24 wk
+10r •
I I I I I I I I r
-160 -120 -80 -40
ATotal Plasma Thiols
-| I I I I I I I I I— I— 1
+40 +80 +120 +160 +200 +240
-10
-20
-30
-40
-50
— 60
-70
A ESR
Fig. XXXVI Correlation between the change in total.plasma thiol 
(PSH) and the change in ESR in 22 sulphasalazine 
treated patients over a 24 week treatment period 
(Spearman-Rank).
value or the degree of change in any parameter (Mann-Whitney u test p 
> 0.05).
Section 4 
Discussion
The results of this study demonstrate that sulphasalazine has a 
significant effect on plasma thiol levels similar to that found with 
gold salts and penicillamine (64, 178) and disagrees with previous 
work which could demonstrate no such effect (140). This finding of a 
rise in plasma thiol concentrations lends further evidence to the 
claim that sulphasalazine has "second line" properties. The main 
effect of sulphasalazine on plasma thiol concentrations is an increase 
in the fast reacting thiols. This suggests a change in albumin 
conformation (202) and is similar to the effect of penicillamine which 
also causes an increase in the concentration of "fast reacting" thiols 
(195). Using different techniques an increase in the reactivity of 
serum thiol groups has been shown with various other second line drugs 
but not with first line agents (177, 119). The change in serum thiol 
levels over 24 weeks correlates with change in ESR and in disease 
activity index but follows rather than precedes the improvement in 
these indices. This implies that alterations in serum thiol levels 
are more likely to reflect change in disease activity rather than 
produce it.
The changes in intracellular thiol concentration and superoxide 
dismutase a c t i v i t y  m a y  be m o r e  f u n d a m e n t a l  to the a c t i o n  of 
sulphasalazine. Most patients remaining on therapy for 24 weeks
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showed clinical improvement and thus, overall, the patients studied 
can be regarded as an "improver" group. In this group, however, the 
initial changes in the intracellular measurements indicate a "pro- 
inflammatory" change, namely an increase in thiol levels and reduction 
in s u p e r  o x i d e  d i s m u t a s e  activity. Again similar early "pro- 
inflammatory" c h a n g e s  have been seen p r e v i o u s l y  w i t h  s o d i u m  
aurothiomalate in responders but not in non-responders or placebo 
treated patients (176) and it may be that cellular defence against 
free radical attache is enhanced by these changes in the early stages 
of therapy.
In patients with rheumatoid arthritis undergoing therapy with NSAIDs 
alone, there is usually a good correlation between red cell lysate 
superoxide dismutase activity and lysate thiol levels (194) and again 
this w a s  n o t e d  at the b e g i n n i n g  of the p r e s e n t  study. Thi s  
correlation, h o w e v e r ,  brealcs d o w n  w i t h  sulphasalazine therapy 
indicating, once more, that it interferes in some subtle way with 
erythrocyte free radical defence mechanisms. Interestingly sodium 
aurothiomalate alters the nature of this correlation but does not 
abolish it thus suggesting some difference in the activity of these 
two drugs (176). None of these intracellular changes (either early or 
late) show significant correlation with clinical or simple laboratory 
parameters of inflammation. The early parodoxical changes in 
intracellular thiol concentration and superoxide dismutase activity 
taken in conjunction with the change in the relationship between - ne 
two measurements and especially the failure to demonstrate a 
significant correlation between them and the clinical indices suggest, 
perhaps, that changes in intracellular scavengers of free radicals i^ a^y 
be fundamental to the action of sulphasalazine rather than merely a
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reflection of disease activity. Such alterations in these potent 
scavenging compounds could be related to major changes in cellular 
metabolism and protective mechanisms and, taken in conjunction with 
the changes in serum thiol concentrations may represent major changes 
in the redox potential across the cell membrane. Unfortunately 
because of the volume of blood required it was not possible to carry 
out similar studies in leucocytes but it would seem probable that 
similar changes occur in these cells. It is also of interest to note 
that a drug which is not a thiol compound nor is metabolised to a 
thiol compound has second line properties and produces profound 
changes in both extracellular and intracellular thiol concentrations. 
This disproves previous claims that a thiol group or even an ethane 
thiol group is necessary for such activity (196, 197). It is unclear 
which portion of the sulphasalazine molecule is responsible for 
producing changes in these scavengers of oxygen derived free radicals. 
Theoretially the most likely candidate would be an aromatic ring but 
similar rings are found in numerous NSAIDs which do not share the 
above properties.
Section 5 
Conclusions
The major conclusions from this study are that sulphasalazine affects 
intracellular and extracellular thiol concentrations and intracellular 
superoxide dismutase activity. This gives further support to the 
claim that it is a second line drug. The facts that changes in 
intracellular parameters are initially of a paradoxical nature, 
precede extracellular changes and do not correlate directly with
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disease activity suggest that the intracellular effect may reflect a 
more basic action of the drug and may represent a mechanism of action. 
Finally it dispels the myth that a thiol group is necessary before a 
drug can affect thiol levels.
153
Summary 
Chapter 9
Second line drugs such as penicillamine and sodium aurothiomalate 
alter the levels of available thiol groups both within and outwith the 
cells and also affect the intracellular superoxide dismutase activity. 
This is thought to be related to the possession by these drugs of an 
aliphatic thiol group. Among other functions of these various intra 
and extracellular substances are the "scavenging" of oxygen-derived 
free radicals and the maintenance of cell membrane integrity.
Similar c h a n g e s  to t h ose seen w i t h  p e n i c i l l a m i n e  and s o d i u m  
aurothiomalate were seen here in 22 rheumatoid patients treated with 
sulphasalazine for 24 weeks. These patients showed an initial fall in 
red cell lysate superoxide dismutase activity with a rise in red cell 
lysate thiol levels ("pro-inflammatory" changes). These changes 
subsequently reversed and by 24 weeks lysate thiol levels were 
significantly lower than the pre-treatment levels. Over this period a 
gradual rise was seen in extracellular thiol levels.
These changes may represent the mode of action of sulphasalazine and 
they certainly show that the possession of an aliphatic thiol group is 
not a necessary pre-requisite to the production of marked changes in 
the free radical scavenging system.
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chapter 10
A study to determine the active therapeutic moiety of sulphasalazine 
in rheumatoid arthritis
Section 1 Introduction
Section 2 Patients and methods
Section 3 Results
Section 4 Discussion
Section 5 Conclusions
Summary
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Section 1
Introduction
The preceding chapters have demonstrated that sulphasalazine is an 
effective second second line agent in rheumatoid arthritis and, 
although a r e l a t i o n s h i p  b e t w e e n  d ose and e f f i c a c y  has been 
demonstrated, no relationship could be demonstrated between the 
measured circulating levels of various metabolites and efficacy of the 
drug. Hence no light has been shed as to which component (if either 
alone) of the sulphasalazine molecule is responsible for its second 
line action.
A small proportion of ingested sulphasalazine is absorbed directly, 
reaches the systemic circulation and is then excreted unchanged in rhe 
urine. Most of the ingested dose, however, reaches the large bowel 
intact a n d  is s p l i t  at its azo b ond by b a c t e r i a l  a c t i o n  to 
sulphapyridine and 5-ASA (Fig XXXVII). Most of the sulphapyridine is 
subsequently absorbed, reaches the systemic circulation and is 
eventually excreted via the kidneys either in its unchanged form or 
after hepatic metabolism. The 5-ASA, on the other hand, remains 
largely within the large bowel lumen and is excreted in the faeces. 
The little 5-ASA which is absorbed is metabolised by the liver and 
then rapidly excreted by the kidney. Very low levels of 5-ASA are 
achieved in venous blood.
The aetiopathogenesis of rheumatoid arthritis is unknown although it 
is generally thought to be associated with some undefined antigenic 
stimulus. Many and varied antigens are produced by the bacterial 
flora of the bowel and it has been proposed that this is a likely
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Fig. XXXVII Sulphasalazine and its azo cleavage products
source of a n t i g e n  p r o d u c t i o n  (154). in a d d i t i o n ,  gut w all 
permeability seems to be altered in rheumatoid patients either as a 
feature of the disease or its treatment (203, 204, 205). It is
conceivable, therefore, that sulphasalazine acts by some local action 
within the bowel either by altering bowel flora by virtue of the 
sulphapyridine c o m p o n e n t  (38), by an e f f e c t  on b o w e l  w a l l  
prostaglandins and perhaps permeability as a result of the action of 
5-ASA (34) or possibly sulphasalazine itself. It should be noted, 
however, that 5-ASA differs from para aminosalicylic acid (an 
antituberculous drug) only by the presence of the amino group on C5 
rather than C4 and thus it too may have some antibiotic action. 
Although only a small percentage of ingested sulphasalazine is 
absorbed unchanged, because of the large doses used, a significant 
amount is absorbed as is most of the sulphapyridine. It is also 
possible that one of these compounds or perhaps a metabolite of 
sulphapyridine exerts its effect after absorption and that the second 
line effect may be unrelated to any local activity within the 
gastrointestinal t r a c t .  As d e s c r i b e d  in C h a p t e r  1 b o t h  
sulphasalazine, and to a lesser extent, its metabolites also display a 
spectrum of immune modulating activity which may represent a mode of 
action in rheumatoid arthritis.
Both products of azo cleavage of sulphasalazine are available 
commercially; sulphapyridine as an antibiotic and 5-ASA for the 
treatment of ulcerative colitis. In this chapter I have used oral 
preparations of both drugs separately in an attempt to identify the 
active compound and hopefully separate the active and toxic moieties 
and also perhaps to comment on and improve our understanding of the 
aetiological and pathological mechanisms of rheumatoid arthritis.
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Section 2
Patients and methods
Sixty patients with active definite or classical rheumatoid arthritis 
(146) were randomly allocated to sulphapyridine 2g/day or 5-ASA 
(Asacol; Tillots Laboratories) 1.2g/day (30 patients per group). The 
sulphapyridine compound used differs from that in sulphasalazine in 
that it is a v a i l a b l e  for a b s o r p t i o n  m u c h  h i g h e r  up the 
gastrointestinal tract, thus most is absorbed before it reaches the 
terminal ileum and therefore may not be able to exert a local effect 
in the lower gastrointestinal tract. The 5-ASA preparation used 
(Asacol) contains 5-ASA bound to an acrylic resin (Eudragit S) which 
is carried intact to the terminal ileum and colon before the 5-ASA is 
released and thus closely parallels the kinetics of the 5-ASA portion 
of sulphasalazine (206, 207). These particular doses were chosen as
they represent, to the nearest whole tablet, a dose equimolar to 3g 
sulphasalazine. During the course of the study no patients received 
other second line agents or corticosteroids and none had received such 
drugs in the preceding 3 months. Patients continued to receive their 
NSAID's throughout the study period.
Patients were initially commenced on 1 tablet per day (500mg 
sulphapyridine or 400mg 5-ASA) and the dose was increased by weekly 
increments of 1 tablet per day until the allocated dose was reached. 
Although the physician looking after the patients was aware of 
treatment allocation and the patient was able to identify the colour 
and number of tablets taken (but not the name of the treatment) all 
assessments were carried out blind by the metrologist (constant 
throughout the study) and the appropriate laboratory.
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Clinical assessment comprised Ritchie articular index, 5 point pain 
score, mean hand grip strength and duration of morning stiffness while 
laboratory assessment consisted of Westergren ESR, haemoglobin level, 
platelet count and IgM rheumatoid factor measured by an ELISA 
technique. Disease activity index was calculated as described in 
Chapter 4.
Section 3 
Results
At the start of the study the two groups of patients were comparable 
for age, disease duration and all inflammatory indices (Table LIV) 
(p > 0.05 Mann-Whitney U test). Twenty one patients remained on 5-ASA 
and 17 on sulphapyridine for the 24 week follow up period and were 
available for assessment. Reasons for and week of discontinuation of 
therapy are s h o w n  of T a b l e  LV. The m o s t  f r e q u e n t  r e a s o n  for 
discontinuing sulphapyridine was upper gastrointestinal symptomatology 
while in 5 - A S A  t r e a t e d  p a t i e n t s  the m o s t  c o m m o n  r e a s o n  for 
discontinuing therapy was inefficacy. One patient in each group 
stopped therapy at the week 24 visit and was thus available for 
assessment. No significant differences in inflammatory or demographic 
parameters between patients who discontinued therapy and those who 
continued therapy were demonstrable.
Table LIV shows the medians and ranges for various parameters at wk 0 
and 24. There was significant improvement by 24 weeks for most 
indices in the sulphapyridine treated patients but not the 5-ASA 
treated patients (with the exception of articular index) and, in fact.
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in the latter group there was significant deterioration in haemoglobin 
and I g M  r h e u m a t o i d  f a c t o r  l e v e l s  (Table LVI). D ata for ESR, 
haemoglobin and hand grip strength are displayed in Figs XXXVIII, 
XXXIX and XL. Despite the failure to demonstrate any difference 
between the groups at the outset, at 24 weeks there was a significant 
difference between the groups in respect to ESR, articular index, mean 
hand grip strength, IgM rheumatoid factor and disease activity index 
and in all cases this was in favour of milder disease activity in the 
sulphapyridine treated patients (Table LVI).
The improvement in the ESR in the sulphapyridine treated patients was 
not apparent by week 6 but had appeared by week 12 (Table LVII).
Section 4 
Discussion
The r e s u l t s  d e s c r i b e d  here d e m o n s t r a t e  u n e q u i v o c a l l y  t hat 
sulphapyridine possesses second line activity in rheumatoid arthritis. 
The improvement in articular index seen with 5-ASA suggests that this 
drug may have a mild first line effect. The fall in haemoglobin may 
possibly represent gastrointestinal blood loss commonly seen with this 
class of drug or, like the rise in IgM rheumatoid factor, may 
represent increased disease activity in the 5-ASA treated patients. 
It is of interest to note that a difference could be demonstrated in 
the absolute values for inflammatory indices at 24 weeks between the 
two groups whereas this could not be demonstrated between 2nd line 
drugs and placebo in previous studies (126). This, paradoxically, 
could also be related to a mild first line effect of 5-ASA which by
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providing a degree of s y m ptomatic benefit may have allowed patients 
with more severe disease to remain on treatment.
When compared to the 30 sulphasalazine treated patients in the first 
study (Table X) sulphapyridine shows a similar pattern of toxicity 
with a hig h  i n c i d e n c e  of e a r l y  d r o p  out b e c a u s e  of u p p e r  
gastrointestinal side effects with both drugs and a similar pattern of 
efficacy (Table XII). Subsequent studies of sulphasalazine have, 
however, shown a lower drop out rate. In addition the rate of onset 
of action appears, if anything, slower with sulphapyridine than with 
sulphasalazine. No statistically significant improvement could be 
demonstrated in haematological indices at 6 weeks with sulphapyridine 
(although the improvement in ESR fell just short of statistical 
significance) but with sulphasalazine some improvement was seen by 
this stage. It would thus appear that the direct administration of 
sulphapyridine rather than sulphasalazine confers no benefit either in 
terms of reduced toxicity or more rapid rate of onset of action and 
numbers studied are insufficient to comment on any difference in 
efficacy. The a b s e n c e  of a m o r e  rapid onset of a c t i o n  w i t h  
sulphapyridine is hardly surprising as, with the administration of 
sulphasalazine, sulphapyridine is detectable in venous blood after 4-6 
hours. The lag phase of several weeks before onset of action must 
therefore either be associated with equilibration of the serum levels 
with some other compartment or with the time taken to alter either 
directly or indirectly some as yet undefined biological process.
This study used "to the nearest whole tablet" an equimolar amount of 
sulphapyridine to that in 3g s u l p h a s a l a z i n e .  The e x a c t  m o l a r  
equivalent to 3g sulphasalazine is 1.8g of sulphapyridine whereas in
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this study I gave 2g (tablet size = 500mg). In addition, a proportion 
of ingested sulphasalazine is absorbed as such and excreted unchanged 
and thus the bioavailable sulphapyridine in sulphasalazine will 
probably be less than in a s u l p h a p y r i d i n e  p r e p a r a t i o n .  This 
discrepancy in bioavailable sulphapyridine in the two studies makes 
direct comparison difficult although it seems unlikely that there is 
a marked difference between the compounds.
In practical terms, therefore, there would seem to be little point in 
changing from sulphasalazine to sulphapyridine in the treatment of 
rheumatoid arthritis and instead effort should perhaps be expended in 
finding an equally effective but less toxic sulphonamide. Initial 
reports on the use of sulphamethoxazole suggest that it too has a 
second line effect but again toxicity appears to be a major problem 
(175). During the previous phase of interest in sulphonamides in the 
treatment of rheumatoid arthritis in the late '30s and early '40s the 
concensus agreement appeared to be that these drugs were ineffective 
(26) a l t h o u g h  one stu d y  on an i n t r a m u s c u l a r  p r e p a r a t i o n ,  
soluseptasine, suggested a beneficial effect (208). It was Nana 
Svarz's belief in the activity of sulphonamides, despite these 
discouraging results, however, that eventually led to the production 
of sulphasalazine.
The findings of this study are in direct contrast to the situation in 
the treatment of inflammatory bowel disease where it is thought that 
5-ASA is the active agent (36, 37, 209). Potentially more important,
however, than an attempt to find a less toxic second line agent in 
rheumatoid arthritis is the fact that sulphapyridine, an established 
antibiotic, is an effective antirheumatic second line agent and this
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in turn raises the question as to the role of infection in the 
initiation or perpetuation of the r h e u m a t o i d  d i s e a s e  process. 
Sulphapyridine was first introducted as an antibacterial agent in 1938 
by May & Baker and was known as M & B 693. Sulphonamide drugs produce 
their antimicrobial effect by acting as competitive antagonists of 
para amino benzoic acid (PABA) in the bacterial synthesis of folic 
acid. Replication of certain bacteria which require to synthesise 
their own folic acid is therefore inhibited and sulphonamides thus 
have a bacteriostatic effect. In addition to being bacteriostatic 
against c e r t a i n  g r a m  n e g a t i v e  and g r a m  p o s i t i v e  o r g a n i s m s  
sulphonamides are also effective against nocardia, chlamydia and a 
number of protozoa including plasmodium. It is interesting to note 
that many other second line drugs (ie gold, chloroquine, levamisole 
and dapsone) also have antimicrobial activity and were all, in fact, 
initially introduced for the treatment of infection (210, 211, 212). 
It has often been suggested that rheumatoid arthritis may have a 
microbiological origin and although viral infections are most often 
implicated (213) many non viral organisms have also been implicated in 
the aetiology and pathogenesis of rheumatoid arthritis. It has been 
suggested that in rheumatoid disease tissues are affected by direct 
invasion by fastidious organisms such as corynebacterium (214), 
mycoplasma (215), bacterial L forms (216) or even free living amoebae 
(217) and that such organisms may either directly produce an 
inflammatory reaction or cause some alteration of the immune response. 
Although evidence of infection by these organisms appears from time to 
time in the literature their role in the rheumatoid disease process is 
unproven and t h e i r  p r e s e n c e  may m e r e l y  r e f l e c t  i n c r e a s e d  
susceptibility to these infections in rheumatoid arthritis. Another
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hypothesis for the role of bacteria in the rheumatoid disease process 
involves the passage of bacterial antigenic material from the gut and 
it has been suggested that peptidoglycans from bacterial cell walls 
play a role in the production of immune complexes in rheumatoid 
arthritis (218). Again only circumstantial evidence is available. It 
has been proposed that there is increased permeability of the gut wall 
in rheumatoid arthritis although this may merely be an effect of 
NSAIDs (203, 204, 205). In addition, o v e r g r o w t h  of c o l o n i c
Clostridium perfringens in swine is associated with a chronic nodular 
arthropathy r e s e m b l i n g  r h e u m a t o i d  a r t h r i t i s  (219). S u c h  an 
association in human rheumatoid disease is, however, much more 
controversial (220, 221).
It is possible, however, that sulphapyridine and sulphasalazine are 
working via some other mechanism such as an effect on the i m m u n e  
response or an alteration of folic acid metabolism. Many of the anti­
inflammatory and immune regulating properties of sulphasalazine, 
however, do not s e e m  to be shared to a great e x t e n t  w i t h  
sulphapyridine (31, 34), although the inhibition of killer cell
activity is an action of the sulphapyridine rather than the 5-ASA 
component (30). One of the other actions of sulphapyridine is upon 
folate metabolism and there is certainly some well documented but ill 
defined abnormality of folate metabolism in rheumatoid arthritis 
(222) and it is just conceivable that sulphapyridine exerts its effect 
via a direct action on folate metabolism.
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Section 5
Conclusions
In conclusion the findings from this study have shown sulphapyridine 
to have a second line effect with a broadly similar pattern of 
efficacy and toxicity to its parent compound, sulphasalazine. More 
work is needed to demonstrate what, if any, advantage one drug exerts 
over the other in clinical use. In contrast 5-ASA shows at best only 
a mild NSAID type activity but no second line properties. Previous 
attempts to identify a pathogenic role for micro-organisms in the 
aetiopathogenesis of rheumatoid arthritis have failed but the finding 
that yet another antimicrobial drug has second line properties once 
more raises questions regarding the role of an infective process in 
the causation or perpetuation of rheumatoid arthritis although 
alternative mechanisms of action are equally likely.
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Summary 
Chapter 10
Although it is effective in the treatment of rheumatoid arthritis 
sulphasalazine is a relatively toxic drug. In an attempt to separate 
toxicity from efficacy I have investigated separately the two 
components of s u l p h a s a l a z i n e ,  n a m e l y ,  s u l p h a p y r i d i n e  and 5- 
aminosalicylic acid (5-ASA) for antirheumatic activity. In addition 
such an a p p r o a c h  m i g h t  t h r o w  s o m e  f u r t h e r  lig h t  on the 
aetiopathogenesis of rheumatoid arthritis. Of 30 patients randomly 
allocated to 2.0g/day sulphapyridine, 17 continued treatment for 24 
weeks, whereas 21 of the 30 patients allocated to 1.2g/day 5-ASA 
continued for 24 weeks. Significant improvement was seen in most 
inflammatory parameters in the sulphapyridine but not the 5-ASA 
treated patients and although initially comparable the sulphapyridine 
treated group had milder disease by 24 weeks. The toxicity profile of 
sulphapyridine, however, was very similar to that of sulphasalazine 
and no obvious advantage was observed in the use of sulphapyridine 
over that of sulphasalazine. It is of interest to note that another 
drug with antimicrobial activity has been shown to be beneficial in 
the treatment of rheumatoid arthritis and this promotes some 
speculation on the aetiology of the disease.
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Section 1
Introduction
In general most of the proposed aims which I outlined in Chapter 3 
have been fulfilled. These are discussed below. In addition Study 1 
raised some interesting questions on the place of a placebo group in a 
trial of a new second line agent and this too is discussed below.
Section 2
Discussion of various aspects of the thesis
2.1 The efficacy of sulphasalazine in the treatment of 
rheumatoid arthritis
Study 1 demonstrated significant improvements in laboratory and 
clinical indices of inflammation in the sulphasalazine treated 
patients. A similar improvement was seen in the sodium aurothiomalate 
treated patients but no such change was seen in those patients 
allocated to placebo. A difference was also demonstrated between 
sulphasalazine and placebo groups and between sodium aurothiomalate 
and placebo groups in the degree of improvement produced in the 
various inflammatory parameters at both 6 and 12 months. There, 
therefore, seems to be little doubt that, over the short and medium 
term, sulphasalazine is an effective second line drug in the treatment 
of rheumatoid arthritis. Analysis of drug efficacy in Studies 2 and 3 
confirm this finding. In addition a-number of open studies of 
sulphasalazine published before (8, 9, 140) and after (143,-144, 145) 
my own work also show it to be an effective drug. Only two other
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controlled studies have been carried out, one against penicillamine 
(141) and one (published in abstract form only) against placebo (142). 
Again, both of these studies have shown sulphasalazine to have second 
line properties. It is perhaps noteworthy, however, that in my series 
of 90 patients available for 1 year follow up 10 (11%) discontinued 
therapy because of inefficacy between 6 months and 1 year. Other work 
has also pin-pointed this high failure rate on prolonged follow up 
(145) although it was singularly lacking in Farr's study (144). 
Further long term studies will be necessary to examine this problem.
Although from what is published in the gastroenterology literature 
sulphasalazine appears to be a relatively safe drug, a number of 
serious or potentially serious side effects (leucopenia, mucocutaneous 
toxicity, hepatitis) were found in patients studied in this series. 
Other workers in the rheumatology field, however, have found either 
little serious toxicity (141, 144, 145) or serious toxicity of a
different nature (macrocytic anaemia) (8, 9). Thus, although serious 
side effects do occur in rheumatoid patients, the exact incidence is 
unclear and further (multicentre) studies of large numbers of patients 
will be required to define the incidence of these problems.
2.2 The influence of a number of variables on the efficacy and 
toxicity of sulphasalazine in rheumatoid arthritis
Study 2 showed that the efficacy of sulphasalazine in rheumatoid 
arthritis bears a direct relationship to the dose expressed as mg/kg 
body weight and the most effective dose would appear to be in excess 
of 40mg/kg. This dose relationship has not been previously described
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with sulphasalazine and, in fact, there is no well documented 
relationship between dose and efficacy with any second line agent. In 
order to define the m a x i m u m  tolerable dose at which a dose response 
relationship can be demonstrated further studies need to be carried 
out. In addition, the fact that the dose response relationship of 
this particular second line drug is not of the "all or none" variety 
suggests that it may be useful to investigate the dose response 
relationship of other established second line drugs. Despite this 
relationship between dose and efficacy no association between serum 
levels of sulphasalazine, sulphapyridine, acetyl sulphapyridine or 
total sulphapyridine and efficacy could be demonstrated. A similar 
situation prevails with other second line drugs (155, 156, 157, 158).
A greater total drop out rate and a greater drop out rate because of 
adverse effects was observed in elderly patients. A greater drop out 
rate because of upper gastrointestinal symptoms was also seen in slow 
acetylators. In addition there was a suggestion that older patients 
may not show such a good therapeutic response to sulphasalazine and, 
although the overwhelming evidence is that there is no difference in 
the degree ;Of improvement seen between slow and fast acetylators, 
discontinuation of therapy because of inefficacy in the first 6 months 
was confined to fast acetylators.
No effect of gender, disease duration, number of previous second line 
drugs or initial disease severity on either toxicity or clinical 
response could be demonstrated and, interestingly, even patients with 
an initial low ESR or "slightly active" disease showed a clinical 
improvement. This suggests that the only indication for this form of 
therapy should be the overall assessment, by an experienced physician.
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of a potential for response to the drug. In the context of second 
line studies this finding has conflicting implications. Although 
response is seen in patients with an initial low ESR and thus these 
patients can benefit from therapy, the absence of a haematological 
response in these patients would make it difficult to differentiate 
first and second line drugs. In practical terms, however, most 
patients eligible for second line therapy will have a raised ESR and 
thus this phenomenon would probably not influence the final result of 
a randomised trial.
No relationship was discovered between toxicity and serum creatinine 
concentrations and no predictors of serious toxicity were found.
Patients who actually received prochlorperazine from their GP for 
their upper gastrointestinal symptoms were more successful at 
continuing therapy and reaching their allocated dose, but most 
patients eligible for prochlorperazine did not take it and it may be 
that those who did take it were a self selected group with less severe 
gastrointestinal s y m p t o m s  w h o  w e r e  w e l l  e n o u g h  to a w a i t  a 
prescription.
2.3 Single dose pharmacokinetics in elderly rheumatoid patients 
with special reference to toxicity
In single dose studies elderly patients who, with eventual chronic 
dosing, experienced upper gastrointestinal symptoms achieved greater 
peak serum levels and areas under the serum concentration time curve 
than those who suffered no upper gastrointestinal symptoms. This 
suggests that these troublesome side effects are related to serum
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levels of sulphasalazine or its metabolites. Elderly patients excrete 
a greater proportion of the ingested dose in their urine than did a 
previously documented group of young normal volunteers and this 
implies increased absorption, reduced biliary excretion or altered 
distribution. Further studies with intravenous dosing and also steady 
state pharmacokinetics would be useful in further elucidating this 
problem.
2.4 The clinical use of sulphasalazine in rheumatoid arthritis
The m o s t  i m p o r t a n t  r e c o m m e n d a t i o n s  for the c l i n i c a l  use of 
sulphasalazine in rheumatoid arthritis concern dose and monitoring. 
One should aim to achieve a dose in excess of 40mg/kg body weight and, 
if dose related upper gastrointestinal symptoms are a problem, it is 
probably of use to allow access to prochlorperazine to help achieve 
this dose. Monitoring of white cell count (and platelet count) should 
be carried out regularly (fortnightly) for the first 12 weeks (all 
cases of leucopenia occurred within this period). Thereafter until 
more data are available it should probably be monitored six weekly. 
In addition, in view of the risk of drug induced hepatocellular 
damage, liver function tests should be monitored at weeks 0, 6 and 12 
and 12 weekly thereafter. Despite the finding of an increased 
incidence of p r o b l e m s  n e c e s s i t a t i n g  drug w i t h d r a w a l  in s l o w  
acetylators and in the elderly, these groups did not appear to have 
any higher risk of serious, potentially life threatening, side 
effects. Thus, in the present state of knowledge, there is no 
justification for regarding old age or slow acetylator phenotype as a 
contraindication to treatment.
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other important practical considerations are that prolonged disease 
duration, low ESR or the number of previous second line treatments 
have no demonstrable effect on the response to sulphasalazine in 
patients in whom second line therapy is clinically indicated.
2.5 The effect of sulphasalazine on scavengers of oxygen-derived 
free radicals in rheumatoid arthritis
Patients described in Chapter 9 showed a rise in extracellular thiol 
levels. Although previous work failed to demonstrate such a change 
(140) it is not surprising to find a rise in extracellular thiol 
levels as these are thought merely to reflect disease activity (100). 
What, perhaps, is more surprising is that sulphasalazine produces 
alterations in the intracellular thiol levels and superoxide dismutase 
activity similar to those seen with sodium aurothiomalate and 
penicillamine (78, 176, 198) although neither sulphasalazine nor its 
metabolites contain an aliphatic (non-aromatic) thiol group which, it 
has previously been suggested (196, 197), is an important determinant 
of second line function, especially for drugs which are thought to act 
on the free radical scavenging system of cells.
Although this finding is of interest in proving that an aliphatic 
thiol group is not a pre-requisite of second line drugs which affect 
the free radical scavenging system, the present study has shed no 
light upon the necessity of these cellular changes for a second line 
effect although the lack of correlation of intracellular changes with 
various inflammatory parameters suggests that, these changes represent 
something other than merely a reflection of disease activity. To 
answer this question fully it would be necessary to dissociate the
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biochemical and clinical effects or alternatively to study the effect 
of a drug whose sole action is to alter the free radical scavenging 
system.
2*6 The active moiety of sulphasalazine in rheumatoid arthritis
The final study described in Chapter 10 shows, beyond doubt, that 
sulphapyridine is the active component of sulphasalazine in the 
treatment of rheumatoid arthritis. Unfortunately this is also the 
component of sulphasalazine responsible for most of its toxic effects 
and thus it displays no obvious practical benefit over sulphasalazine 
in the treatment of rheumatoid arthritis. This contrasts directly 
with the finding in inflammatory bowel disease that 5-ASA is the 
active component (36, 37, 209).
In t e r m s  of the m o d e  of a c t i o n  of s u l p h a s a l a z i n e  or the 
aetiopathogenesis of r h e u m a t o i d  a r t h r i t i s  the f i n d i n g  that 
sulphapyridine and not 5-ASA is active adds little although it does 
raise the possibility that a microbial process is involved. Further 
studies of antimicrobial drugs in the treatment of rheumatoid 
arthritis are indicated and these studies should probably first of all 
concentrate on the comparison of absorbable and non-absorbable 
agents. Other possible mechanisms of action of sulphapyridine also 
exist.
2.7 The place of a placebo group in the study of new second line 
agents in rheumatoid arthritis
In addition to the above comments pertaining to the stated aims of the
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thesis the results obtained in Study 1 also raise questions about the 
usefulness of a placebo group in studies of new second line drugs. In 
this study only 6 (20%) patients remained on placebo at 1 year and, 
despite all groups being comparable at the start of the study, those 
placebo patients who achieved 1 year treatment had a significantly 
lower initial ESR than both the sulphasalazine group and those placebo 
patients who discontinued therapy. This implies that, largely because 
of the symptomatic benefit of second line drugs, even in a blind 
situation, there is selection within the placebo group throughout the 
course of the study so that those placebo patients available for 
comparison at the final analysis had mild initial disease thus 
invalidating any direct comparison with groups treated with active 
drugs. In addition, within group comparisons make it obvious when a 
potential second line drug is effective whereas, even in the self­
selected group who continue treatment, no improvement is seen in the 
placebo group. These two facts question the usefulness or, indeed, 
the need for a placebo group in this type of study.
Section 3 
The work presented in a broader context
3.1 A Summary of the novel aspects of this work, its
contributions to the overall body of knowledge and its 
implications for rheumatology
This thesis contains several novel features both in the approaches 
used and in the findings. Approaches which were new to the field of 
second line drug research include attempts to relate the degree of
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Gff^icacy of a second line drug to dose (previous studies of other 
agents have concentrated upon the demonstration of efficacy with low 
dose therapy on the assumption that response is "all or none") and 
attempts to relate variations in drug handling to efficacy and 
toxicity, although subsequently interest has been displayed in the 
relationship between sulphoxidation status and the efficacy of d- 
penicillamine.
In this thesis I also explore the effect of sulphasalazine upon the 
group of substances (thiols and superoxide dismutase) which are 
largely responsible both for maintaining the redox potential across 
cell membranes and for scavenging oxygen-derived free radicals.
In addition to those methods mentioned above several standard 
approaches which have not previously been used in the investigation of 
sulphasalazine in the treatment of rheumatoid arthritis were employed, 
eg. a double blind comparison of sulphasalazine with placebo, the 
clinical use of individual drug metabolites in an attempt to identify 
the active moiety and a systematic investigation of variables which 
may affect the efficacy or toxicity of the drug.
As a result of these and other approaches several new findings have 
emerged;-
1) Sulphasalazine compares favourably with placebo in producing an 
improvement in both c l i n i c a l  and l a b o r a t o r y  i n d i c e s  of 
inflammation in rheumatoid arthritis.
2) The efficacy of sulphasalazine is related to dose but is not 
related to serum levels of sulphasalazine or its metabolites and 
is unrelated to acetylator phenotype.
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3) Nausea and vomiting, the most common adverse effect, bears a
relationship to the serum levels of sulphasalazine and its 
metabolites and is commoner in slow acetylators.
4) The possession of a low ESR or previous multiple second line
therapy does not preclude response in clinically suitable
individuals.
5) Sulphasalazine affects the concentrations of various scavengers 
of oxygen derived free radicals. Previously it has been 
suggested that for a second line drug to exert such an effect 
either the drug itself or a metabolite must contain an aliphatic 
thiol group.
6) Sulphapyridine is the a c t i v e  m o i e t y  of s u l p h a s a l a z i n e  in
rheumatoid arthritis. 5-ASA has no demonstrable second line 
effect.
7) Despite adequate matching at the beginning of the study, because 
of a differential in the rate of drop out due to inefficacy, 
patients who could continue placebo to the 24 week assessment 
were a self selected group with milder initial disease. This 
questions the applicability of a placebo group to this sort of 
trial.
These f i n d i n g s  have s i g n i f i c a n t l y  add e d  to our knowledge and 
understanding of sulphasalazine in rheumatoid arthritis and have 
several important implications in a number of fields. In the day to 
day practice of rheumatology, sulphasalazine will be a useful addition 
to the available group of second line drugs and information from this 
thesis regarding dosage and monitoring schedules will be of value in
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allowing the most efficient use of this drug. In our understanding of 
the r h e u m a t o i d  d i s e a s e  p r o c e s s  and h o w  this m a y  be alt e r e d ,  
sulphasalazine has been shov/n to be capable of altering the oxygen- 
derived free radical scavenging system in a manner other than merely 
reflecting disease activity. This gives some further weight to the 
hypothesis that such an effect may be a necessary part of the second 
line effect and disproves the theory that an aliphatic thiol group is 
a pre-requisite for alteration of this system. In addition, the 
finding that sulphapyridine alone is a second line drug is of interest 
and may be of potential importance in understanding the rheumatoid 
process. Finally, in the area of recognition of new second line 
agents doubt has been cast upon the place of a placebo control group.
3.2 Fruitful areas for further research
All research asks more questions than it answers and the work 
described above is no exception. I have listed below several areas in 
which further research may be of use in answering some of these 
questions.
1) A large (almost certainly multicentre) prospective study is
required to define the exact incidence of some of the less common
side effects of sulphasalazine and long term follow up is 
required to further define the problem of late relapse.
2) Further investigation of the dose/effect relationship is required
to i d e n t i f y  the m a x i m u m  t o l e r a t e d  dose at w h i c h  such a
relationship exists.
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3) Studies of other second line drugs are required to 
investigate possible dose/effect relationship.
4) Studies of the effect of other potential second line drugs on the 
free radical scavenging system are required to investigate 
further the relationship between this system and second line 
activity. In addition, attempts should be made to measure those 
scavenging systems within the leucocyte where their relevance to 
inflammation may be more apparent.
5) Studies of other antimicrobial agents in the treatment of 
rheumatoid arthritis and a further search for a causative micro­
organism m a y  y i e l d  u s e f u l  i n f o r m a t i o n .  A l t e r n a t i v e l y  
investigation of folate metabolism in rheumatoid arthritis or of 
the immunological effects of sulphasalazine and sulphapyridine in 
rheumatoid arthritis may be of use.
Section 4 
Conclusions
From work carried out in this thesis I can state the following
conclusions :-
1) Sulphasalazine is an effective second line drug in the treatment 
of rheumatoid arthritis.
2) Potentially s e r i o u s  t o x i c i t y  m a y  o c c u r  w i t h  the use of 
gulpbasalazine in rheumatoid patients. These problems tend to 
occur in the first few weeks of treatment.
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3) Sulphasalazine exhibits a dose/response relationship in the 
treatment of rheumatoid arthritis but no relationship can be 
demonstrated b e t w e e n  s e r u m  l e v e l s  of s u l p h a s a l a z i n e ,  
sulphapyridine, acetylsulphapyridine or total sulphapyridine and 
efficacy of the drug. The o ptimum dose is in excess of 40mg/kg 
body weight/day.
4) Other than dose there are no good clinical predictors of 
efficacy.
5) No clinical predictors of potentially serious toxicity can be 
demonstrated. Upper gastrointestinal symptoms, however, are more 
common in slow acetylators. The overall drop out rate due to 
adverse effects is higher in elderly patients and those elderly 
patients who stop therapy because of nausea and/or vomiting 
achieve h i g h e r  p e a k  l e v e l s  and a r eas under the c u r v e  for 
sulphasalazine, sulphapyridine, and total sulphapyridine on 
single dosing.
6) Sulphasalazine alters the oxygen-derived free radical scavenging 
and redox status of red blood cells. Such changes, therefore, 
are not solely dependent upon the thiol content of a drug. 
Intracellular parameters appear to change independently of 
disease a c t i v i t y  thus s u g g e s t i n g  such c h anges are m o r e  
fundamental to the action of sulphasalazine.
7) Sulphapyridine is the a c t i v e  (and toxic) c o m p o n e n t  of 
sulphasalazine in the treatment of rheumatoid arthritis.
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Summary 
Chapter 11
In this chapter I discuss the relevance of the results of the 
foregoing studies and suggest further possible areas of research.
Study 1 showed sulphasalazine to be an effective second line drug in 
the treatment of rheumatoid arthritis and it is thus a useful addition 
to the small supply of such agents. This finding is confirmed in 
subsequent studies. Unfortunately it has more potentially serious 
side effects than anticipated (especially leucopenia, mucocutaneous 
toxicity and hepatitis). The haematological and liver problems occur 
in the first 12 weeks of treatment and thus the most intensive 
monitoring should be concentrated in this period. There is also some 
suggestion of a high late failure rate and further large long term 
studies are required to help answer this question.
In S t u d y  2 a d i r e c t  r e l a t i o n s h i p  is s h o w n  b e t w e e n  d o s e  of 
sulphasalazine and the degree of improvement although no relationship 
is seen between serum levels of the various metabolites and efficacy. 
The o p t i m u m  dose would appear to be in excess of 40mg/kg body 
weight/day. A relationship is apparent between old age and both total 
drop out rate and drop out rate because of toxicity and between slow 
acetylator p h e n o t y p e  a n d  d r o p  o u t  r a t e  b e c a u s e  of u p p e r  
gastrointestinal symptoms. However, neither of these variables are 
useful p r e d i c t o r s  of s erious toxicity. E l d e r l y  p a t i e n t s  w h o  
experience upper gastrointestinal problems attain higher peak levels 
and areas under the curve for sulphasalazine, sulphapyridine and total 
sulphapyridine. The rate of drop out in elderly patients or in the
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whole population is not, however, related to renal function as 
measured (crudely) by serum creatinine concentration. There is, in 
fact, a suggestion that older rheumatoid patients excrete a greater 
proportion of the ingested dose in their urine. No other factors were 
found to be related to efficacy or toxicity.
Sulphasalazine, although it does not contain a thiol group, has been 
shown in these studies to alter both the intra- and extracellular 
thiol concentrations and also intracellular superoxide dismutase 
activity in a similar pattern to that found with sodium aurothiomalate 
and penicillamine. These substances are involved in free radical 
scavenging and in maintaining cell membrane integrity and these 
changes may represent the basic mode of action of second line drugs. 
In order to investigate further this point similar measurements need 
to be made with other second line drugs.
The final study shows sulphapyridine and not 5-ASA to be the active 
component of sulphasalazine. Unfortunately it is also the toxic 
component and offers little, if any, advantage over sulphasalazine. 
The fact that an antimicrobial agent produces benefit in rheumatoid 
arthritis allows us, once more, to consider an infectious aetiology of 
the disease. Further studies of antibiotics, both absorbable and non­
absorbable, may be of use in further investigating this problem.
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Appendix I
Functional Index
In Studies 1 and 2 functional index was assessed using the following 
administered questionnaire. Three points are scored for a "yes", one 
for a "no" and 2 for a "sometimes". The maximum possible score is 90 
(147) .
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MAME: HOSPITAL NUMBER:
ADDRESS:
AGE:
We are interested to know how you are managing at home with normal 
daily activities without the help of aids or appliances:
Please put a tick in answer to each of these questions "yes", "no" or 
"sometimes".
MOBILITY YES NO SOMETIMES
(1) I am able to walk about out of doors.
(2) I can manage any steps and stairs I have 
at home.
(3) I can use public transport. 
TRANSFER
(4) I can get in and out of bed.
(5) I can take a bath.
(6) I can get on and off the toilet.
PERSONAL CARE
(7) I am able to put on my own make up.
(8) I can manage to wipe myself after using 
the toilet.
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PERSONAL CARE (CONT) YES NO SOMETIMES
(9) I can manage to dress and undress my top 
half.
(10) I can manage to dress and undress my 
lower half.
(11) I can manage to brush and comb my hair.
(12) I can manage to do up and undo fastenings 
on my clothing.
EATING
(13) I can manage to cut my food up.
HOUSEHOLD AND KITCHEN
(14) I can turn my taps at home.
(15) I can manage to prepare vegetables.
(16) I can manage to unscrew jars and bottles.
(17) I can manage to lift saucepans.
(18) I can manage to use the top of the cooker,
(19) I can manage to use the oven.
(20) I can manage to open tins.
(21) I can manage to open packets (eg bacon 
or cheese).
(22) I can manage washing clothes.
(23) I can manage ironing clothes.
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HOUSEHOLD AND KITCHEN (CONT) YES ^  SOMETIMES
(24) I can pick up objects from the floor.
(25) I can grip electric plugs.
(26) I can manage my front door key.
OTHER ACTIVITIES
(27) I can write or type a letter.
(28) I can use scissors.
(29) I can open my purse and handle change.
(30) In spite of my arthritis I can visit my 
friends.
ANYTHING YOU WOULD LIKE TO ADD?
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Appendix 2
Statistical Tests
Statistics used are mainly non-parametric and all tests are two- 
tailed. A significance level of p < 0.05 is regarded as significant. 
Statistical analysis was carried out either manually using standard 
methods (148) or by computer using the Statistical Package for the 
Social Sciences programme (SPSS) (223) on the Glasgow University Main 
Frame Computer. Formulae used in statistical analysis are as 
follows :-
(1) Wilcoxon matched-pairs signed-rank test:-
This test is used when comparing paired data at different 
time points, eg, ESR at week 0 and week 24.
It is expressed as:-
T - (n + 1)
where n = number of pairs.
T = sum of the ranks with the less frequent sign.
Z can be converted to a p v a l u e  u s i n g  s t a n d a r d  
statistical tables.
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|2) Mann-Whitney U test.
This is used to compare two sets of unrelated data, e.g. 
initial ESR in patients randomly allocated to 1.5g SASP with 
initial ESR in patients randomly allocated to 3g SASP. It 
is expressed as:-
(n^+1)
U = njr\2 +   - R^
2
where n^ = number in the smaller group.
TI2  = number in the larger group.
R^ = sum of the ranks in the smaller group.
When rï2  £20 the p value can be calculated directly from a 
statistical table. When ng > 20 then Z is calculated as 
follows :-
n-i n
U -
r'2
Z =
(n^ ) (n2) (n^ + n2 + D  
12
The Z value can then be converted to a p value using 
statistical tables.
(3) Kruskal-Wallis one-way analysis of variance. This test is
used in a similar situation as the Mann-Whitney U test when 
there are > 2 groups, eg, when comparing the initial ESR's 
in the patients randomly allocated to sulphasalazine, sodium
aurothiomalate or placebo. It is expressed as:-
k
12
1)
]
H = __________  \  - 3 (n + 1)
n ]
where k = the number of groups.
nj = the number of cases in the sample.
n = total number in all groups (=%nj) .
Rj = the score of ranks in the sample.
the p value can then be read from standard statistical
tables.
(4) Spearman-Rank Correlation Coefficient.
All correlations were carried out using this test, eg. the 
correlation of the change in ESR with the change in plasma 
thiol concentration. It is expressed as:
di2
n n
where di = the difference between the ranks of two variables 
in an individual.
n = the number of individuals.
The rg (the Spearman-Rank Correlation Coefficient), can then 
be converted to a p value using statistical tables.
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(5) Chi Squared.
This test is used to compare two or more groups with 
reference to the proportions of individuals falling into a 
particular c a t e g o r y  or catego r i e s ,  eg, the n u m b e r  of 
patients ^ 65 years old who discontinued therapy with the 
number of patients < 65 who discontinued therapy. It is 
expressed as:-
(0 - E) 2
where 0 = the observed number of individual cases to fall 
within a particular category.
E = the number of individual cases expected to fall 
within a particular category.
The X  ^  value can then be converted to a p value using 
statistical tables.
(6) Life table analysis:- Log rank test (224).
This test is used to compare the life table curves of two 
treatment groups e.g. the number of patients discontinuing 
sulphasalazine b e c a u s e  of i n e f f i c a c y  w i t h  the n u m b e r  
discontinuing placebo for this reason. The log rank test 
involves counting the number of drop outs observed in each 
group (0) and comparing it with the extent of exposure to 
the risk of drop out in that group (E). The extent of 
exposure for each treatment group can be calculated at the 
time each drop out occurs using the formula:-
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Extent of exposure = e a
r
Where e = the number of drop outs occurring in all groups at 
the particular time point.
a = the number at risk in the individual treatment 
group at that particular time.
r = the total number at risk in all treatment groups 
at that particular time.
The overall extent or risk of exposure to drop out (E) over 
the entire study period can then be calculated for each 
treatment group by summating the individual extents of 
exposure at each time point, ie, E e a
This value of E can then be inserted into the equation:-
(O - E) ^
T h e X  ^ value can then be converted to a p value using 
standard statistical tables.
(7) Power calculations
The power of a clinical trial is the probability that if the 
experimental treatment produces a real difference that this 
difference w ill be d e m o n s t r a t e d  and w i l l  r e a c h  a 
predetermined level of s t a tistical s i g n i f i c a n c e .  The 
arithmetic complement of the power is t h e e r r o r  which 
represents the probability of a "false negative" result^ ie 
our failure to reject a null hypothesis which is in fact
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false. The calculation of power can only be carried out on 
parametric data and for this reason when I made a power 
calculation comparing the sulphasalazine treated group with 
the placebo group and the sodium aurothiomalate group, I 
assumed normal distribution and thus the power of the test 
calculated is m e r e l y  on a p p r o x i m a t i o n  a l t h o u g h  any 
differences will be slight.
As an example the calculation of the power of the test to 
show a significant difference between the change in ESR 
between sulphasalazine and placebo groups is shown below.
Placebo 
n = 17
mean change in ESR 
standard deviation
= - 0.765 
= 19.515
Sulphasalazine 
n = 18
mean change in ESR 
standard deviation
= - 29.667 
= 27.808
Sodium
aurothiomalate 
n = 15
mean change in ESR 
standard deviation
= - 37.267 
= 32.010
The combined estimate of the standard deviation (O') is 
therefore calculated as;-
(17-1) 19.515^ + (18-1) 27.808^ + (15-1) 32.010
26.7
^  = 713
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We know that the distribution of the ESR difference in the 
placebo group can be expressed as 
X P ^ - N  (- 0.8, 713/17)
The null hypothesis is:- 
Ho ; /ip - yus = 0
where:-/is represents the mean ESR difference in the 
sulphasalazine group and
/ip the mean ESR difference in the placebo group.
If Ho is true then:- 
xs'^ N (- 0.8, 713/18)
xp - x s ^  N (0, 713/17 + 713/18)
= N (0, 81.6)
Hence we must calculate the critical value (C) which we 
would have to obtain before we could reject Ho under these 
circumstances at the 5% level.
Let y = xp - xs
y N (0, 81.6)
We want to find C such thatr- 
P (Y < C) = 0.975
z < c - 0
y8î.6 _
= 0.975 where Z = normal deviate
ysi.6 = 1.96 (from area under curve standard
tables)
=> C = 17.71
The alternative hypothesis is:
Hi ! pP ~ ~ ~ 0.8 - (- 29.7) = 28.9
Let y<^ n (28.9, 81.6)
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The power of the test is
Pr (reject Ho when Ho is false)
= P (y < - 17.71) + P (y > 17.71)
= P (y < - 17.71) + 1 - P (y < 17. 71)
= 1 + P f z  < - 17.71-28.9 - P z < 17.71-28.9
= 1 + ® (- 5.160) - m (- 1.239)
1 + 0 - 0.107 (from area under curve standard tables)
= 0.893
ie, when comparing the change in ESR in the placebo group 
with the change in ESR in the sulphasalazine group using 
parametric statistics, the likelihood we will demonstrate a 
difference at the 5% level if a true difference exists is 
89%.
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Appendix 3
Case reports of serious toxic events
Section 1 Leucopenia (1) 
(2)
(3)
(4)
(5)
(6)
(7)
Section 2 Hepatitis (1)
(2)
Section 3 Thrombocytopenia
Section 4 Acute dyspnoea
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Section 1
Leucopenia
Case 1
JD, a 64 year old housewife with a 1 year history of erosive 
seropositive rheumatoid arthritis was commenced on sulphasalazine 
0.5g increasing by 0.5g/day increments each week to 1.5g/day. She had 
received no previous 2nd line drugs.
Concurrent medications were atenolol and bendrofluazide for her 
hypertension plus indomethacin for her rheumatoid. She was noted to 
be a slow acetylator. At the c o m m e n c e m e n t  of therapy WBC = 8.1 x 
10^/1; Hb = lO.Og/dl; plats = 664 x 10^/1; ANA was negative. Five 
weeks after commencement of sulphasalazine (dose 1.5g/day) WBC had 
fallen to 3.8 x 10^/1. Sulphasalazine was continued and 2 weeks later 
WBC had fallen to 1.1 x 10^/1 (10% polymorphs). At this time the 
patient had mouth ulceration. She was admitted to hospital, all 
medications were stopped and she was treated by reverse barrier 
nursing and intravenous gentamicin. She subsequently developed a 
pyrexia of 38.4°C. Repeated cultures of urine, faeces, blood, mouth 
swabs and vaginal swabs failed to grow any pathogens. Bone marrow 
examination showed depressed granulocytopoeisis with only occasional 
myelocytes, no segmented forms were seen. ANA was negative. White 
blood count-gradually rose to 3.5 x 10^/1 over the next 3 weeks. She 
then developed leucocytosis of 20.4 x 10^/1 (neutrophilia) but again 
no organisms were grown. Clinically she improved and was discharged 
from hospital 6 weeks after admission. HLA haplotype showed her to be 
Al, 3, B7, 8, Dr3, 4. Eight months later she was clinically well on
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fenclofenac and sodium aurothiomalate.
Case 2
AC, a 70 year old female with a 2 year history of seropositive erosive 
rheumatoid arthritis was c o m m e n c e d  on s u l p h a s a l a z i n e  0 . 5g/day 
gradually increasing to 3g/day. She had received no previous 2nd line 
therapy. Concurrent therapy consisted of indomethacin and cimetidine. 
At the commencement of therapy total WBC was 9.8 x 10^/1 and she was 
noted to be a fast acetylator. Nine weeks later (on 3g/day) she 
presented with a WBC = 0.5 x 10^/1 with a profound neutropenia, 
platelet count and haemoglobin were within normal limits. Three weeks 
before the acute presentation WBC was 7.3 x 10^/1, she was treated 
conservatively with reverse barrier nursing and antibiotics and within 
5 days of stopping sulphasalazine WBC rose to 10.9 x 10^/1. As ner 
WBC rose she developed a purulent tonsillar and peritonsillar 
discharge. Bone marrow film on the day following admission showed 
arrest at the myelocyte stage with a few metamyelocytes present. 
Blood cultures were consistently negative and sputum culture revealed 
a mixed growth of staphylococcus, pneumococcus and streptococcus. No 
viral aetiology of the neutropenia was demonstrated and ANA was 
consistently negative. Eighteen months later she remained well on d- 
penicillamine.
Case 3
JF, a 54 year old female with a 20 year history of active seropositive 
erosive rheumatoid arthritis, previously well controlled on first line 
drugs, was commenced on sulphasalazine 0.5g/day increasing by weekly
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increments of 0.5g/day to reach 3g/day at 6 weeks. At initiation of 
treatment haematological parameters were as follows: Hb = 10.3g/dl,
plats = 385 X 10^/1, WBC = 6.6 x 10^/1, ESR = 50mm/hr and ANA was 
negative. At this time serum B12 was noted to be low at 82pg/ml, 
serum folate 1.6ng/ml and red cell folate 80ng/ml (lower limit of 
normal = 150pg/ml, 2.2ng/ml and 106ng/ml respectively). She was noted 
to be a fast acetylator.
Other medications consisted of fenclofenac 600mg b.d., dihydrocodeine 
60mg b.d., ferrous sulphate 200mg t.i.d. After 8 weeks of treatment 
WBC fell to 3.8 x 10^/1 (54% polymorphs, 40% lymphocytes, 6%
monocytes). Sulphasalazine was continued and 2 weeks later WBC had 
fallen further to 3.3 x 10^/1 (61% polymorphs, 30% lymphocytes, 7% 
monocytes, 2% eosinophils). Sulphasalazine was stopped 1 week later 
when the patient was reviewed although by this time the WBC had risen 
to 4.0 X 10^/1. Three weeks after stopping sulphasalazine WBC was 5.2 
X 10^/1. Schilling test showed normal absorption of B12 without the 
addition of intrinsic factor. Unfortunately ANA titres and 
reticulocyte counts were not carried out during the period of 
leucopenia. Two months following the cessation of sulphasalazine the 
patient's disease activity necessitated another 2nd line agent and she 
was commenced on hydroxychloroquine. There has been no recurrence of 
her leucopenia.
Case 4
AF, a 41 year old female with a 2 year history of seropositive erosive 
rheumatoid arthritis was commenced on sulphasalazine in a dose of
0.5g/day to be increased in weekly increments of 0.5g/day to 3g/day.
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Her only other medication was fenclofenac in a dose of up to 
1200mg/day. At commencement of therapy WBC = 4.8 x 10^/1, Hb = 
10.7g/dl, plats = 451 x 10^/1, ESR = 80mm/hr, ANA = 1/256 with normal 
DNA binding, serum B12 and folate levels were within normal limits. 
Ten weeks after commencing treatment (dose = 3g/day) she complained of 
perioral paraesthesia and at the same visit WBC was noted to be 2.5 x 
10^/1 (74% polymorphs, 20% lymphocytes, 6% monocytes) with a Hb of 
11.2g/dl and plats of 295 x 10^/1, ESR 60mm/hr. ANA titre at this 
time was 1/1000 with normal DNA binding. Apart from a rather "bizarre 
personality" she had never exhibited any clinical features of SEE and 
she had no evidence of Sjogren's syndrome. Within 1 week of stopping 
treatment WBC rose to 4.6 x 10^/1. Three months later she was 
receiving only intermittent fenclofenac therapy and had shown no 
recurrence of her leucopenia.
Case 5
RH, a 67 year old female with a long history of seropositive erosive 
rheumatoid arthritis was commenced on sulphasalazine 0.5g/day 
increasing g-radually to 3g/day. Previous second line treatment 
consisted of sodium aurothiomalate injections which were stopped 
because of lack of efficacy. Concurrent medication consisted of 
ketoprofen. At commencement of therapy WBC v/as 6.5 x 10^/1 and she
was noted to be a fast acetylator. Within 2 weeks of starting
treatment WBC had fallen to 2.2 x 10 /I (26% neutrophils). 
Sulphasalazine was discontinued and WBC rose within 3 weeks to 4.9 x 
XO^/1. Bone marrow examination in the recovery stage was normal and 
ANA was negative. The patient remained clinically well throughout.
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Case 6
EC, a 43 year old female with a 3 year history of seropositive 
rheumatoid arthritis who was receiving indomethacin 150mg/day plus 
naproxen lOOOmg/day in addition to diazepam 4mg nocte was commenced on 
sulphasalazine 0.5g/day eventually aiming at 1.5g/day. At the time of 
commencing sulphasalazine WBC was 3.4 x 10^/1 (polymorphs 79%, 
lymphocytes 13%, monocytes 8%) with a relative lymphopenia. 
Haemoglobin was 12.3g/dl and platelets 319 x 10^/1. Rheumatoid factor 
titre was strongly positive with a Rose Waaler titre of 1/1024 and ANA 
was positive in a titre of 1/64 with a membranous pattern. She was a 
slow acetylator. White count was monitored fortnightly and 4 weeks
after commencing sulphasalazine WBC had fallen to 2.6 x 10^/1 (38% 
polymorphs, 46% lymphocytes, 10% monocytes, 6% basophils). 
Sulphasalazine was stopped on this occasion but recommenced in a dose 
of 1.5g/day 2 weeks later when WBC had risen to 4.0 x 10^/1. Within 2 
weeks, however, WBC had fallen again to 2.5 x 10^/1 (44% polymorphs, 
41% lymphocytes, 12% monocytes, 2% eosinophils, 1% basophils) and 
sulphasalazine was stopped. There was no change in haemoglobin or 
platelet count over this period. Six months later while on 
hydroxychloroquine WBC was 4.8 x 10 /I.
Case 7
AN, a 41 year old lady with a 31 year history of seropositive 
rheumatoid arthritis who was receiving indomethacin 200mg/day was 
commenced on sulphasalazine 0.5g/day aiming at an eventual dose of 
1.5g/day. At the time of commencing treatment WBC was 5.0 x 10^/1, 
haemoglobin of 10.9g/dl and platelet count 441 x 10^/1. She had
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previously received penicillamine, auranofin and chlorambucil but had 
stopped the latter 3 months previously because of leucopenia of 3.2 x 
10 /I. Auranofin had been stopped because of proteinuria and 
penicillamine because of inefficacy. On starting sulphasalazine ANA 
was 1/256 with normal DNA binding and serum B12 was low at 115pg/ml. 
She was a slow acetylator. WBC was monitored weekly and after 8 weeks 
had fallen to 3.8 x 10^/1. Sulphasalazine was discontinued and 
following this WBC rose to 4.7 x 10^/1 and 6 months later she was 
doing well on hydroxychloroquine with WBC 5.9 x 10^/1. Schilling test 
showed normal absorption of Vitamin B12.
Information on the 7 leucopenia patients is summarised on Table LVIII.
Section 2 
Hepatitis
Case 1
AK, a 69 year old female with a 2 year history of seropositive erosive 
rheumatoid arthritis and known Paget's disease of bone was commenced 
on sulphasalazine 0.5g/day increasing by weekly increments of 0.5g/day 
to 3g/day. Other medications consisted of indomethacin 50mg t.i.d. 
At commencement of therapy serum aspartate transaminase (AST) and 
alanine transaminase (ALT) were within normal range at 21u/l and 13u/l 
respectively. Serum bilirubin level was normal at 7umol/l and 
alkaline phosphatase was raised at 880u/l (this had remained constant 
since presentation 18 months previously and had been shown by heat 
inactivation studies to be of bone origin). After 5 weeks treatment 
she developed nausea (dose 2.5g/day) and discontinued treatment.
201
% s
'à
•g g
II
üh
1 I
JQ
&
If
■y
IT)
rH
X
f— i
oô
co
3
\
i
s
en
X%
k
(N
R
•y •
o
m
co
X
m
10
co
en
P4
R
>
o
PO
X
co
o
PO
I
k
CN
>
uo
d
(N
X
uo
d
o
PO
Cm
vo
^ d? dP 
OO PO 
• rH 
PO '—  — '
S
w
y
>
uo
00
X
CD
uô
CO
>
I
I
I
•S
"y
I
4->
nil in -H
I P I t
I
(0 i■P <u
11
E
II Iu m
& Q S
%
X 6
"S
X
m
d
^ g
m  rH
d ^
6? <#> Sm ^ o  
d
|i
1%
CM
Û I
%
^ d? 
CM
%
X
00
fi
'ë
I
i_
,H ^
Routine liver function tests checked 3 days later revealed a slight 
increase in AST and ALT to 49u/l and 39u/l respectively with a marked 
rise in alkaline phosphatase to 1210u/l. Bilirubin remained normal at 
6u/l. Two weeks later a further rise is AST, ALT and alkaline 
phosphatase to levels of 79u/l, 99u/l and 2000u/l respectively had 
occurred but bilirubin remained normal. Within 2 months levels had 
all returned to pre-treatment values. At no time was she clinically 
jaundiced and apart from nausea had no symptoms attributable to liver 
disease. Other investigations showed negative ANA, negative hepatitis 
B surface antigen, negative antimitochondrial and anti-smooth muscle 
antibody titres and titres against both Epstein-Barr and 
cytomegalovirus were less than 1/16.
One year later LFTs remained normal on indomethacin and fenclofenac. 
Case 2
A 50 year old female with a 22 year history of erosive seropositive 
rheumatoid arthritis was commenced on sulphasalazine O.Sg/day 
increasing to 3g/day (fast acetylator). Previous 2nd line drugs had 
consisted of chloroquine and sodium aurothiomalate. Other drugs at the 
time of commencing sulphasalazine were ketoprofen and indomethacin. 
At the beginning of sulphasalazine treatment liver function tests were 
normal (AST 26u/l, ALT 29u/l, alkaline phosphatase 107u/l, bilirubin 
4u/l, yOT 17u/l, albumin 40g/l), ANA was positive in a titre of 1/64 
with normal DNA binding, serum IgA, IgG and IgM levels were within 
normal limits. Eight weeks later repeat liver function tests 
remained normal. After 12 weeks treatment, however, transaminases had 
risen dramatically (AST 609u/l, ALT 1449u/l) with a raised Y GT
2 0 2
(211u/l). Alkaline phosphatase and bilirubin remained within normal 
limits. Sulphasalazine was stopped. Shortly after this she developed 
severe upper abdominal discomfort with nausea. Within 3 weeks of 
stopping sulphasalazine, liver biochemistry had largely returned to 
normal except for a^GT of 68u/l. Other investigations at the time of 
the maximum rise in liver enzymes revealed negative titres for 
Epstein-Barr and cytomegalovirus, hepatitis B surface antigen was 
negative, ANA was positive at 1/64, anti-mitochondrial and anti-smooth 
muscle antibodies were negative. Liver biopsy was reported as showing 
acute hepatitis with perivenular confluent necrosis and foci of liver 
cell necrosis within the parenchyma suggestive of possible drug 
toxicity.
Section 3 
Thrombocytopenia
A 73 year old female with a 30 year history of seronegative erosive 
rheumatoid arthritis was commenced on sulphasalazine 0.5g/day with the 
aim of gradually increasing the dose to 3g/day (Study 4). In addition 
she was receiving naproxen, paracetamol and ferrous sulphate. Sodium 
aurothiomalate therapy had been discontinued 1 month previously 
because of leucopenia (3.6 x 10^/1; sternal marrow aspirate 3 weeks 
later was normal). On commencement of sulphasalazine haematology 
showed WBC = 4.6 x 10^/1, Hb = 10.4g/dl, platelets = 291 x 10^/1. ANA 
had been positive on 2 previous occasions in a titre of 1/16. She was 
started on sulphasalazine but stopped after 4 weeks because of upper 
gastrointestinal symptoms. Three weeks later she presented with a 
history of easy bruising and 1 episode of epistaxis. On examination
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she had a petechial rash on her lower legs with echymoses on her upper 
and lower limbs. Two small fundal haemorrhages were seen. Spleen was 
not palpable. Platelet count was 30 x 10^/1 and the following day was 
< 5 X 10^/1 (10 days previously platelets = 163 x 10^/1). WBC = 3.5 x 
10^/1. Clotting factors were normal, no circulating platelet specific 
antibodies were demonstrable, sternal marrow aspiration suggested 
peripheral platelet destruction. ANA was raised at 1/1000 
(homogeneous) and DNA binding 6.5% (normal). Radioisotope spleen scan 
showed spleen size to be upper limit of normal. She was commenced on 
prednisolone 40mg/day and by 6 days her platelet count had risen to 
120 X 10^/1. Steroids were slowly reduced and when seen 6 months 
later was receiving 8.5mg prednisolone/day and was well with a 
platelet count of 375 x 10^/1.
Section 4 
Acute Dyspnoea
A 37 year old female (AM) with an 18 year history of seropositive 
erosive rheumatoid arthritis was commenced on sulphasalazine in a dose 
of 0.5g/day to be increased weekly by 0.5g/day increments to 3g/day. 
She was also receiving indomethacin 250mg/day. After 3 weeks (dose
1.5g/day) she developed dyspnoea accompanied by a dry cough and 'flu 
like symptoms (fever, myalgia and nausea). This settled on stopping 
sulphasalazine but when it was reintroduced 1 week later symptoms 
recurred and once again disappeared on stopping sulphasalazine. Unfor­
tunately these episodes were managed by her general practitioner and 
no chest radiograph or eosinophil count v/as. available from this time. 
She has since been commenced on d-penicillamine and remains well.
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